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Background: The discovery of mutations in the isocitrate dehydrogenase (IDH) 1/2 gene 
induced a paradigm shift in the determination of diagnosis, prognosis and treatment of glioma. 
In 2016 the World Health Organisation (WHO) incorporated mutations in IDH1/2 into the 
diagnostic criteria for intracranial tumours as they have been demonstrated in 70-80% of WHO 
grade II-III gliomas, as well as in grade IV secondary glioblastoma (GBM)1. 
Methods: This thesis explores several  methods to further investigate and understand the non-
invasive detection of IDH mutation as well as the pathophysiology of the mutation. Firstly, the 
extraction of quantitative features from MR images of glioma patients, and the subsequent 
application of machine learning strategies in order to carry out non-invasive classification 
according the IDH mutational status. Second was use a metabolomics analytical approach to 1 
and 2 dimensional NMR spectroscopy to understand the metabolic implications of the 
presence of the mutation. Finally, the exploration of the utility of a novel magnetic resonance 
spectroscopy (MRS) sequence for the non-invasive detection of the IDH mutation induced 
oncometaboite 2-hydroxygluerate (2-HG). 
Results: The use of multiway ANOVA allowed for selection of imaging features that were 
independent of external variables to be used in the classification of images into IDH Mut and 
WT. The precision metrics indicated that the investigation warrants further investigation to 
ensure the validity of classification. A Metabolomics approach to multi-dimensional NMR 
spectroscopy allowed for the identification of a metabolic phenotype associated with IDH 
mutation. 2-HG, Myo-Inositol, Alanine, Choline, 3-hydroxybutyrate and Methyl succinate were 
all found to be significantly altered between IDH Mut and WT tumours, which may aid in 
understanding the malignant behaviour of these tumours, as well as providing a potential 
spectroscopic fingerprint for diagnosis. Finally, the utility of a novel semi-LASER MRS sequence 
for the detection of 2-HG non-invasively failed to yield reliable and accurate results. 
Conclusion: Although the radiomics investigation was unable to reliably classify images into 
IDH Mut and WT based on image texture features alone, the NMR metabolomics experiment 
revealed  an IDH Mut metabolic phenotype that may provide both biological and diagnostic 
information. Taken together, the future of personalized tumour healthcare and diagnostics is 
likely to incur a multifaceted approach, bringing together information from a variety of sources 












1.1 Background  
Gliomas represent the most common form of intracranial tumours in adults, accounting for 
81% of malignant brain tumours2. They may arise anywhere within the central nervous system 
but are most often observed within the brain. These tumours originate from either astrocytic, 
oligodendrocytic or a mixture of the two lineages, and have been classified by the World Health 
Organisation (WHO) into both a grading system, and histological and molecular subgroups1. 
Gliomas are most commonly categorised into grades I-IV based on their malignant behaviour. 
 Brian tumours are typically synonymous with high morbidity and mortality due to a vast 
range of factors including their problematic localisation and often locally invasive and 
aggressive nature. This heterogenous set of tumours are known to arise from neuroglial 
progenitors, and hence are classified into their subcategories based on morphological likeness 
to the neuroglial cell types found in the healthy human brain. Other descriptive factors that 
are often used in pathological categorisation include location (specific cortices, brain stem 
lesions, optic nerve), distinctive differentiation patterns (for example pilomyxoid and pilocytic) 
and anaplastic features3. When considering the WHO grading system, features of anaplasia are 
of particular importance when assigning malignancy grade to an individual tumour, whereby 
WHO grade I displays the least malignant behaviour, and WHO grade IV exhibits the most 
aggressive, infiltrative malignant conduct.  
 The past decade has seen extensive progress being made in understanding the 
molecular mechanisms that drive the pathogenesis of gliomas. In May 2014, the international 
society for neuropathologists (ISN) called a meeting in Haarlem, Netherlands, in order to 
determine the best method of incorporating molecular information into tumour diagnostics. 
The resultant “ISN Haarlem guidelines”, whereby a layered categorisation system was 
proposed with histological classification (layer 2), WHO grading system (layer 3) and molecular 
information (layer 4) listed below an integrated diagnosis (layer 1), so as to reduce the inherent 
interobserver variability that most often accompanies traditional pathological diagnosis, and 
to increase the accuracy of prognostic prediction4. These developments have increased our 
awareness of molecular and genetic events that contribute towards and drive malignancy, so 
much so that in 2016, the WHO incorporated a list of molecular markers into the diagnostic 
criteria for tumours of the central nervous system (table 1.1). This new integrated approach to 
pathological diagnosis, combining both traditional morphological characteristics and genetic, 
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epigenetic and transcriptional aberrations has paved the way for not only increased diagnostic 
classification, but also facilitation of a more personalised approach to targeted therapies in the 
treatment and management of the disease4. The utility of such a strategy has been 
demonstrated in Sahm et al., whereby the disputed group of oligoastrocytomas may be 
completely resolved into discrete groups of either oligodendroglioma or astrocytoma based 
on the status of three particular molecular makers; mutations in the isocitrate dehydrogenase 
1 or 2(IDH1/2) gene, loss or retention of expression of nuclear alpha-thalassemia/mental 












Table 1.1 List of the molecular markers that have been identified as important in the diagnosis and 
prognosis of glioma by the WHO and incorporated into the WHO diagnostic criteria 2016  
 
 
1.2 Epidemiology  
Primary brain tumours are the 9th most common form of tumour in the UK which accounts for 
3% of all newly diagnosed tumours. The incidence rate in 2017 for the UK was reported at 18.8 
cases per 100,000 population5. These tumours have a higher incidence rate amongst older 
members of the population where in 2017 23% of new cases were in patients aged 75 and 
over5. Gliomas, in particular grade IV GBM have a dismal mortality, whereby the average 
survival time post-diagnosis is 12-18 months, with only 25% of GBM patients surviving more 
than 12 months, and only 5% of patients surviving over 5 years5. 
Marker Diagnostic/Prognostic Significance 
IDH1/2 Mutation Usually first genetic event, prognostic marker 
for survival and treatment response 
1p/19q 
codeletion 
Marker for oligodendroglioma and predictive 




Predictive of improved outcome in anaplastic 
oligodendroglioma, astrocytoma and GBM. May 
be predictive of response to alkylating agents 
such as temozolomide   
ATRX loss If lost, correlates with reduced median survival 
and increased genetic instability 
PTEN has been shown to corelate with poor prognosis 
in grade III glioma and GBM 
EGFR 
amplification 
Indicative of increased tumour invasiveness in 




Gliomas, much like other tumours, may be considered as a genetic disease of a single cell 
originating from a specific lineage. The architecture of these genetic alterations gives rise to 
the clinical manifestation of the tumour, and initial genetic and molecular events shape the 
evolution of populations of malignant cells within each lesion. These distinctive features of 
brain tumours are increasingly involved in the categorisation and diagnosis of glioma. 
 The most common subtypes of glioma to be observed in the young adult population 
are diffuse WHO grade II and III tumours. Such lesions may be distinguished by their distinct 
infiltrative nature within the brain parenchyma and an innate propensity to both recur and 
progress towards an increasingly malignant phenotype. The aforementioned inclusion of 
molecular markers into the diagnostic criteria has previously expedited the differentiation of 
mixed oligoastrocytomas into distinct classes of astrocytoma and oligodendroglioma, averting 
the requirement for the mixed subtype6. Both the astrocytic and oligodendrocytic genotypes 
may carry mutations in the IDH1/2 gene7,8. The role of IDH1/2 mutations in the pathogenesis 
of glioma will be discussed in further detail in following sections, however this mutation is likely 
to represent the primary tumour-initiating event of diffuse gliomas9. Malignant evolution of 
diffuse, lower grade gliomas into grade IV glioblastoma (GBM), is most often restricted to those 
tumours defined as an astrocytic subtype, and occurs due to the homozygous deletion of the 
CDKN2A-CDKN2B locus, among other genetic modifications10. Anaplastic astrocytoma (AA) is 
an invasive, malignant primary tumour that is more common amongst younger primary CNS 
tumour patients (median age 41 years)11. These tumours have been demonstrated to share 
common pathological lineage to that of secondary GBM whereby the most pronounced 
difference between AA and GBM is that AA are lacking in endothelial proliferation and necrosis. 
IHD mutation, much like in secondary GBM, plays an important role in the pathological and 
malignant progression of AA11,12. 
 WHO grade IV GBMs are the most commonly observed glioma and display the most 
aggressive, malignant phenotype. These tumours primarily present with demographics >50 
years of age, nevertheless GBM may also occur (to a lesser extent) in children and young adults. 
Interestingly, there is a growing body of evidence to suggest that GBM in young demographics 
are molecularly and genetically distinct from their counterparts observed in adults13. Recent 
findings have shown there to be six subgroups of GBM characterised by distinct molecular 
alterations and methylation profiles13.  
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1.4 IDH Mutation in Glioma 
The field of neuro-oncology has undergone a paradigm shift following the identification of 
mutations in the IDH 1/2 genes in glioma and gliomagenesis. Such mutations have been 
suggested to play an important role in the development and progression of intracranial 
gliomas, often marking the first genetic transformation to occur, and imparting a range of 
downstream effects on a myriad of cellular processes14. Mutations in IDH1/2 genes have been 
identified in 70–80% of WHO grade II-III gliomas, and these mutations are particularly 
prevalent in grade IV secondary glioblastomas (GBM) arising as a progression from lower grade 
tumours, suggesting such mutations may act as a driving force behind malignant progression1,7. 
Mutations in IDH1/2 confer a gain-of-function neomorphic enzymatic activity, resulting in the 
aberrant production and subsequent accumulation of 2-hydroxygluarate (2-HG), which has 
been suggested to be an oncometabolite for this genetic mutation15. Magnetic resonance 
spectroscopy (MRS) has been identified as a tool in the diagnosis of IDH mutant gliomas via the 
non-invasive detection of 2-HG16–19. Alongside diagnostic applications, non-invasive detection 
and quantification of 2-HG levels within the mutant gliomas is highly desirable for the 
development of targeted treatment and response monitoring. The mutated pathway has been 
identified as a candidate target for novel therapies, and imaging strategies capable of 
accurately examining 2-HG levels will aid in longitudinal assessments of treatment response, 
whilst accelerating pharmaceutical translation from bench to bedside20–22. 
 
1.5 Biochemistry of IDH Mutation in Glioma  
IDH is known to occur in three structural isoforms, namely IDH1, 2 and 3; however, only 
mutations in IDH1/2 have been identified in human gliomas15. IDH1 is localised to the 
cytoplasm and peroxisomes, whereas IDH2 is localised to the mitochondria23. Both of the 
IDH1/2 isoforms function to catalyse the oxidative decarboxylation of isocitrate into α-
ketoglutarate (αKG) using NADP+ as a cofactor24. Mutations in both IDH1 and IDH2 are 
ubiquitously expressed within the tumour tissue; moreover, they consistently occur in a 
heterozygous manner and are most commonly observed in the IDH1 isoform. Remarkably, 
within gliomas,  less than 90% of these point mutations occur at a single residue within the 
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active site of the IDH1 isoform, where the Arginine 132 residue is replaced with a histidine 
(IDH1R132H)14. The much less frequent mutations in the IDH2 analogue occur at Arginine 172,  
 
 
Fig 1.1. Simplified schematic of metabolic pathways associated with IDH1/2. Mutations in IDH1/2 
catalyze the production of the oncometaboite 2-HG via reduction of αKG. Accumulation of 2-HG within 
the cytoplasm surpasses the detection threshold of MRS at clinical filed strengths, and therefore may 
be utilized as a biomarker for the non-invasive detection of the mutation. H2O2 = hydrogen peroxide, 
GSH = glutathione, GSSG = glutathione disulphide, H2O = water, NADP = nicotinamide adenine 
dinucleotide phosphate, NADPH = nicotinamide adenine dinucleotide phosphate hydrate, Acetyl-CoA = 
acetyl coenzyme A IDH1 = isocitrate dehydrogenase 1, IDH2 = Isocitrate dehydrogenase 2, 2-HG = 2-




where the most common mutation is IDH2R172K. Alterations in the conformation of the 
catalytic site of the enzyme confer a gain-of-function neomorphic enzymatic activity, whereby 
mutant IDH1/2 catalyses the reduction of αKG into the oncometabolite 2-HG (Figure 1.1)15. 
The subsequent accumulation of the metabolite within mutated cells is facilitated by the 
heterozygous manner of the mutation and the dominant effect that the gain-of-function 
mutant imparts over the remaining wild type (WT) allele, which serves to provide the mutant 
enzyme with a continuous supply of αKG to be aberrantly reduced into 2-HG. 
The full impact of accumulation of 2-HG within tumour cells is yet to be elucidated, but 
recent work suggests that it may have a pivotal role in altering the genetic, epigenetic and 
metabolic profile of the IDH mutant cells, driving the phenotype towards a more malignant 
state. One well-established mechanism of phenotypic alteration is inhibition of α-ketogluarate-
dependant deoxygenases and histone demethylases, including the Ten Eleven Translocation 
(TET) family of 5-methlycytosine hydroxylases, leading to genome-wide alterations in 
methylation and histone patterns15. This proposed inhibition allows for IDH mutant gliomas to 
be classified into a distinct subgroup amongst intracranial tumours, whereby they exhibit a 
CpG island methylator phenotype and vastly altered histone methylation pattern26. This 
aberrantly methylated phenotype has been suggested to contribute to tumourgenesis. 
Interestingly, the occurrence of IDH mutations is highly restricted to a narrow spectrum, 
encompassing an exclusive list of malignancies. For example, these mutations are frequently 
observed in grades II to III gliomas and secondary GBM but not in primary GBM. The observed 
pattern in mutation occurrence suggests that its involvement in tumourgenesis may be linked 
to prevention of histone demethylation normally required for linage specific differentiation 
into terminally differentiated progenitors27,28, in addition to altering the activity of 
chromosomal topological-regulating proteins29. A further molecular mechanism by which 
mutations in the IDH1/2 genes have been suggested to contribute to tumourgenesis is via the 
ability of accumulated 2-HG to stimulate activity of the egl-9 family hypoxia inducible factor 
(EGLN) prolyl 4-hydroxylases. Activation of these enzymes facilitate- the ubiquitination and 
proteasomal degradation of hypoxia inducible factor, a process that has been shown to 
enhance the proliferation of astrocytes in culture30. 2-HG has also been suggested to indirectly 
contribute to increased exposure to oxidative stress, as the conferred neomorphic enzymatic 
activity observed in mutant cells incurs a reduction in NADPH levels, a molecule that normally 
functions as a prerequisite for the reduction of glutathione disulphide into the antioxidant 
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glutathione (Figure 1.1)31. Although a decrease in glutathione levels increases exposure to free 
radicals and reactive oxygen species, it has been suggested that the cellular depletion of 
glutathione contributes to the increased sensitivity to adjuvant radiotherapy in IDH mutated 
gliomas31.  
One approach that has been adopted for probing IDH mutation uses 13C MRS to 
monitor the production of 2-HG from its substrate αKG in a rat glioma model32. This preclinical 
study used Dynamic Nuclear Polarization labelled 1-13C αKG to examine the metabolic activity 
of tumour cells, providing information pertaining both the metabolic origin of the aberrantly 
produced 2-HG, as well as tracking of real-time metabolism. It was demonstrated that the 
injected hyperpolarized 1-13C αKG was converted to hyperpolarized 1-13C 2-HG in both cell 
lysates and in vivo in orthotopic tumours. In comparison to 13C, 1H MRS provides total, steady-
state 2-HG levels present throughout the tumour environment, inclusive of both the 
intracellular and extracellular compartments. Alternatively, 13C MRS provides real-time, 
dynamic information on the metabolic fate of 13C α-KG, and thus directly probes the enzymatic 
activity of cytosolic mutant IDH1 in glioma cells. The study of dynamic metabolite processes 
permitted by 13C MRS offers the opportunity to instantly gain a picture of the metabolic activity 
taking place within a tumour. The monitoring of active mutant IDH enzymes, as well as 2-HG 
synthesis, confirms the proposed biochemical pathway leading to the accumulation of 2-HG 
within glioma cells. In addition, utilization of a non-radioactive hyperpolarized 1-13C αKG probe 
highlights clinical applicability of such detection methods for the accurate tracking of 
oncogenic metabolic activity when monitoring disease progression; moreover, as IDH targeted 
therapies emerge, such techniques delivering high-quality information on 2-HG synthesis may 
be invaluable in the development and monitoring of novel compounds through clinical 
trials33,34.  
Taken together, the production and accumulation of 2-HG within IDH mutated glioma 
cells not only offers an interesting avenue for investigation into the underlying pathological 
events that contribute to glioma formation and progression, but correspondingly presents as 
a potential biomarker for diagnostic confirmation of IDH mutational status, in addition to 
prospective opportunities to monitor treatment and develop targeted therapies. 
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1.6 2-HG as a Biomarker  
Although the downstream consequences of metabolic reprogramming observed in IDH 
mutated gliomas are yet to be fully elucidated, the incorporation of IDH status into the WHO 
diagnostic criteria indicates a significant diagnostic and prognostic role of the genetic 
abnormality. IDH status is currently confirmed by immunohistochemistry or genetic 
sequencing, requiring tissue samples obtained at surgery.  
As cancer treatments move towards personalised medicine, the need for robust and 
quantitative biomarkers becomes increasingly important. The ability of 2-HG to act as a 
surrogate marker of IDH status is highlighted by the fulfilment of several criteria. Firstly, it is 
known that > 99% of all IDH mutated cells exhibit 2-HG levels several orders of magnitude 
above the physiological trace amounts observed in healthy brain cells. In fact, accumulation of 
the metabolite occurs in such an extensive manner that its concentration reaches well into the 
millimolar (mM) range (5–35 mM) 35, far surpassing the sensitivity threshold of MRS at clinical 
field strengths (~1 mM)36. Secondly, there is virtually no background 2-HG present in healthy 
brain tissue. The 2-HG metabolite contains an asymmetric carbon within its backbone and is 
therefore produced as two enantiomers, either D-R- or L-S- confirmation. The D-R-2-HG 
stereoisomer is the metabolite that is produced by the neomorph enzymes resulting from IDH 
mutation, whereas the L-S-2-HG isomer is produced as a result of limited oxygen availability 
within a tissue. Both stereoisomers function to inhibit αKG-dependant enzymes. 
Physiologically, both enantiomers of this metabolite are rarely produced, and form only as 
transient errors of normal metabolism to be swiftly degraded by endogenous 2-HG 
dehydrogenases15. Finally, there is only one other known cause of elevated levels of 2-HG 
within brain tissue, a rare genetic disorder known as hydroxyglutaric aciduria, a condition 
recognised early in brain development due to the presentation of a range of additional clinical 
manifestations37. 
 
1.7 Prognostic Implications of IDH Mutation 
Overall survival (OS), treatment response and probability of malignant transformation are all 
factors that correlate with IDH mutation34,38,39. The prognosis of glioma is dependent on 
several factors including tumour grade as defined by the WHO classification1. Infiltrative low 
grade gliomas (LGGs) (grade II) have a median survival of 7–10 years, whilst high grade gliomas 
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(HGGs) (WHO grade III and IV) have a poorer prognosis with a median OS ranging from a few 
months to a few years39. LGG (including oligodendroglioma, astrocytoma and mixed glioma) 
have an incidence rate of 0.63/100,000 adults per year and hold the potential to undergo 
malignant transformation into WHO grade III anaplastic glioma or grade IV secondary GBM40. 
Mutations in IDH1/2 within LGGs are highly prevalent, and can be observed at a rate of 70–
80% in all tumours within this subgroup. The influence of IDH mutation on LGG patients has 
been highlighted in the stratification of oligodendroglioma, astrocytoma and mixed glioma41. 
That study evaluated the accumulation of a number of additional genetic aberrations alongside 
IDH mutation, including hypermethylation of O-6-methylguanine DNA methyltransferase 
(MGMT) promotor region, 1p/19q co-deletion and TP53 mutation. It was reported that all 
genetic subsets, inclusive of IDH mutation, showed hazard ratios 3–5 times more likely to 
undergo malignant transformation. Although LGG have been stratified with regards to the 
prognostic influence of IDH mutation, the importance of the genetic abnormality in this subset 
of tumours is still a topic of debate, as others have failed to identify such a significant 
correlation42,43. In addition to the increased risk reported by Leu et al.43, a study conducted by 
Sanson et al.44 observed a significant increase in OS in patients harbouring an IDH mutation. 
Conversely, other studies have not found a link between IDH status and OS42,43,45. Kim et al. 
reported no significant influence of IDH on progression free survival (PFS) or OS in a cohort of 
nearly 200 LGGs45. Furthermore, Juratil et al. failed to identify any predictive value of the 
mutation with regard to OS, PFS and mean time to malignant transformation (MTT) in a 
multivariate analysis46. This investigation did, however, identify that a higher rate of patients 
with mutated IDH were to develop into a secondary high grade glioma. A comprehensive 
analysis of cellular tricarboxylic acid cycle metabolites was conducted on a range of glioma and 
non-glioma patients, with both IDH mutant and WT genetic profiles. However, this study failed 
to identify 2-HG as an early biomarker in determining the prognostic course of glioma 
patients45. 
Whilst the influence of IDH mutation on the malignant progression of grade II gliomas 
is yet to be fully understood, the favourable impact on patient outcome for grade III gliomas is 
recognised. A number of studies have outlined the prognostic, rather than predictive influence 
of IDH mutation on grade III gliomas42,43. A prospective study by the European Organization for 
Research and Treatment of Cancer (EORTC) determining the prognostic significance of IDH 
mutation in anaplastic oligodendroglioma patients found that IDH mutant oligodendrogliomas 
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had a better OS. However, the study did not find a link between IDH status and response to 
adjuvant radiation and chemotherapy47. Comprehensive, multiplatform integrative genomic 
analysis of low and intermediate grade gliomas demonstrated that lesions histologically 
identified as grade III display only a modest difference to those identified as grade II, whereby 
the majority of observed differences results in a slight increase in frequencies of chromosome 
9p and 19q losses48. Such analyses highlight the suggested molecular progression through 
grade classification, initiated by mutation in IDH1/2 and acquisition of the CpG island 
methylator phenotype. Despite the modest differences in genetic profile, the confirmation of 
IDH mutation in grade III is considered to reflect improved PFS and OS47. 
In WHO grade IV GBM, IDH mutation has been repeatedly shown to be predictive of 
improved response to temozolomide treatment and radiotherapy in secondary GBM 
malignancies that have transformed from lower grade gliomas48,49. The presence of IDH 
mutation has additionally been associated with improved PFS and OS of secondary GBM50. 
Secondary GBM that also harbour hypermethylation of the MGMT promoter region alongside 
IDH1/2 mutation have the best prognosis51. Although the underlying molecular mechanisms 
behind IDH mutation and its proposed influences on diagnosis, prognosis and the suggested 
predictive capacity of the mutation are yet to be identified, there appears to be overwhelming 
evidence that this genetic alteration has a significant role to play in understanding the 
underlying pathology of gliomagenesis and tumour progression. There is therefore an unmet 
need for the development and implementation of a reliable and robust, non-invasive assay for 










2. Principles of 
Experimentation
 
There are numerous applications of nuclear magnetic resonance for the study of glioma 
metabolism and diagnostics with reference to IDH mutation. In this chapter I will introduce and 
discuss the principles that underpin the MR methods explored in this work, including nuclear 
magnetic resonance imaging and both in- and ex-vivo MR spectroscopy. 
 
2.1 Basics of Nuclear Magnetic Resonance  
Nuclear magnetic resonance (NMR) refers to the phenomenon of specific atomic nuclei 
absorbing and remitting radiation of specific frequencies when exposed to an externally 
applied magnetic field. Quantum theory can aid in understanding the principles underpinning 
NMR, and may allow us to explain how we are able to generate images (Magnetic Resonance 
Imaging) and spectra (Magnetic Resonance Spectroscopy) in order to probe the human body 
to asses a vast range of biophysical properties52. 
 
2.2 Nuclear Spin Properties  
The nucleus of an atom is comprised of a given number of protons and neutrons. These 
subatomic particles are fermions, and as such, according to spin-statistic theory from within 
any reasonable relativistic quantum field theory, possess a half integer spin value. Spin is an 
intrinsic property of any quantum particle, and here we may think of this property as a particle 
rotating about its own axis. Atoms consisting of an odd number of protons and neutrons are 
considered to possess a non-zero spin, and any spinning charged particle is known to emit 
electromagnetic radiation. One fundamental property of electromagnetic waves dictated by 
Maxwell’s wave theory, is that they are comprised of an electric field E and a magnetic field B, 
positioned perpendicular to each other. Therefore, the nucleus of a hydrogen atom consisting 
of a single proton, with a non-zero spin emitting electromagnetic radiation, possesses a 
magnetic moment along the axis of that spin. This nuclear magnetic field attributed to 
hydrogen atoms is analogous to that of a bar magnet. 
The interaction between a nuclear spin placed within a magnetic field can be explained 






Η̂𝑜𝑛𝑒 𝑠𝑝𝑖𝑛 = −𝛾Β0?̂?𝛧 
 
Where  is the gyromagnetic ratio, which is a fundamental property of the spin. ?̂?𝛧 is an 
operator representing the z-component of the nuclear spin angular momentum, which is the 
component that interacts with the applied magnetic field. The eigenvalues of this Hamiltonian 













These are the two energy levels of a single spin-half in a magnetic field B0 (Fig. 2.1). 
 
 
Fig 2.1 Energy level split for a population of 1H spins (I = 1/2). In the absence of a magnetic field the 
energy levels are almost absent, however when a magnetic field is applied along the Z-axis there is a 
splitting of spin states.  
 
 
Following this rule of quantum theory, it can be determined that a hydrogen atom has 2 energy 
states, -⅟2 and +⅟2. This was classically demonstrated and quantised in an experiment 









∆𝜠 = 𝜸ℏ𝑩𝟎 
When 𝐵0 = 0 there 
is no split in energy 
level.  
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magnetic field gradient53. They found that a given number of silver ions were deflected into 
one of 2 paths, which dictated the number of ions in the spin up (+⅟2) or spin down (-⅟2) state.  
When considering the previous description of spinning magnetic moments of protons, such as 
hydrogen atoms that are found in abundance in biological tissue, these tiny magnets can either 
be positioned within the higher energy state (+⅟2) whereby they will point upwards, or in the 
low energy state (-⅟2) whereby they will point downwards54.  
One key intrinsic property of a nucleus is the magnetic moment  caused by nuclear 
magnetism. The nuclear magnetic moment  and the nuclear spin angular momentum  are 
proportionally linked to the constant  which is termed the gyromagnetic ratio. Magnetic 
moments can be defined as vectors defining the spin polariazation (equation 3) and may take 
on the value of: 
 
Equation 3 
𝜇 = 𝛾. ℏ. 𝐼 
 
Where 𝛾 is the gyromagnetic ratio, ℏ is Planck’s constant over 2 and 𝐼 is the nuclear spin 
angular momentum(kg-m2/s)55.  
Hydrogen atoms can be found in vast abundance throughout a wide variety of tissues 
in the human body. When considering the above description of nuclear spin in hydrogen 
atoms, these tiny magnets can assume a position within either the high energy state (+⅟2) or 
the low energy state (-⅟2). Under normal conditions, where such atoms have no externally 
applied magnetic field, the distribution of protons occupying either one of the two energy 
states is equal. When an external magnetic field is applied (𝐵0 > 0) the spin state possessing 
the net magnetic moment aligned to the 𝐵0 field is energetically favourable, consequently 
there is a preference for the majority of the spins to align parallel to the 𝐵0 field. This 
anisotropic spin distribution (Σ𝜇 > 0)(euqation4), which results in a positive net 
magnetization at thermal equilibrium is termed the macroscopic magnetization: 
 
Equation 4 




The net magnetization produced by the protons aligned within the magnetic field is subject to 
a torque force. This force, referred to as precession, results from the phenomenon observed 
when a proton is exposed to an external magnetic field, not only does it rotate about its own 
axis, but it begins to ‘wobble’ or precess about the axis of B056. The rate 𝜔0 (rad.s
-1) at which 
this rotation occurs is directly related to the strength of the magnetic field 𝐵0, and is denoted 
by the equation 5, otherwise known as the Larmor frequency:  
 
Equation 5 
𝜔0 = −𝛾B0 
 
0/2 will simply define the Larmor frequency in Hz in equation 6:  
 
Equation 6 
𝜔0 = −𝛾B0/2𝜋 
 
The Larmor frequency can be either positive or negative, suggesting either clockwise (positive) 
or anti-clockwise (negative) precession about the magnetic field. For the purpose of this text 
we are considering H1 nuclei, which incur a positive gyromagnetic ratio, and therefore a 
clockwise precession about the magnetic field (Fig 2.2). 
 
 
Fig  2.2 Precession of the nuclear spin magnetic moment about the B0 externally applied magnetic field 
incurring a positive or negative gyromagnetic ratio.  
𝑩𝟎  
𝜸 > 𝟎 
𝑩𝟎  
𝜸 < 𝟎 
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2.3 Polarization at Thermal Equilibrium 
The alignment of spins to the applied 𝐵0 is not a ubiquitous arrangement within the system 
due to thermal motion of particles enforcing a dynamic balance between the two energy 
states, which may be determined by the strength of the magnetic field and the temperature 
within the system. The excess of spins aligned parallel to the 𝐵0 may be explained by the 
Boltzmann’s distribution equation, which can be given by equation 7: 
 
 Equation 7 














Where N is the number of spins,  is the reduced Planck constant, 𝜔 is the Larmor frequency 
(Hz), K is Boltzmann’s constant and T is temperature in kelvin. Taking into account equation 8, 
this means the equilibrium spin density 𝜌eq,i  at a given spin state i will be equal to: 
 











The polarization of a spin system is proportional to the longitudinal magnetization over its 
maximum value. Therefore, equation 9 shows that in a half spin system (e.g. 1H), where 𝛮 ↑ is 
the number of spins aligned along the 𝐵0 and 𝛮 ↓ is the number of spins aligned opposite to 
the 𝐵0, the system polarization 𝑃 is equal to equation 9 where 𝛾 is the gyromagnetic ratio, ℏ 
is reduced Planck’s constant, 𝜅 is the Boltzmann’s constant and T is temperature in Kelvin: 
 
 Equation 9 
𝑃 =
𝛮 ↑ −𝑁 ↓




















The thermal energy is always much greater than the split between the two energy states of 
the spins, making the thermal equilibrium population very small. The high temperature limit is 
met, where the exponential is less than 1 i.e. 
𝐸𝑖
𝜅𝐵𝑇
, the polarization equation stated above, for 
a half spin, may be simplified to equation 10: 
 






Using this equation, we are able to understand why it is possible to generate increased 
amounts of signal at higher magnetic fields, as polarization is linearly related to the 𝐵0, and the 
gyromagnetic ratio. The spins are able to absorb radiofrequency radiation equal to the 
difference in energy states. Therefore, at higher 𝐵0 more spins will become aligned with the 
magnetic field, resulting an increased magnetic moment and increased interaction with 
detection coils.  
The longitudinal magnetization 𝑀𝑧, represents a very small excess of nuclear spins due 
to the random thermal motion, and may be represented by equation 11: 
 
 Equation 11 








2.4 Excitation and Detection of Signal 
The precession of the magnetization vector is the phenomenon that we actually detect during 
an NMR experiment. A radio-frequency coil, often composed of a transmit and receive 
component is placed around the sample from which a measurement is to be taken. The coil is 
aligned along the xy-axis. An oscillating field within the radiofrequency range, with the 
frequency  tuned and matched to the Larmor frequency of the sample spins we wish to 
measure, will induce an energy level transition. Equation 12 describes the energy absorbed by 



















= 𝛾ℏ𝐵0 = −𝛾𝜔0 
 
 
The introduction of the RF pulse causes the precessing spins aligned along the magnetization 
vector 𝑀𝑧 to undergo phase coherence, producing a non-zero vector in the transverse plane 
𝑀𝑥𝑦, shifting the majority of the previously defined polarization away from the Z-axis. As the 
precessing magnetization vector cuts through the detection coil placed over the sample 
perpendicular to the position of the coil, an oscillating current is generated which can then be 
amplified and detected to produce the free induction decay. As the RF pulse is switched off 
the transverse magnetization 𝑀𝑥𝑦, will begin to decay to its zero value 𝑀0 at a rate dictated by 
the constant 𝑇2
∗, whilst the longitudinal magnetization will begin to decay to its equilibrium 
value 𝑀0. Within the stationary reference frame this relaxation process occurs as a dense 
spiralling precession about the 𝐵0 where 𝑀0 spins at the Larmor frequency whilst undergoing 
𝒎𝒛 = +𝟏 𝟐⁄  
  












Fig 2.3 Excitation of spins 1/2. On the left the Boltzmann distribution of spins dictates that the bulk 
magnetization occurs along the Z axis (𝐵0) and the spins have random phases. An RF pulse is appled 




both longitudinal (z-axis) recovery and transverse (x,y-plane) relaxation (figure 2.3) If we view 
this process within the rotating frame, then it is simplified and the 𝑀0 returns to equilibrium 
along a linear path whereby both longitudinal and transverse relaxation occur exponentially. 
 
2.5 Relaxation Mechanisms 
Relaxation can be outlined as the process by which the bulk of the magnetization within a 
system returns to equilibrium over time. At equilibrium, as previously established, 
magnetization occurs only along the direction of the applied magnetic field, otherwise known 
as z-magnetization. Rather than measuring this longitudinal magnetization, in NMR 
experiments the transverse magnetization, 𝑀𝑥𝑦, is measured.  
Following the application of a 90 RF pulse, the bulk magnetization (𝑀𝑧) is flipped into 
the transverse plane. As the RF pulse is turned off, the spins, which are now in the transverse 
plane, will begin to precess about the 𝐵0, and it is this precession that we detect in the form 
of an FID. Rather quickly, the spins begin to lose this phase coherence inducing a relaxation in 
transverse magnetization termed the spin-spin relaxation, or the T2 relaxation. If this relaxation 






Where 𝑡 is the time (milliseconds) following the flip into the transverse plane, and 𝑀0 is the 
initial magnetization. This transverse relaxation occurs much more rapidly than longitudinal 
recovery. Immediately following RF pulse, the spins can be considered as pressesing in phase 
with each other. Due to slight variations in magnetic field strength at both the microscopic and 
nanoscopic levels, these spins experience slightly different magnetic fields and therefore begin 
to precess at slightly different frequencies. These differences in precessional frequencies lead 
to magnetic interactions between neighbouring nuclei inducing further dephasing until the 
transverse component of the net magnetisation vector has a value of zero. Transverse 
relaxation follows and exponential decay curve described by equation 13. In any real-world 
experimental situation, this transverse relaxation occurs at a faster rate than we would 
normally predict via inter-spin nuclear interactions. The reason for this increase in rate of decay 
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is the inhomogeneities within the main magnetic field 𝐵0. These inhomogeneities arise due to 
a number of reasons including poor shimming, magnetic susceptibility at boundaries between 
different tissue types and the presence of magnetic particles. This accelerated 𝑇2 is referred to 
as 𝑇2
∗ and follows the same relaxation equation as previously described. This 𝑇2
∗ relaxation can 
be recovered using a spin echo acquisition, and the recovery is possible because the 𝑇2
∗ 
relaxation is not random, but rather is dependent on position within the field and is therefore 
not a true relaxation process.55  
The signal that is obtained from the FID obtained by measuring this relaxation is actually 
the T2*, which takes into account the inhomogeneities within the 𝐵0. Equation 14 shows that 













As the 𝑀𝑥𝑦 magnetization begins to relax, the z-magnetization that was flipped into the 
transverse plane begins to slowly recover so that it reaches the thermal equilibrium value of  
𝑀0. This phenomenon is termed the spin-lattice, or 𝑇1 relaxation, as it is influenced by the 
lattice of nearby spin systems. It may be defined by equation 15: 
 
 Equation 15 





Where 𝑀𝑍 is the component of magnetization along the longitudinal (z) axis, 𝑀0 is the 
unperturbed magnetization vector, 𝑡 is the time since recovery began and 𝑇1 is the relaxation 
constant that determines recovery54.  
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Fig 2.4 When a magnetic field gradient in the orientation of z is superimposed onto the 𝐵0 every local 
spin at position z is exposed to a unique magnetic field strength. The result is a location-dependent 
Larmor frequency. When the RF excitation bandwidth is chosen (∆𝜔) only magnetisation of the spins 
in slice ∆𝑧 will be excited into the transverse plane. In cartesian acquisition, the k-space is filled line by 
line. Each phase encoding gradient accounts for a separate line of the k-space. The data is Fourier 
transformed in order to create the image. 
 
 
2.6 Image Formation and Reconstruction 
The concept of utilising the NMR phenomenon in order to create an image can be traced back 
to the original experiments of Mansfield and Lauterbur in 197357. They showed that by 
applying spatially varying magnetic fields, or gradients,  spatially dependent precession 
frequencies  can be used to generate tomographic imaging planes57,58.  
 In an MRI system the gradients are resistive electromagnets that are embedded within 
the main body of the magnet and are used to modulate the main magnetic field creating spatial 
dependence in precession frequency. Three distinct gradient systems are used to modulate 
the field in the x, y and z planes respectively. These gradient systems are referred to as the 
phase encoding, frequency encoding and slice select gradients depending on the orientation 
of the imaging plane. The gradients combine in a linear fashion in combination with the 𝐵0 to 
produce magnetic field gradients that can be oriented in any direction. The three orthogonal 
directions created by these gradients spatially localise the NMR signal within a 3D space by 
altering the Larmor frequency with modulations of the magnetic field experienced by the spins  
as a function of distance along the given gradient. The spatial encoding procedure can be 
described in three steps. 
 First the slice selection gradient is applied (Gss). This is turned on simultaneously with 
the RF pulse and localises the excitation to a 2D plane with a thickness of Δ𝑧. The frequency of 




























centre on the Larmor frequency within a slice of tissue with thickness Δ𝑧. Where Δ𝑧 depends 
on the excitation bandwidth and the steepness of the Gss. 
 The second gradient applied in the acquisition of an image is the phase encoding 
gradient (Gpe). Application of this gradient causes the spins that have been excited by the RF 
pulse and Gss (the imaging plane) to precess at different frequencies along the direction of the 
gradient. Where the Gpe is lower than the 𝐵0 these spins will precess slower, and where it is 
higher than the 𝐵0, these spins will precess faster. The result of this is a phase shift that is 
dependent on the length and amplitude of the pulsed Gpe. The spins continue to precess at 
the same frequency after the Gpe is turned off, maintaining their phase shift with respect to 
their position along the Gpe. 
 The final spatial encoding gradient is the frequency encoding gradient, which is often 
referred to as the read out gradient (Gro), as it is applied for longer than the other two spatial 
encoding  gradients and coincides with the readout of the RF coil. Much like the Gpe, the Gro 
causes the spins to precess faster at higher gradient strength and slower at the lower end of 
the gradient. The RF coils detect the precession frequencies during the application of this 
gradient, resulting in a composite detection signal encompassing many different frequencies 
corresponding to all points along the Gro. This process is repeated for a series of different 
Gpe’s thus allowing the Gro to read out one line of phase encoded data per repetition. This 
process is continued until the whole field of view (FOV) has been sampled.  
 All the data acquired during the above process is done so within the time domain, and 
is stored as complex data points in a mathematic matrix known as k-space. Images are 
comprised of points distributed along x and y planes, whereas the datapoint within the k-space 
are distributed along the Kx and Ky. Each point in k-space contains both frequency and phase 
information (figure 2.4). In order to transform the data from the time domain in to the 
frequency domain, and therefore produce an image, Fourier transformation must be applied54. 
 
2.7 Gradient Echo and Spin Echo 
The order and composition in which gradient pulses are applied during an MR examination is 
referred to as a pulse sequence. The most common types of pulse sequence are gradient echo 
(GRE) and spin echo (SE) sequences. Following excitation into the transverse plane, spins 
undergo dephasing due to local inhomogeneities within the magnetic field.  During an SE 
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experiment, a 180 pulse is applied shortly after the excitation pulse. This causes the rotational 
direction of the dephasing spins in the transverse plane to become reversed, causing the spins 
to rephase again. As a result, spins will be in phase again, producing a spin echo exactly after 
twice the time between the excitation pulse and the 180 refocusing pulse. This is termed the 
time to echo (TE).  
 In a GRE sequence, the echo is achieved by intentionally dephasing and rephasing the 
frequency encoding gradient by application of a positive and negative gradient lobe, as 
opposed to application of a 180 refocusing pulse. During a GRE sequence only 1 RF pulse is 
applied, and the echo may be recorded much quicker when compared to a SE acquisition. This 
generally results in shorter TE and TR values, and this can facilitate rapid signal acquisition. 
Further to this, the gradient reversal is only capable of refocusing those spins that have been 
dephased by the application of the gradient itself. Therefore, phase shifts resulting from tissue 
susceptibility, magnetic field inhomogeneities or chemical shift are not cancelled out as they 
are during the SE acquisition. Image contrast is therefore dictated by inherent 𝑇2
∗.  
 
2.8 MR Spectroscopy  
Up until this point the discussion has been focused around the precssion of protons at a specific 
Larmor frequency which is determine by the gyromagnetic ratio and the strength of the 
magnetic field. However, it is important to note that the movement of electrons from other 
nuclei, both around and within a given molecule, has the ability to create an induced magnetic 
field 𝐵𝑖 that changes the local magnetic field 𝐵𝑙𝑜𝑐 that is experienced by the observed nucleus. 
This may be defined by equation 17: 
 
 Equation 17 
𝐵𝑙𝑜𝑐 = 𝐵0 − 𝐵𝑖 
 
As a result, the observed resonance frequency also changes and can be described by equation 
18: 
  
 Equation 18 
𝜔0 = 𝛾𝐵𝑙𝑜𝑐 
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Where 𝜔0 is the Larmor frequency in Hz, of the observed nucleus and 𝛾 is the gyromagnetic 
ratio. This deviation of the Larmor frequency of the observed nucleus away from the reference 
resonance frequency is known as the chemical shift. There is a requirement for the chemical 
shift to be independent of field strength, so that spectra acquired across different 
spectrometers can be compared. In order to achieve this field independence, chemical shift 
values (𝛿) are expressed with respect to the frequency of a reference nucleus proportional to 
the magnetic field in parts per million, which can be represented by equation 19: 
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Where 𝜔𝑟𝑒𝑓  is the Larmor frequency of the reference molecule - Trimethylsilyl propanoic acid 
(TSP) for 1H spectroscopy. The difference in electron distribution between molecules 
perpetuates different spin environments. These small differences in resonance frequency 
manifest as chemical shift and allow us to determine structural molecular properties. When a 
scan is acquired in the absence of magnetic field gradients the resultant FID contains all the 
frequency components. When the Fourier transform of this FID is taken, the result is a 
graphical representation of the observed frequencies from the individual nuclei of molecules 
along the horizontal axis52.  
 
2.9 Coupling  
The presence of two or more neighbouring spins either within the same molecule, or from an 
adjacent molecule, can cause the spins to perturb each other. Scalar, or 𝐽-coupling arises from  
interactions that take place between via bonding electrons. This coupling gives rise to the 












Fig 2.5 An energy diagram of both uncoupled and coupled spin systems, A (red) and B (blue). The large 
white arrow in the centre represents the nuclear spin state and the smaller white arrow in the periphery 
represents the electron spin state. Within an uncoupled spin system, the energy difference between 
the different energy states of A (Δ𝐸𝐴1) are equal, as are the energy differences of the transitions of 
nucleus B (Δ𝐸𝐵1). The two different energy differences are then reflected as single peaks on the NMR 
spectrum. When the spin systems are coupled, the nuclear spins of A and B are always aligned anti-
parallel to each other. This can force nuclear spins to be parallel with their electron spins, which is 
energetically less favourable. When both nuclear spins are anti-parallel to each other, and their electron 
spins are anti-parallel to their nuclear spin, this energy state is more favourable. This results in 4 distinct 
energy differences, namely Δ𝐸𝐴1 ≠ Δ𝐸𝐴2 and Δ𝐸𝐵1 ≠ Δ𝐸𝐵2 . This coupling results in the spitting of 
both the A and B peaks. 
 
the resonance from each of the spins split the peak into two symmetrical lines about the 
chemical shift known as a doublet. 𝐽-coupling is typically only observed when the nuclei are in 
close proximity and are not identical. There are two types of coupling, that seen between very 
similar nuclei, known as homonuclear coupling, and that seen between different nuclei, known 
as heteronuclear coupling52.  
 In order to explain the coupling phenomenon we must first revisit the understanding 
that spins may reside in two different energetic states, either as a high energy state (+⅟2) 
otherwise known as spin up (↑), or they may occupy the lower energy state (-⅟2) otherwise 
known as spin down (↓), where the cumulative difference between these two energy states  
Δ𝐸 gives rise to a single resonance frequency. One simple way of thinking about the two lines 
seen within a doublet is that they each represent the two possible spin states of the coupled 
spin, whereby one line represents the up (↑) state and the other represents the down (↓).  
 Let us now consider two spins, A and B, that are not coupled to each other (figure 2.5). 
There are four possible energy states that these spins may occupy, these are (A-up B-up ↑↑, A-
up B-down ↑↓, A-down B-up ↓↑, A-down B-down ↓↓), and possess the same probability of 
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occurrence. As the spin states may transition from one to another, there is an energy 
difference, Δ𝐸𝐴 corresponding with the spin-up to down transition of proton A from ↑↑ to↓↑, 
which is equal to the energy difference of the spin-down to -up transition (↓↓ to ↑↓). Similarly, 
there is also a distinct energy difference associated with the transitions of proton B between 
the different spin states  Δ𝐸𝐵. These two individual energy differences give rise to two separate 
peaks within the spectrum at the resonant frequencies of A and B (figure 2.5)52.  
 When spins are coupled to each other, the interaction between the nuclear spin and 
the electron spin can affect the energy states that are possible. In quantum mechanics it is 
stated that when electron spins are coupled, they must always be oriented anti-parallel to each 
other. A result of this rule is that nuclear spins that are coupled to each other are forced into 
a parallel orientation along with the electron spins (↑↑ or ↓↓), which in turn results in increased 
energy levels. When we consider the antiparallel nuclear spins (↑↓ or ↓↑), both the coupled 
electron spins, and the electron nuclear spins are antiparallel, which is energetically favourable 
(lower energy). The consequences of this are that the energy differences associated with the 
spin transitions are no longer equal to each other, and we now have four distinct spin 
transitions with corresponding energy differences. These four separate energy differences give 
rise to four individual resonant frequencies that can be observed as two split peaks, or 
doublets. The magnitude of this splitting and shifting away from the central frequency is 
typically expressed by the coupling constant 𝐽, which is field independent52.  
 
2.10 1H-13C 2D Heteronuclear Single Quantum Coherence Coupling (HSQC) NMR  
Although 1D NMR experiments are often sufficient for the identification of a wide variety of 
small molecules, larger, more complex molecules, and other small molecules that are severely  
overlapped by others, may be significantly harder to resolve from a 1D experiment. 2D NMR 
allows the supplement of an further set of experimental parameters that in turn result in the 
addition of a second dimension, which may facilitate ease in interpretation of such spectra.  
1H-13C 2D HSQC NMR is a technique that is used to correlate the 1H chemical shift with 
the 13C chemical shift using the 1𝐽CH coupling. This experiment relies on the transfer of 
detectable signal from nuclei with a low gyromagnetic ratio, to nuclei with a higher  
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Fig 2.6 The pulse sequence for a typical HSQC experiment. The sequence begins with an equilibrium 
magnetisation on the 1H which is transferred to the 13C via an IEPT sequence (parts A and B). The 13C 
spins evolve over time period 𝑡1 (part C) with a centrally placed 180 pulse on the 
1H in order refocus 
the evolution of the coupling. The magnetisation is then transferred back from the 13C to the 1H (part 
D). The spin echo allows the anti-phase signals to become in-phase and can then be observed using 
broadband 13C decoupling 
 
gyromagnetic ratio in order to increase the detectable signal. The HSQC experiment achieves 
this by applying an Insensitive Nuclei Enhanced by Polarization Transfer (INEPT) sequence, 
allowing a specified evolution time, and then a retro-INEPT sequence in order to transfer the 
magnetization back onto the 1H52. A diagram of the HSQC pulse sequence can be seen in figure 
2.6.  
The application of the first INEPT sequence involves a 90 pulse on the 1H followed by 
a 180 refocusing pulse of 𝜏/2 on both the 1H and the 13C channel. Following the 90 pulse and 
prior to the 180 pulse, an antiphase state is generated on the 1H spins. The 180 pulse allows 
the transfer of this antiphase state from the 1H to the 13C spins. Subsequent to the 
magnetisation transfer, following a time period of 𝜏/2, a 90 pulse is applied in order to flip 
the 13C spins into the transverse plane. This completes the first INEPT sequence, and the 13C 
spins now evolve for 𝑡1, whilst a centrally placed 180 pulse on the 
1H is applied refocusing the 
evolution of the coupling. Now the retro-INEPT sequence is applied in order to transfer the 
magnetisation from the 13C back to the 1H. This begins with the application of a 90 pulse on 
both channels to flip the 1H into the transverse plane, followed by a spin echo period, allowing 
the antiphase signals to become in phase, followed by detection on the 1H channel52. 
 The following chapters will discuss a number of investigations that both directly and 









3. Radiomics for the Detection 
of IDH Mutation 
 
3.0 Chapter synopsis 
Radiomics is a rapidly emerging and evolving field of image analysis, and has shown great 
promise in medical imaging diagnostics. This study explores the use of a radiomics approach in 
order to classify MR images of glioma into IDH Mut or WT. In order to achieve this a database 
of patient images that were acquired between 2016-2019 was analysed, and all glioma patients 
whom underwent IDH investigation, as well as T1 post-contrast and T2 imaging were included. 
All imaging studies that were included in the study underwent a series of normalisation steps 
in order to account of unwanted variability within the images. 
 This investigation specifically focuses on the utility of image texture features generated 
in python using third party software. These mathematically derived features reflect the 
distribution and interrelationship of the greyscales within the image. Here it is hypothesised 
that the presence of IDH mutation may induce micro-environmental changes within the 
imaged tissue that may, in turn, altered the spin environments of the protons that are 
manipulated during MRI acquisition in order to produce the signal.  
 The extraction of large amounts of imaging variables inherently facilitates the 
production of highly dimensional data. This study has explored a number of avenues for the 
handling of such data, including the use of genetic algorithms (GA) as well as random forests 
in conjunction with multi-way ANOVA. Although GAs have seldom been explored with respect 
to medical imaging data, they have been previously shown to perform well when dealing with 
micro-array data, which is often also plagued with the curse of high dimensionality59. Here the 
novelty of the use of GAs in imaging has been demonstrated, and future investigation may 
facilitate their more widespread use. Although GAs provide an elegant way of handling data 
with huge numbers of variables, a more convenient and less computationally demanding was 
required here, forming the rationale for the use of random forests. Although these popular 
classifiers allow for both feature selection and classification, it was shown that metadata 
associated with the acquisition of the images was introducing a large amount of unwanted 
variability, so further feature selection steps incorporating principal component analysis and 
multi-way ANOVA were used.  
 The results of this work may aid in the building body of evidence for the non-invasive 
classification of MR images into IDH Mut and WT.  
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3.1 Introduction  
3.1.1 Radiomics  
A biomarker may be defined as “a characteristic that is objectively measured and evaluated as 
an indicator of a normal biological process, pathological development or pharmacological 
response to therapeutic intervention”60. Biomarkers can be measured or obtained from a 
number of sources including tissue biopsy, blood, urine or imaging. The latter source provides 
both qualitative and quantitative information pertaining to a tissue, process or disease that 
one wishes to probe whilst remaining entirely non-invasive. Qualitative information requires 
interpretation by an expert clinician following years of training and is often subjected to 
fluctuating degrees of interobserver variability, whereas quantitative biomarkers are 
established on mathematical definitions that are standardised and transferrable.  
 The role of medical imaging in the assessment and management of cancer has evolved 
extensively over the past decade from a primary diagnostic tool into a central role in the 
context of individualised cancer treatment61. The use of investigatory methods such as 
genomics, metabolomics and proteomics have been the primary focus of personalised 
treatment strategies for many years62. However, the true spatial and temporal heterogeneity 
of tumours that is facilitated by local variations in factors such as oxygenation, blood supply, 
gene expression profiles, subpopulation evolution and metabolism are both common tumoral 
features, as well as integral to the treatment and management of the pathology63–65. Biopsy 
samples obtained through invasive and often risk-prone surgical procedures, taken from 
localised regions of the tumour, fail to reflect the inherent heterogenous landscape of the 
lesion66. Conversely, medical imaging is able to sample the entire pathology, non-invasively, 
multiple times over. A number of studies have postulated that genetic and molecular 
characteristics may be echoed in phenotypic manifestations that can be captured via medical 
imaging67–69.  
 The exponential growth in computing power and recent developments in machine 
learning techniques have allowed for the emergence of new processes for the extraction and 
analysis of quantitative features arising from the conversion of medical images into mineable 
datasets70. The term radiomics was first employed in 2010, when quantitative imaging findings 
were used to characterise the phenotype and environment of the tumour, reflecting gene 
expression71. A number of radiomics studies immediately followed, some of which highlighted 
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that the reliability and reproducibility of the calculated features was heavily dependent on a 
number of factors including image acquisition, reconstruction, pre-processing and 
segmentation72–76. The framework for this -omics based approach to imaging science was 
explicitly outlined by Lambin et al in 2012, and has since been utilised in almost all areas of 
medical imaging61.  
 The utility of radiomics in contributing to predictive and prognostic oncological models 
depends strictly on a basic 3 step workflow, namely 1. Image acquisition 2. Computation of 
radiomic features 3. Statistical analysis and machine learning. To fully extend any proposed 
model into a clinical setting, a prospective multicentre study would ideally be employed as a 
fourth and final step. Radiomics is offered as a supportive tool in clinical decision making, 
providing auxiliary evidence alongside other patient characteristics upon which diagnosis and 
prognosis can be suggested. Although the technique has been applied to a variety of different 
conditions, both within and outside of medical imaging, its application in oncology is probably 
the best described.  
 The mining of radiomic data in pursuit of correlation with genomic profile and 
mutational status has gained much traction since the advent of radiomics The value of this 
application is rooted by the fact that almost every cancer patient will undergo some form of 
imaging study during their care, and in fact most will have multiple imaging studies across 
several timepoints to monitor and track disease progression. However, not all of these patients 
will undergo genomic profiling. Moreover, when tissue samples are obtained for profiling, they 
are gathered from a distinct area of the tumour at a single timepoint, subjecting such 
investigations to sampling error.  
 
3.1.2 Methodology and Implementation  
Quantitative features of an image may be referred to as image texture, which is a reflection of 
pixel intensities, how they are distributed and the interrelationship between neighbouring 
groups of pixels. In this study the rationale for investigating if texture features are able to 
discern IDH mutation using the radiomics workflow stems from the fact that the mutation 
facilitates intracellular changes that are detectable via magnetic resonance spectroscopy 
(MRS). If those changes in cellular environment are detectable via MRS, then the same 
intracellular changes may invoke both macro and microscopic changes within images acquired 
of the same tumour. The differences within the images acquired may give rise to alterations in 
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image texture when comparing Mut tumours with WT.  Eventually, by combining both MRS 
and MRI findings, there would be a building body of evidence to non-invasively detect the 
presence of IDH mutation within clinical decision making. Texture analysis has the potential to 
measure whole tumour heterogeneity by correlating mathematically derived parameters with 
clinical outcomes in order to predict tumour biology77,78. 
 There is a requirement for the procurement of data to be used within the radiomics 
workflow to be acquired under stable conditions in a standardised manner. Clinical MRI data, 
however, is subject to a wide range of variabilities. The exponential advancement of the 
technology has led to an enormous range of both hardware and software for the acquisition 
and reconstruction of images being used in institutions worldwide. Radiomic features are 
subject to influence from parameters such as magnet strength, pulse sequence variation, 
signal-to-noise ratio and spatial resolution. There is some debate over the robustness of 
radiomic features and the models generated from them due to the presence of acquisition 
induced variability. Conversely, some studies, such as that conducted by Mayerhoefer et al, 
suggest that variations in acquisition protocols such as repetition time, echo time and sampling 
bandwidth have little-to-no effect on the features generated76. All medical images, including 
MR images, must undergo pre-processing prior to feature extraction. Pre-processing steps 
include image segmentation, interpolation, intensity normalisation, bias field correction, grey 
level quantization and filtration79.  
 The radiomics workflow has been outlined in figure 3.1 and consists of a number of 
pre-processing and feature calculation steps. All steps involved within the workflow can be 
carried out in commercial, open source or locally constructed software. Here we have used 
only opensource software that is freely available to download for any potential user. This is to 
hopefully facilitate the reproducibility of the study, so that any other centre is available to 
recapitulate the investigations free of charge. One of the first steps is image segmentation, 
which involves drawing a region of interest (ROI) either manually, automatically or semi-
automatically. It appears that features calculated from 3D volume of interests (VOI) are more 
reliable than those that are determined from 2D single slice areas of an image80. Furthermore, 
if the full potential of the radiomics workflow to reflect tumour heterogeneity is to be achieved, 
it would stand to reason that a 3D VOI would be more representative of the overall pathology. 
 To improve image matrix resolution and deal with potential mismatch of image 
acquisition parameters, image interpolation is applied to remap the original matrix onto an 
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isotropic grid spacing. For the generated texture features to be rotationally invariant, and so 
that images from different samples are comparable between cohorts, samples and batches, 
isotropic spacing is essential81. Texture features are sensitive to changes in voxel size, therefore 
image interpolation has the potential to heavily influence the end result of any radiomics 
investigation82. To enable reproducibility, consistent isotropic voxel spacing across all 
measures within a study is imperative. There is no clear consensus as to whether up-sampling 
or down-sampling is preferable in any given case, although there have been some studies, such 
as those conducted by Mayerhoefer et al that suggest up-sampling by transforming the original 
image into a higher matrix size can expedite improved texture classification83.     
 Following interpolation, image grey levels must undergo discretisation to reduce the 
intensity scale to make feature calculation tractable84. There are two distinct methods for 
image discretisation, namely fixed bin number and fixed bin size81. The optimal method of 
discretisation that yields the least inter- and intra-observer variability is modality dependant. 
It should be noted however, that only the fixed bin number method is suitable for images 
consisting of arbitrary units, such as those that make up most conventional MR images. The 
details of this method and its implementation will be explored later in this chapter. 
 Feature generation can encompass either or both agnostic or semantic texture features 
to be used in the radiomics workflow. Semantic features include location, shape, vascularity 
and necrosis, all of which may be quantified via a scoring system, however these are still 
subject to varying levels of inter-observer variability. Agnostic features are mathematically 
derived from assessment of the distribution, inter-relationship, and local variation of grey 
scales within the segmented region of the image. Hundreds, if not thousands of features may 
be generated per image using different combinations of filters and grey level matrices. One 
significant issue when dealing with such datasets, whereby the number of features to be 
analysed is greater than the number of samples is data dimensionality. Highly dimensional data 
is often subject to overfitting and inherently contains large amounts of redundant data. To 
overcome this, the use of classifier models such as support vector machine, regression models 
and random forests are used to reduce false discovery rate and to select the most 
discriminative features. We have explored a number of classifier options to probe the data for 
texture features that may be able to discern IDH Mut and WT from standard MR imaging. 
 Radiomics uses the agnostic features that reflect grey level value, interrelationship, and 
spatial distribution79. First-order statistics in radiomics originates from the histogram 
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projection of grey level intensities from within the segmented region of the image. Values that 
are calculated include the mean, median, standard deviation, skewness, kurtosis and entropy 
of the histogram. The mean is the average intensity of the image histogram and can be 
reflected in the brightness of the image. Standard deviation is the spread of intensities about 
the mean, whereby higher values indicate a large range of intensity values within the 
segmented ROI and may reflect increased heterogeneity of the underlying tissue within the 
ROI. Skewness is representative of the asymmetry of the histogram, and kurtosis is reflective 
of the magnitude of pixel distribution, whereby a more positive kurtosis indicates that the 
height of the histogram is taller than a normal gaussian distribution. Entropy depicts the 
irregularity of intensity distribution within the segmented region, where a high entropy value 
represents a heterogeneous distribution and may be indicative of a heterogenous tumour 
environment. 
 Second-order statistics look at examining the spatial relationship of intensity values 
within the segmented region by construction of grey level dependency matrices70,85. The 
concept of dependence matrices was first investigated with the advent of the grey level 
cooccurrence matrix (GLCM) by Haralick et al86. The GLCM explores the combinations of grey 
level intensities from voxels that make up the 3D volume in all directions. Over time the 
development of further dependence matrices has allowed for other intra-regional intensity 
relationships to be investigated. The grey level run length matrix (GLRLM) examines the 
number of consecutive voxels with the same intensity value, and the grey level zone length 
matrix (GLZLM) allows the quantification of groups of voxels with given values to assess the 
homogeneity of an area. Further to both first-order and second-order statistics, are higher-
order statistics that come from the application of filters or transforms, prior to feature 
extraction. The details surrounding the calculation of texture features and the various statistic 
levels will be discussed in further sections of this chapter in more detail.  
 
3.1.3 Radiogenomics in Glioma 
Radiomics refers to the general field in which patient images are converted to large mineable 
quantitative datasets that may be leveraged in pursuit of decoding tumour phenotype for 
clinical diagnostic and prognostic purposes. Radiogenomics refers to the application of 
radiomics by which imaging features are correlated with gene expression profiles/molecular 
phenotypes. The genetic profile of a tumour is used clinically to determine prognosis, diagnosis 
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and treatment strategy, as the genomic instability of a lesion represents one of the hallmarks 
of cancer. It therefore stands to reason that there has been a recent surge in popularity of 
radiogenomic studies that involve the application of the relatively new and rapidly evolving 
field of radiomics correlating with genetic profiles. 
Despite the basic outline, and the great promise offered in contributing towards clinical 
decision making, translation of radiogenomics into the clinic has been somewhat restricted by 
its own practice. The lack of reproducibility in a number of recent studies has highlighted that 
there is a clear unmet need to standardise the process, so that this emerging technology can 
eventually become incorporated into routine clinical practice. Computation of radiomic 
features is a convoluted and complex procedure, incorporating a great number of steps (figure 
2.1), which if not fully conveyed when published, can result in the misinterpretation and 
inaccurate reporting of both methodologies and results. Other key limitations accompanying 
a large number of radiomics-based studies include incorporation of high false positive rate, 
limited patient numbers and overfitting of proposed models. 
As a result of these shortcomings the image biomarker standardisation initiative (IBSI) 
was formed. The IBSI is an independent international collaboration with the aim of 
standardising the computation, extraction and usage of imaging biomarkers with the outlook 
of faster and more relevant clinical translation of quantitative imaging markers identified by 
high-throughput image analysis81.  
 
3.1.4 Scope of Study 
This study was set out to investigate the utility of radiomics in the classification of MR images 
into IDH Mut or WT based on imaging texture features for diagnostic purposes. Several 
methods have been employed in order to examine the possibility of constructing a translatable 
model in order to aid in the non-invasive determination of the presence of IDH mutation. The 
use of standard MR imaging alone (T1 and T2 -weighted) forms an important role in the 





3.2 Methods  
3.2.1 Data Collection 
This retrospective study was approved by the Walton Centre Research Tissue Bank research 
ethics committee (REC) approval (Reference number 15/WA/0385). All patients whose images 
have been included in this study submitted informed consent to be included in the study. 
Patients were originally identified for this study based on completion of IDH pathology test. All 
patients included in the study had been imaged between 2016 and 2019. IDH mutational status 
was confirmed by either histopathology or sequencing, or a combination of the two. The final 
pathological diagnosis, as given by neuropathology consultant, was taken as the mutational 
status for each patient included in the study. 486 patients were first identified, of which 303 
had 3D T1 contrast enhanced spoiled gradient echo imaging studies with repetition times (TR) 
8.1-9ms and echo times (TE) 1.4-3.1ms. Of these, 92 imaging studies were discounted due to 
poor image quality from motion and high levels of susceptibility artefact. This left a total of 211 
3D T1 contrast imaging data sets to be included in the investigation, of which 152 patients 
carried WT IDH, and 59 carried Mut IDH. Of the 486 patients, 208 Axial T2 imaging data sets 
were selected whereby the data was acquired using a spin echo sequence TRs 3000-6680ms 
and TEs 80-103ms. Of these axial T2 studies, 52 were discounted, again due to poor image 
quality due to the inclusion of imaging artefacts, leaving a total of 156 axial T2 imaging studies 
including 62 IDH Mut and 94 IDH WT patients. All images were anonymised and exported as 
DICOM images before being converted to NifTi format using MRICron software. All image 
acquisition parameters and patient demographics can be found in appendix 1. 
 
3.2.2 Pre-processing  
A number of pre-processing steps preceding radiomic texture feature extraction were 
optimised for this investigation. Pre-processing steps were carried out using a combination of 
Advanced Normalisation Tools (ANTs)87 toolbox, 3D slicer88 and Pyradiomics89. An outline of 
the steps followed in the processing of images and extraction of features can be found in figure 
3.1. The first pre-processing step was to correct for intensity inhomogeneity within the images. 
Intensity inhomogeneity, bias or gain field is a potential confounder in any MR image analysis90. 
The term refers to the low frequency, non-anatomical variation in signal intensity of the same 
tissue class over the image domain, and its presence can heavily impede on quantitative image 
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Fig 3.1 A scheme to demonstrate the steps taken to achieve image feature calculation whilst following 
the IBSI guidelines for image biomarker identification. Boxes in blue describe the number of pre-
processing steps to be carried out across the entire raw data image stack. Boxes in green indicate pre-
processing steps prior to feature calculation stipulated by the IBSI. Following image segmentation (into 
both whole brain and tumour volume) this ROI may then be processed into two entities, intensity mask 
and morphological mask. This is only required for absolute units, since this study is concerned with the 
arbitrary units of MRI, only the morphological mask is required. Both the image and the morphological 
mask must be interpolated to produce rotational invariance. Feature calculation can be seen in the red 
boxes and classified into a number of families: IH: intensity histogram; IVH: intensity volume histogram; 
GLCM: grey level co-occurrence matrix; GLRLM: grey level run length matrix; GLSZM: grey level size 
zone matrix; NGTDM neighbourhood grey tone difference matrix; NGLDM: neighbourhood grey level 
dependence matrix; GLDZM: grey level distance zone matrix. Adapted from Zwanenburg et al.81  
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biomarker calculation and extraction91. For this study the N4BiasFieldCorrection algorithm 
within the ANTs toolbox was used to correct for this potential source of error92. The 
N4BiasFieldCorrection uses a B-spline approximator that allows greater control at magnetic 
field strength of 3T and above than its predecessors, permitting the specification of a mask to 
allow smaller control point spacing. The advantages of these features include multiresolution  
approximation strategy which employs hierarchical fitting of sequentially higher levels of 
frequency variation of the bias field, and an iterative incremental update of the bias field92. To 
implement these features and achieve the optimal intensity inhomogeneity correction output, 
a region mask must be generated prior to application of the N4 correction algorithm.  
To generate a binary brain mask the AntsBrainExtraction.sh wrapper function, part of 
the ANTs toolbox, was used87. This function requires an atlas, an intensity mask and an optional 
extraction mask along with the input image, to carry out parameterised B-spline registration 
step of the extraction process. There are a number of publicly available datasets that exist to 
generate such atlases using the BuildTemplateParallel.sh function within the ANTs toolbox. A 
number of templates were constructed from publicly available datasets to both generate 
individual whole brain binary masks for each patient, as well as accurately removing the skull 
and meninges from around the brain. Multi-subject templates are designed to possess features 
that are representative of an entire population, therefore the higher the number of datasets 
contributing to the creation of a template, the more likely such a template will possess mutual 
information relating to the subject dataset that the template is being warped to. Initial 
experiments were carried out using the LPBA40 dataset93 to create an atlas for use in the ANTs 
brain extraction algorithm. Further optimisation steps used both the Kirkby94 and NKI95 
datasets, consisting of 21 and 10 subject respectively, to create suitable atlases. The template 
that was found to produce the optimal brain extraction result and therefore the most accurate 
binary brain mask was created from the IXI dataset96. This dataset contained T1 pre- and post-
contrast images along with T2 images from 600 patients. T2 FLAIR templates were downloaded 
from the brainder database97. To assess the performance of each of the template on the ability 
to delineate the brain region from the skull on each of the images, the extracted images from 
the BrainExtraction.sh wrapper function used to create the binary brain mask were visually 
inspected.  
 Following construction of the optimal template, intensity mask and extraction mask, 
each patient dataset was corrected for intensity inhomogeneity. To ensure that each patient  
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Fig 3.2 Example of tumour segmentation result. Only the enhancing region of the tumour was included 
in the segmentation, as this is the active part of the tumour, and will provide the least amount of inter-
patient variability. The central region of the tumour was not included in the segmentation for feature 
calculation as it can contain varying amounts of active tumour and necrotic regions. Inclusion of this 
region is a potential source of bias when considering statistical analysis. (a) GBM patient axial view of 
segmented tumour whereby the enhancing region has been included and all other parts negated. (b) 
sagittal view of segmented tumour. (c) Coronal view of the segmented tumour (d) Superior view 3D 
rendering of the extracted brain (transparent green) with a 3D rendering of the segmentation result in 
situ (solid pink). (e) lateral view of the 3D tumour and brain. (f) Anterior view of the 3D tumour and 
brain. 
 
dataset and its mask were in the same physical space, the header information from the patient 
image was copied onto the mask image. The parameters used for the N4 algorithm were: 
number of iterations 100x100x100x100, convergence factor 0.00000001 and spline distance 
200. The rationale for the conduction of the intensity inhomogeneity correction prior to brain 
extraction and removal of the skull and meninges is such that the subsequent registration steps 
involved in the brain extraction algorithm use a combination of rigid, affine and deformable B-
d. e. f. 
a. b. c. 
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spline registration models to map the atlas image onto the patient data. If low frequency field 
inhomogeneity were to persist throughout the image during these steps, the registration 
would be sub-optimal as the brain extraction algorithm presumes a given grey level intensity 
range for a certain tissue class. 
For this step the previously constructed extraction template, built using the IXI dataset 
was used. The brain probability mask, also generated using the antsBuildTemplateParallel.sh 
function was specified. In addition, a brain extraction registration mask was specified to limit 
the metric computation to within a specific region. All other parameters were kept as default.  
Subsequent to brain extraction, a region of interest in which radiomic features were to 
be calculated was generated. Here we looked at two regions of interest, both the whole brain, 
for which the brain mask generated as an output from the previous brain extraction step was 
used, as well as the enhancing region of the tumour. For this study we chose to include only 
the enhancing region of the tumour, as seen on T1 post contrast images, as this region 
represents the most aggressive area of the disease98. Furthermore, calculation of radiomic 
features from within this region alone should allow the most homogenous sampling, as the 
inherent heterogeneity of gliomas means that inclusion of the entire tumour will introduce 
varying proportions of necrotic regions, proliferative regions and invasive borders. In a further 
attempt to adhere to the previously described image standardisation methods, and to reduce 
variability and eliminate bias from the application of statistical methods, only the enhancing 
region of the tumour was used. To segment the enhancing region of the tumour on all T1 post 
contrast images, a semi-automated approach was adopted. For tumour segmentation 3D slicer 
was utilised along with the segmentation wizard module99. For this process an initial ROI 
encompassing the entire tumour volume was delineated using the model marker placement 
tool. Next a thresholding range was determined to eliminate non-enhancing voxels. The 
resultant segmentation was then reviewed and edited using the paint tool to exclude any blood 
vessels or residual meningeal tissue that remained from brain extraction, that may have been 
included within the enhancing threshold range. A number of T1 post-contrast images were 
excluded at this point, as the tumour was too small and close to the skull and not 
distinguishable from meninges, or the enhancing region was too small to calculate texture 
features across. A total of 131 IDH WT tumours were included, along with 24 Mut tumours, 
giving a total of 155 patient images to be included in the intra-tumoral analysis. An example of 
a segmented T1 post contrast tumour region can be seen in figure 3.2 
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Once the region for quantitative feature generation had been determined, the pre-processing 
steps required to normalise the images with respect to intensity distribution and spatial 
division ahead of feature calculation can be carried out. For this process a .yaml text file was 
written to be used as an argument in the command line implementation of pyradiomics, the 
software of choice for feature calculation100. Image texture features require isotropic voxel 
spacing so that they are rotationally invariant and to facilitate evaluation of images derived 
from different patients and cohorts81. A large number of imaging texture features are 
susceptible to alterations in voxel size, therefore image interpolation can have a significant 
effect on the texture features generated. To facilitate reproducibility, it is crucial to maintain 
isotropic voxel spacing. Interpolation algorithms aim to translate image intensities from the 
original image grid to a revised interpolation grid. When considering such grids, it is important 
to remember that voxels are spatially represented by their centre. Here we used ITK B-spline 
interpolator due to the computational efficiency and increased accuracy of point estimation 
using the generation of third order polynomials derived from large neighbourhoods of intensity 
values at every voxel centre. The use of this interpolation method can incur out-of-range 
intensities in acute intensity transitions, however it is also likely to enhance the preservation 
of tissue contrast differences. The resampled pixel spacing was set at 1.0x1.0x1.0 for T1 post 
contrast images and 2.97x2.97x2.97 for T2 images. These spacings were determined by 
calculating the mean voxel spacing in the x and y plane from a sample of 50 representative 
images included within each cohort.  
To render the calculation of image features tractable, image discretisation is 
required101. There are two potential approaches to discretisation, one involves the 
discretisation to a fixed number of bins and the other to a fixed bin width. However, the fixed 
bin number method is not recommended when dealing with arbitrary image intensities such 
as in MRI, as this method maintains a direct relationship between the original image scale, 
which in MR images can vary immensely between different patient, scanners, protocols and 
centres. For this reason, the fixed bin number method was be used, whereby the grey level 














Let 𝑋𝑔𝑙,𝑘  be the intensity of voxel k that has been corrected to the lowest occurring intensity 
value 𝑋𝑔𝑙,𝑚𝑖𝑛 observed within the ROI, divided by the bin width 𝑋𝑔𝑙,𝑚𝑎𝑥 − 𝑋𝑔𝑙,𝑚𝑖𝑛/𝑁𝑔 and 
rounded up to the nearest integer. This method allowed us to impart a normalisation effect on 
the data, which is very useful when handling arbitrary units in MRI where an image intensity 
range can be enormous. It also allows us to maintain contrast within the image. Other 
variations of intensity discretisation have been described and used, such as intensity histogram 
equalisation102, however this method alters contrast and may impact image texture. Here we 
used 64 bins to discretise the images.  
 Other additional setting parameters were also used to standardise the images ahead 
of feature extraction. The ‘correct mask’ parameter was selected, which uses a nearest 
neighbour interpolator to resample the mask to the image geometry. As a Laplacian of 
Gaussian filter was applied, a pad distance of 3 was selected. Filters were also applied to images 
for additional feature extraction. Laplacian of Gaussian filter was applied for edge 
enhancement, with sigma vales of 1.0 and 3.0. The lower sigma value enhances finer features 
within the image, and the greater sigma value will enhance the more coarse features. A 
wavelet bandpass filter with a bin width of 10 was also applied, yielding 8 decompositions per 
level, which is equal to all possible combinations of applying either a high or low pass filter in 
each of the three dimensions. Pyradiomics utilises the parameter file containing the 
specifications for pre-processing settings as an argument during the input of each image. The 
above listed settings were applied to each image immediately prior to feature extraction. 
 
3.2.3 Feature Calculation  
Feature calculation is the final image processing step to generate quantitative data that can be 
assessed using machine learning. This step is where feature descriptors are used to quantify 
attributes within the defined ROI. Here we generated features from the following classes: 
1. First order statistics (19 features) 
2. Grey level cooccurrence matrix (24 features) 
3. Grey level run length matrix (16 features) 
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4. Grey level size zone matrix (16 features) 
5. Grey level dependence matrix (14 features) 
All feature calculation was carried out in Pyradiomics89. All of the feature classes were 
calculated on both the original images, as well as all images derived from application of the 
aforementioned filters. All matrices from which the texture features are calculated are both 
translationally and rotationally invariant.  
 Here we chose to pursue texture features in order to classify the images into IDH Mut 
or WT as these are mathematically defined, well reported and easy to calculate with third party 
software such as PyRadiomics100. Further to this, the different filters that were applied were 
chosen due to their ability to enhance and supress different clusters of greyscale groups within 
the images. 
3.2.3.1 First order statistics  
First order statistics describe how grey levels within the specified ROI are distributed. 
3.2.3.2 Grey level cooccurrence matrix 
The grey level co-occurrence matrix (GLCM) is a matrix that is able to quantify the relationship 
that discretised grey level intensity values of neighbouring voxels by expressing how their 
combinations are distributed along a given direction. When we are considering a 3D volume, 
such as in this study, the GLCM is a neighbourhood that consists of 26 connected voxels in all 
three dimensions. Within the 3D volumes in this study, there are therefore 13 individual 
direction vectors within such a neighbourhood when we consider the voxel distance as 𝛿 = 1. 
These vectors are: (0, 0, 1), (0, 1, 0), (1, 0, 0), (0, 1, 1), (0, 1, −1), (1, 0, 1), (1, 0, −1), (1, 1, 0), (1, 
−1, 0), (1, 1, 1), (1, 1, −1), (1, −1, 1) and (1, −1, −1). 
 Once the above spatial relationship has been defined, we calculate the GLCM. Let 𝐌𝐗 
be the 𝑁𝑔 x 𝑁𝑔 co-occurrence matrix, where 𝑁𝑔 is the number of discretised grey levels seen 
within the ROI intensity mask, and x is a specific direction vector. Element (𝑖, 𝑗) of the matrix 
describes the frequency at which the arrangements of grey levels 𝑖 and 𝑗 arise in neighbouring 
voxels along the direction 𝐱+ = 𝐱  and along the direction𝐱− = −𝐱. Therefore we have 𝐌𝐗 =
 𝐌𝐗+ + 𝐌𝐗− = 𝐌𝐗+ + 𝐌𝐱+
𝑇  103. The following two dimensional example demonstrates how 




1 2 2 3
1 2 3 3
4 2 4 1
4 1 2 3
] 
 
The GLCM for 𝐌𝐗+ =→  then beomes: 
 
𝐏 = [
0 3 0 0
0 1 3 1
0 0 1 0




And the GLCM for 𝐌𝐗− =←  becomes: 
 
𝐏 = [
0 0 0 2
3 1 0 1
0 3 1 0
0 1 0 0
] 
 
To achieve rotational invariance, the GLCM texture feature values are calculated following 
aggregation of information from the different matrices. There are a total of 24 different texture 
features that are calculable from the GLCM in accordance to the IBSI guidelines81.  
3.2.3.3 Grey level run length matrix 
Grey level run length based features (GLRLM) were introduced by Galloway104 and are an 
additional image texture feature to asses homogeneous runs of grey level intensities 
throughout a discretised image stack. A run length is defined as a number of consecutive voxels 
with the same intensity value along a given direction x as previously defined above. In the 
GLRLM of 𝐏(𝑖, 𝑗|𝐱), the (𝑖, 𝑗)𝑡ℎ element describes the number of occurrences of runs with the 
length 𝑗 for the discretised value 𝑖. The two dimensional example below demonstrates the 
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3 3 3 1 3
2 1 1 1 3
4 2 2 2 3







    








1 0 1 0 0
3 0 1 0 0
4 1 1 0 0
1 1 0 0 0






    
If we consider the above matrix, 𝐌𝐗 is the 𝑁𝑔 × 𝑁𝑟 GLRLM, in which 𝑁𝑔 is the total number of 
discritised grey level intenisites present within the defined ROI, and 𝑁𝑟 is the longest possible 
run length direction along vector 𝐱. The matrix element 𝐏(𝑖, 𝑗|𝐱) of the GLRLM is the 
occurrence of the given grey level 𝑖 of run length 𝑗. 𝑁𝑧(𝐱) is the total number of runs along the 
given direction 𝐱 which is equal to: 
 







A total of 16 high order statistic texture features can be calculated from the GLRLM when 
following the IBSI guidelines81 
 
3.2.3.4 Grey level size zone matrix  
In addition to the GLCM and GLRLM, texture feature may also be calculated from the grey level 
size zone matrix (GLSZM). This matrix allows quantification of groups, or zones of grey levels. 
A zone may be defined as a group, or neighbourhood of connected voxels that share the same 
grey level intensity105. Whether a voxel lies within a given neighbourhood is dictated by its 
connectedness. Here we are looking for voxels connected to all 26 neighbouring voxels in all 3 
dimensions. By definition the GLSZM is always rotationally independent, whereby one matrix 
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0 0 0 1 0
1 0 0 0 1
1 0 1 0 1
1 1 0 0 0







There are a total of 16 features calculable from the GLSZM that agree with the IBSI guidelines81. 
 
3.2.3.5 Grey level dependence matrix  
The GLDM is focussed around the concept of a neighbourhood of connected voxels within a 
specified distance 𝛿 that are dependent on a central voxel. A neighbouring voxel 𝑗 is deemed 
to be dependent on the central voxel with the grey level 𝑖 if |𝑖 − 𝑗| ≤ 𝑎. In a grey level 
dependent matrix 𝑷(𝑖, 𝑗) the (𝑖, 𝑗)𝑡ℎ element describes the number of times a voxel with the 
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0 1 2 2
1 2 3 0
1 4 4 0
1 2 0 0











3.2.4 Feature Selection Using GALGO Genetic Algorithm 
The application of filters and the utilization of all calculatable features from the above four 
matrices, along with the inclusion of first order features, resulted in the generation of 973 
variables for each patient image. As this number supersedes the number of participants within 
the study (211 T1 and 156 T2 datasets), there is a requirement to reduce the data 
dimensionality to eliminate redundant features that may not contribute to the molecular 
classification of tumours. Here we have used a software package GALGO, which is 
implemented in the statistical programming environment R and utilises genetic algorithms 
(GA) to solve variable selection problems.. Although this group of algorithms has seldom been 
explored within the context of medical image analysis, especially in the field of radiomics, they 
have shown to be effective when applied to highly dimensional micro array data, and the 
dimensionality of the dataset in this study shares some characteristics59. The value of this 
approach is rooted in the splitting of data into a large number of small models and finding the 
best combination of variables over several iterations.  
  The primary goal of this study is the selection of texture features whose profile, in some 
way, associates with the IDH mutational status of the glioma that was imaged. In statistical 
language this is known as ‘supervised classification’, and there are a number of different 
methods that can carry out ‘tests’ to determine if the texture features that we have generated 
from the images are able to distinguish the tumour phenotype. The methods of testing can be 
subdivided into either univariate or multivariate methods. Univariate methods look to evaluate 
each variable (e.g. texture feature) one at a time, to determine its ability to discriminate 
between to the testing groups (e.g. IDH Mut vs IDH WT). Such methods have been shown to 
perform well in certain circumstances, such as applications in functional genomics106,107. These 
methods, however, have been found to be ineffective when applied to complex biological 
questions. One conceptual limitation when applying such methods to highly dimensional 
imaging texture data is that the derivation of features is not always obvious, and there may be 
varying factors that can be attributed to a myriad of physiological processes within the tissue 
being imaged that contribute to their eventual calculation. It is therefore important to assess 
how these features perform as a group in being able to distinguish between the two 
histological subtypes. Multivariate methods may be more suited for the analysis of such data, 
since variables are considered in combination to identify interactions between imaging  
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Fig 3.3 a Flow diagram to demonstrate the stages of the GA approach to feature selection prior to 
classifier construction. If the chromosome fitness function score, awarded based on accuracy of 
classification, reaches above the pre-defined level, then the process is terminated as a solution has 
been reached.  
 
features and disease state. There are, however, an excessively large number of possible models 
that may be constructed from different combinations of the hundreds of texture features and 
it is not possible to critically evaluate these using the available computing resources. One 
possible alternative to this in depth scrutinization of each of the individual model, is to use a 
search procedure that is able to ‘explore’ looking for sets of variables that are good  at 
classification, but perhaps not optimal. This procedure has been demonstrated and applied 
successfully in the context of microarray data108–110. GALGO is a software package that 
supports the development of statistical models using multivariate variable selection 
strategies111.  
 GAs work by applying in silico models of evolution by natural selection as search 
procedures for variable selection. This process works by evolving sets of chromosomes (groups 
3. Is the 
fitness > 
goal?
4. New chromosome formed: 
reproduced proportionally to 
the fitness
5. Random Crossover 
between chromosome 
pairs
6. Random mutations on 
new population of 
chromosomes
SELECT
1. An initial population of 
chromosomes is formed 
from random genes
2. Chromosomes are 
evaluated using the pre-
defined fitness function
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of variables) that are able to fit a certain set of criteria (fitness function) from an initial random 
population through cycles of differential replication, recombination and mutation of the fittest 
chromosomes. The concept of applying a model of evolution  to explore sets of variables to 
find those that are ‘good’ for discrimination between testing groups was first introduced by 
John Holland in 1975112. The popularity of GAs increased phenomenally once sufficiently 
powerful computers became readily available. Below is a description of how general GAs work, 
broken down into stages (figure 3.3): 
Stage 1: From the input data, a number of random sets of variables (chromosomes) are 
created. These sets of variables (chromosomes) can form a population of chromosomes 
(niche). 
Stage 2: The ability of each of the chromosomes within the niche to predict the group 
membership of each of the samples is assessed (fitness function). This is accomplished by 
training a statistical model. The GA then tests the accuracy of prediction of each of the 
chromosomes and assigns a score based on the accuracy, which is referred to as the fitness 
function. 
Stage 3: When a chromosome is awarded a score that is higher than the predefined fitness 
function, this chromosome is then selected and the procedure stops. If the cut off score is not 
reached, then the procedure continues onto the next stage. 
Stage 4: The population of chromosomes is replicated, whereby the strongest chromosomes 
with the highest fitness function scores will generate more offspring.  
Stage 5:  The information contained within the chromosomes is combined through the process 
of genetic crossover. This involves taking two randomly selected chromosomes and swapping 
sections of variables between them. By employing this method, it is possible to increase the 
search capacity for possible solutions. 
Stage 6: Mutations are randomly introduced into chromosomes, by way of adding, deleting 
and swapping individual variables. 
Stage 7: The process loops back to stage 2 until a chromosome that is accurate enough is 
produced.  
For the calibration of GLAGO the following parameters were used. K-nearest neighbour was 
the classifier of choice, chromosome size:10, max solutions: 200, goal fitness: 0.80, save 
frequency:30. Due to the imbalance in sample size of each testing group, whereby there were 
much fewer Mut patients when compared to the WT patients (which is representative of the 
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normal distribution), we attempted two approaches at correcting for this.  The first approach 
was to subsample the data by creating a subsample index in R, and the second method was to 
introduce a weighted error.  
 
3.2.5 Random Forest for Radiomic Classification of IDH Mutation  
The large number of texture features generated (973) compared to the relatively smaller 
sample size can result in overfitting of classifiers. Furthermore, within the data there may be 
varying degrees of correlation and redundancy between many of the generated features. In a 
further attempt to optimise feature selection with respect to classification of tumour IDH 
status we employed a random forest classifier approach to select and optimise the feature set. 
Random forests was chosen as an alternative route of investigation to the GA approach as it 
also works by assessing a vast number of small models to find the best combination of variables 
for classification, however it is much less computationally expensive and results can be 
generated much more rapidly. 
Although canonical classification approaches such as support vector machines have 
demonstrated utility in a wide variety of classification problems, the large and heterogenous 
nature of the training data available from texture feature generation in radiomics 
investigations is considered to be beyond the capacity of single classifiers113. This has led to 
the adoption of ensembles of classifiers, bagging and boosting, to address such problems. This 
approach uses a great number of simple models that are trained on parts of the data, followed 
by aggregation of their predictions onto new data. Random forests uses the bagging method, 
whereby the algorithm draws on training examples to a subset of features when training the 
simple, ‘weak learner’ models114. This forms a major part of the rationale as to why random 
forests were the classifier of choice for this part of our investigation, as it provides consistent 
proficiency in the estimation of information value of each of the individual predictor variables 
for accurate classification.  
Here we used the ‘mlr’ package within R to fit a random forest model to these data. 
The structure of the random forest algorithm is such that feature selection comes under the 
category of embedded methods, whereby such algorithms combine the qualities of filter and 
wrapper methods. Random forests are constructed from large groups of decision trees, 
whereby each of the decision trees are built under a random extraction of observations form 
the dataset, and a random extraction of features. Each tree within the forest can only select 
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variables from a subset of features, forcing variation amongst the trees within the model and 
facilitating feature selection and filtering. Furthermore, the construction of an ensemble of 
uncorrelated models allows us to build an overall classifier from a large number of variables 
that can allow accurate predictions. 
 An initial random forest model was fit with default parameters where the data was 
split 2/3 train 1/3 test. A receiver operator curve (ROC) was fit and the mean misclassification 
error was generated. We then carried out K-fold cross validation to assess the performance of 
the model. K-Fold  cross validation is a popular method of carrying out model validation as it 
generally results in a less biased model compared to other methods, as it ensures that every 
observation from the original dataset has the chance to appear in the training and test set115. 
Here we used 10 fold and 5 repetitions resulting in a total of 50 iterations. A ROC was fitted for 
each of the iterations, and a mean ROC was fit to display overall performance. Accuracy, 
precision (equation 20), recall (equation 21) and F1 scores (equation 22) were calculated. 
Accuracy is calculated by dividing the number of correct predictions by the number of total 
predictions. Precision can be defined as: 
 
Equation 20 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =  
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
 
 
Recall is calculated using equation 21: 
 
 Equation 21 
𝑅𝑒𝑐𝑎𝑙𝑙 =  
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
 
 
F1 score is calculated using the formula described in equation 22: 
  
Equation 22 






Factors of tumour size, cellular pathological origin (oligodendroglioma, astrocytoma 
and primary/secondary glioblastoma) and scanner manufacturer were also taken into account. 
Due to the dependence of some of the features on scanner and tumour size, a further variable 
selection approach was adopted. Spearman correlations were calculated to assess the 
influence of tumour size over the descriptors. A multiple linear model approach was adopted  
 
Fig 3.4. Axial slices from the 4 templates constructed from public MRI dataset libraries of 
varying sample size. (a) Template constructed from the LPBA40 dataset consisting of 40 healthy 
volunteer images. (b) Template constructed from the Kirkby dataset consisting of 21 healthy 
volunteers. (c) Template constructed from the NKI dataset consisting of 60 datasets. (d) 
Template created from the IXI dataset, consisting of 600 healthy scans. As the number of 
datasets increases the registration mismatch errors become averaged out and the likelihood 
of sharing mutual information with the target image increases. 
 
to assess the potential influence of factors such as tumour pathology, scanner manufacturer, 




forest model was fit following the same procedure as previously described using variables 
where IDH status was important  but other factors were not. 
 
3.3 Results  
3.3.1 Brain Extraction Optimisation 
The template created from the LBPA40 dataset was formed by averaging 40 datasets from 
healthy volunteers. The quality of multisubject templates created by averaging various subject 
image datasets is dependent on how well they are registered to one another. Potential 
mismatch errors are more likely to be averaged out as the sample size increases, thereby 
increasing the quality of the template and the likelihood of the presence of mutual information 
with the subject dataset to which the template is being registered to. The performance of each 
of the brain extraction attempts using the various constructed templates has varied, whereby 
varying levels of skull and meninges remained in the images post-extraction. Figure 3.4 shows 
axial slices from each of the constructed templates. Upon visual inspection the template 
constructed from the IXI dataset seemed to perform the best as there was the minimum 
amount of skull remaining on these images when compared to other templates such as the 
one constructed from the LPBA40 dataset (figure 3.5). 
 
3.3.2 GALGO for Feature selection 
3.3.2.1 T1 post-contrast whole brain analysis  
 Figure 3.6 shows the fitness function plot from the initial GALGO  investigation using T1 
post-contrast whole brain texture features. This plot allows us to analyse whether or not we 
are managing to get solutions from the GA. Here we are able to see the evolution of the fitness 
function value across the generations of chromosomes. We were able to determine that on 
average, we are reaching a solution at generation 69. The two lines show the average fitness 
for all the chromosomes, as well as those that have not reached the pre-defined fitness 
function respectively. Once the chromosomes have been selected by determining those that 
surpass the fitness function, we need to assess the classification accuracy. GALGO uses the 
bootstrapping method to estimate the error of the models, whereby the error is determined 
by averaging estimates calculated from multiple small samples of the data. The samples of the  
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data from which the individual errors are estimated are constructed by drawing observations 
from the dataset one at a time and then replacing them to the dataset once they have been 
chosen. This is an optimal strategy for error estimation when sample sizes are relatively low. 
Figure 3.7 shows the confusion matrix box plots for the models derived from whole brain T1 
post contrast texture features. The low sensitivity of Mut detection (0.28) seen in figure 3.7 (a) 
may be attributed to the imbalance in the sample size of the testing groups.  
 
Fig 3.5. Comparison between the brain extraction result and mask generation results 
generated from the LPBA40 and IXI constructed templates. (a) Superior section of extracted 
brain, the MR image underneath is the result from extraction using LPBA40 generated 
template, and the red overlay is the result from the IXI generated template. It is evident that 
there remains a relatively large proportion of skull and meningeal tissue from the LPBA40 
extraction (white arrows). (b) Mid axial view (c) Inferior axial view. (d) 3D render of extraction 
result. Green: LPBA40 extraction. Red: IXI extraction. The comparison here is most evident 
when looking at the temporal horn (yellow star). (e) 3D Extraction result from IXI template. 
There is no evident meningeal of skull tissue remaining. (f) Sagittal view. (g) Coronal view 
procedure, the images experienced a large amount of residual skull and meninges.  
a. b. c. 
d. 





Fig 3.6 A fitness function curve for the initial GALGO experiments using data derived from T1 post-
contrast whole brain texture features. Here we are able to determine that we reach the fitness 
threshold of 0.8 by generation 69 of the chromosomes. 
  
























Fig 3.7 A box plot to highlight the distributions of the averages of class prediction for each class.(a) class 
confusion calculated from whole brain T1 post-contrast images without application of subsampling in 
order to account for the imbalance in Mut vs WT. The poor sensitivity of the model when predicting 
Mut tumours may be accredited to this imbalance (b) class confusion calculated from the same dataset 
however this time a subsampling routine was introduced prior to the configuration of GALGO in order 
to account for the imbalance in group sizes. Despite the attempt to correct for this imbalance the model 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig 3.8 Plot to demonstrate the forward selection strategy for the models generated from the GA using 
the most frequent genes. The horizontal axis represents the genes ordered by their rank and the vertical 
axis displays the overall classification accuracy. The coloured dashed lines represent the accuracy per 
class. The thick black line represents the one model that resulted from selection whose fitness value is 
maximum (number 3). However, as we can determine from here, the classification accuracy of this 




In an attempt to account for this, a subsampling routine was introduced prior to the 
configuration of the GA, artificially balancing the size of the testing groups. Despite this 
approach the sensitivity of Mut detection remained very low, as the classification error of each 
of the proposed models was high. This can be seen in figure 3.7 (b).  
Despite the poor performance of the models generated from the configuration of the 
GA in classification of Mut tumours from whole brain texture features, we wanted to explore 
the capabilities of GALGO further and determine how either successful or unsuccessful the 
resultant model would be at classification. The outcome of the GA is a large number of 
chromosomes (groups of features), all of which provide good solutions that ideally surpass the 
pre-defined fitness function, however it is not clear which one should be chosen to develop a 
classifier. Therefore, there is a requirement to build one model that is representative, in some 
way, of the population. Figure 3.8 is a forward selection plot of the best models using gene 
frequency and average fitness to determine success. This selection is carried out by assessing 
the fitness function within all test sets. Model number 3, containing 36 of the most frequent 
genes (features), performed the best in terms of accuracy, however even though this was the 
best performing model, the classification error was  0.7194.  
Figure 3.9 shows a heatmap generated from the best model as a result from forward 
selection whereby hierarchical clustering has been carried out on both the genes (texture 
features) in rows and samples in columns. Although there is clustering of the variables within 
this heatmap, is evident that this is not correlated with IDH mutational status. Further to this, 
Figure 3.10 displays a principal component analysis (PCA) plot of the first 4 principal 
components. There appears to be no separation between the IDH Mut and WT groups based 
on the PCA plot of the best performing model as a result from forward selection.  
 Taken together there was no discernible set of texture features, derived from T1 post-
contrast whole brain analysis, that were able to classify the tumours as IDH Mut or WT using 
this approach for feature selection and model generation. Following on from this, the next step 
was to assess if features that were calculated from only within the tumour, from the same 






Fig 3.9 A heatmap plotted from the best model as determined by the forward selection procedure. 
Hierarchical clustering has been implemented on both the genes (texture features) in rows and IDH 
mutational status in columns. It is evident that even though there seems to be some clustering of 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































28 : 774 : 774
32 : 743 : 743
  7 : 741 : 741
36 : 600 : 600
24 : 571 : 571
35 : 406 : 406
  1 : 391 : 391
14 :   79 : 79
34 :   35 : 35
30 :   87 : 87
37 : 744 : 744
22 : 681 : 681
31 : 706 : 706
  5 : 353 : 353
21 : 503 : 503
19 : 331 : 331
11 : 761 : 761
  4 : 842 : 842
16 : 891 : 891
  6 : 776 : 776
15 : 862 : 862
25 :   97 : 97
27 : 152 : 152
  8 :   13 : 13
18 :   33 : 33
33 :   20 : 20
  3 : 162 : 162
  2 : 161 : 161
23 :   89 : 89
10 : 135 : 135
29 : 876 : 876
12 : 790 : 790
  9 :   80 : 80
20 :   77 : 77
26 :   72 : 72
13 :   29 : 29






Fig 3.10 A PCA plot of the first 4 PCs of the best performing model as determined by the forward 
selection procedure. It is evident  that there is a distinct inability of the model to classify the tumours 
within the images into IDH Mut or WT based on texture features as there is no separation between the 
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3.3.2.2 T1 post-contrast tumour analysis 
The previous investigation into whole brain texture features that may facilitate the 
classification of tumours into IDH Mut or WT using a GA approach for feature selection to build 
the most representative model failed to yield a model that had a reasonable classification 
error. In this section we are taking the same GA approach, but this time only considering 
texture features that have been generated within the enhancing region of the T1 post-contrast 
images. All parameters were maintained as per the previous investigation. Figure 3.11a shows 
the confusion matrix box plot for the T1 post-contrast intra-tumoral data both with and without 
a subsampling scheme applied. The sensitivity of Mut detection was very poor, at only 0.181. 
When comparing this classification error to the previous investigations, where the texture 
features from the whole brain were considered, the features calculated from within the 
enhancing region of the tumour seem to have performed worse following feature selection 
and model generation using the GA approach. Conversely the specificity of WT classification 
was calculated at 0.951, suggesting that detection of a true positive when dealing WT images 
performs well. Despite the poor classification error associated with Mut detection of the 
models generated from the GA, we explored the forward selection procedure to assess what 
effect the classification imbalance would have on overall model performance. Figure 3.11b 
shows the plot to demonstrate the forward selection procedure. The overall classification 
accuracy is shown to be 0.88, which may be misinterpreted as good in terms of model 
performance, however this value is calculated by taking the total of misclassified samples, 
divided by the total number of samples. Therefore, when the distribution of Mut and WT 
samples within the cohort is taken into account, and the poor classification error of the Mut 
samples is considered, it may be determined that the model is not representative. 
Furthermore, the stability of the Mut classification on the graph is poor, adding to the 
uncertainty of the even the best models’ predictive power. To further illustrate this the 
heatmap seen in figure 3.12 shows that there may be some clustering of variables with respect 
to IDH status, however these either reflect only WT classification and not Mut, or are not in 
line with IDH mutational status. The heatmap has been constructed with hierarchical clustering 
applied. Taken together, these results suggest that applying a GA approach to feature selection 
and model generation to image texture features calculated from within the enhancing region 
of the tumour on T1 post-contrast images does not expedite the accurate classification of 






Fig 3.11 (a) Confusion matrix box plot representing the classification errors of the proposed models 
following GA facilitated feature selection based on texture features that were calculated from within 
the segmented tumour. The box plot has highlighted that whilst the sensitivity of WT classification was 
excellent, the sensitivity for Mut classification was in fact very poor, at just 0.181. (b) A plot of the result 
from the forward selection procedure following GA feature selection and classification. Whilst the 
overall classification accuracy (black line) is computed at 0.8817, this is calculated by taking the number 
of misclassified samples and dividing by the total number of samples, and therefore does not reflect 
the poor classification accuracy of the model when dealing with Mut tumours. 
  












































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig 3.12 A heatmap generated from the best performing model as a result of the forward selection 
procedure (labelled as 6 on figure 3.10). Hierarchical clustering has been applied with chromosomes 
ordered in rows and mutational status in columns. There appears to be some very weak clustering 











































































































































































































































































































































































































































































































































































































































































































































































































20 :   87 : 87
15 :   45 : 45
13 : 925 : 925
10 : 527 : 527
19 : 263 : 263
  5 : 439 : 439
14 : 397 : 397
  1 :   49 : 49
  3 :   80 : 80
  9 :   84 : 84
  6 :   64 : 64
17 :   71 : 71
12 :   44 : 44
11 : 130 : 130
16 : 146 : 146
  2 : 560 : 560
18 : 796 : 796
  8 : 345 : 345
  4 : 312 : 312





3.3.2.3 T2 whole brain analysis 
In this part of the investigation we aimed to assess if texture features derived from the whole 
brain of glioma patients were able to distinguish IDH Mut from WT using the GA approach for 
feature selection and model generation. For this analysis only whole brain T2 texture features 
were used. Furthermore, the number of samples included in this part of the investigation is 
smaller, as not all patients underwent T2 imaging investigations. Figure 3.13 displays a plot of 
the fitness function using the same parameters as the T1 post-contrast imaging investigation. 
The plot shows that after the maximum of 200 solutions were reach, none of the chromosomes 
managed to surpass the stipulated fitness function of 0.8. This represents that none of the 
groups of texture features within the chromosomes were able to distinguish IDH Mut from WT 
with a classification error better than 0.8. Additionally, figure 3.14 shows the plot derived from 
the confusion matrix of the class predictions from all chromosomes. Here we can see that the 
sensitivity of Mut classification is once again poor, however, in contrast to the T1 post-contrast 
investigations, the sensitivity of the WT classification is also quite poor, not managing to 
surpass the pre-defined lower limit of 0.8 reaching only 0.763. When considering that we are 
attempting to construct a model for potential translation into clinical decision making, this level 
of sensitivity is far from adequate. Despite the poor average classification error of the GA 
search result, we wanted to explore if there were any models that were able to perform with 
increased accuracy. In order to do this, we carried out the forward selection procedure to 
assess if there were any particular models that were more accurate at classification. Figure 
3.15 shows the results of the forward selection procedure facilitated by GALGO. As was 
highlighted in the confusion plot, the average classification error failed to surpass the minimum 
of 0.8. Here we can see that the best performing overall model (labelled as 3 on the graph) had 
an overall classification error of 0.71, and once again the Mut classification performed more 
poorly than the WT classification. This may be attributed to the imbalance in sample 
distribution. Figure 3.16 is a heatmap ordered with hierarchical clustering applied, showing all 
models used in the forward selection procedure. It is evident that despite the small degree of 
clustering, this is not attributed to the mutational status of the samples. Taken together, all 
the aforementioned results derived from T2 whole brain data demonstrate that we have been 
unsuccessful in applying the GA approach for feature selection and model generation to 





Fig 3.13 A plot of the fitness function over the chromosome generations. From this we can determine 
that we were unable to reach solutions following 200 generations, as the minimum classification error 
was unable to surpass the minimum predefined fitness function of 0.8. 
  
































Fig 3.14 A box plot of the confusion matrix derived from the GA search using texture features generated 
from T2 whole brain analysis. Here we can see that the sensitivity of Mut classification, although 
improved form both T1 post-contrast whole brain and intra-tumoral analysis, it is far below the 
minimum expected of 0.8 at 0.43. Furthermore, the classification error of WT classification is also below 
the minimum expected value of 0.8. The forward selection procedure was then followed in order to 
assess the performance of individual proposed models. 
  
















































































































































































































































































































































































































































































































































































































































































































































































































Fig 3.15 A plot of the result from the forward selection procedure in order to assess the performance 
of individually proposed models. Here we can see that the best preforming models, in both Mut and 
WT classification, fail to surpass the minimum expected classification error of 0.8. the average 




3.3.2 Random Forests for intra-tumoral T1 post-contrast analysis 
Here we have used a random forests classifier approach in an attempt to build a representative 
model that is able to classify the tumours based on image texture features derived from the 
segmented, enhancing tumour region. As the GA approach to feature selection and classifier 
construction proved sub-optimal, the first step that was taken was to plot the raw, imaging 
feature data with respect to IDH mutation, to assess if there are any initial patterns that may 
be attributed to the mutational status of the patient. Figure 3.16 shows a heatmap (a) and PCA  
(b) plot to demonstrate the lack of separation between the two testing groups based on raw 
imaging features. Figure 3.17 shows a receiver operator curve (ROC) for a single random forest 
model, trained on a 2/3 train 1/3 test set of the data with no cross validation. The area under 
the ROC (AUC) represents a performance measure for the classification problem in hand, 
demonstrating the degree, or measure of separability. This value tells us how good the model 
is at predicting Mut’s as Mut’s and WT’s as WT’s. The higher the AUC value, the better the 
model is at distinguishing between these two different classes based on the input variables. 
For this random forest model (fig 3.17) the AUC is 0.796, which can be interpreted as, the 
model has a 79.6% chance of being able to distinguish between Mut and WT. Although, at first, 
this may seem like a well desired result, we cannot assume that this model is going to perform 
the same way on future, unseen data. We need some form of assurance that the predictive 
accuracy of the prediction that the model is producing will be replicated in the future.. Figure 
3.18 shows the previous model (fig 3.17) following K-Fold cross validation with 5 folds and 10 
repetitions. This led to 50 iterations in total, and the ROC’s for each of the models can be seen 
in this figure. The average AUC for all cross validation iterations is 0.744, meaning that there is 
a 74.4% chance that the model will predict a WT or Mut tumour correctly based on the 
inputted texture features.  
 As our end goal is to construct a model that may have clinical translation capacity, this 
machine learning approach, whereby we are likely to predict mutational status of the patient 
wrong 25.6% of the time, is not acceptable. Furthermore, if we assess the distribution of the 






Fig 3.16 (a) a heatmap derived from the raw imaging data, whereby imaging features are on the x axis 
and samples ordered by mutational status (Mut in purple and WT in yellow) are along the y axis. There 
is no pattern within the data that seems to be evident. There is the presence of an outlier within the 
WT’s indicated by the thick red horizontal cluster. (b) PCA plot using the raw texture features. There is 






Fig 3.17 A ROC curve from a single random forest model generated using a 2/3 training 1/3 test split of 
the data. The AUC here is 0.79. Although this is close to the minimum classification error of 0.8, the 
result must be validated, and it is still too low to allow any translational capacity.  
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Fig 3.18 ROCs for each of the 50 models fitted as an iteration during the K-Fold cross validation 
procedure. As is clear from the plot, there is a large variation in the ROCs from all the models. This 
should be taken into account when considering the predictive power of the overall model. The 
aggregated AUC here is 0.74, which is considerably lower than the 0.8 absolute minimum expected.  
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Fig 3.19 Precision metrics from K-Fold cross validation procedure. These include accuracy (red line), 
precision (green line), recall (blue line) and f1 score (purple line). As can be seen form the plot, there is 
a large amount of variation between each of the fitted models during this procedure. Sometimes the 
model does well with good accuracy and f1, but other times it performs very poorly.  
 
of variation throughout the 50 consecutive models that were fitted. To display this further, 
performance metrics including accuracy, precision, recall and f1 score for each of the models 
were plotted (fig 3.19). The models have varied severely between datasets, where by 
sometimes it gains up to 80% predictive accuracy with good f1 scores, and other times it does 
quite poorly. This suggests that some of the test Mut samples are much more similar to the 
WTs than others.  
 As the machine learning algorithms didn’t produce the desired results, additional 
factors, including the pathological origin of the tumour (oligodendroglioma, astrocytoma, or 
primary GBM), tumour volume and manufacturer of MR scanner were considered. First the 
data was visualised using heatmaps (fig 3.20) to observe if any of the categorical variables 
showed any correspondence with the data. None of these factors seemed to have a clear 
separation. Further to this, to describe the variance in the data, PCA was carried out on mean-
centred and scaled data, and visualised coloured by each factor (figs 3.21 and 3.22). The 








Fig 3.20 A heatmap of the data whereby the categorical data pertains to the scanner manufacturer. 
Blue represents the GE scanner, green Philips, and yellow Siemens. Hierarchical clustering has been 
applied. There is clear clustering of the data when this ordering has been applied. 
 
was between GE and Siemens, although there was still a large amount of overlap between 
these two groups in the PCA plot (fig 3.21).  
 The PCA plot coloured by tumour size (20%, 40%, 60%, 80% and 100%) displayed that 
the smaller tumours tend to cluster and do not overlap completely with the larger tumours (fig 
3.22). This suggests that some of the texture features were associated with tumour size, and 
therefore introducing a new, unwanted variance within the data. To assess the impact of this, 
Spearman correlations were calculated between each feature and the tumour size. Those 
features that had absolute correlation >0.5 were selected and the PCA was recalculated (fig 
3.22). This showed that tumour size clearly influenced some of the descriptors.  
 As we established that a number of the features have a dependency on scanner 
manufacturer and tumour size, a further variable selection approach was pursued. A multiple 






Fig 3.21 (a) PCA plot using scanner manufacture as the categorical variable. GE (green), Philips (light 
blue) and Siemens (dark blue). There seemed to be some clustering of point, particularly with reference 
to GE and Siemens. The red point is an unlabelled data point. (b) PCA plot, but with only GE and 
Siemens, there is some clustering, suggesting that scanner manufacturer has introduced unwanted 






Fig 3.22 (a) PCA plot of the data coloured by tumour size (20%, 40%, 60%, 80% and 100%; coloured red, 
yellow, green, blue and purple respectively). It would appear that the smaller tumours tend to cluster 
and do not overlap completely with the larger ones. (b) Following spearman correlation calculation 
between each feature and tumour size, those features that had absolute correlations >0.5 were 
selected and the PCA redone and displayed here. From this we can deduce that tumour size clearly 






















Fig 3.23 (a) A table to show the 18 texture features that were highlighted as important in the 
classification of IDH Mut from WT following multiple linear model fitting. (b) A heatmap of the 18 
variables, whereby samples have been ordered by mutational status. There is clear grouping of the 





Fig 3.24 (a) Box plots to indicate the accuracy, and the AUC of the ROC for the 20 random forest models 
that were fit using the 18 variables identified. The results show a large variation in the AUC as well as 
accuracy. This suggests that there are samples within the data that are much harder to predict than 
others, which is often the case with studies that have low patient numbers. (b) Confusion matrix form 
the first random forest model fitted using the 18 features. This model achieved 83% accuracy, however 
this was somewhat inflated by the large imbalance within the dataset. The performance was achieved 
by weighting the importance of the Mut samples by 1000:1.  
 
accounted for. This allowed the selection of variables where the IDH status was important but 
the other factors were not. From this we were able to identify 18 variables (fig 3.23a) that 
seemed to be important in the classification of Mut’s from WT’s. The data was visualised in a 
heatmap (fig 3.23b)where there is ordering of the variables into groups as we can see 
clustering of red and blue. Further to this, a random forest model was fit to the 18 features 
selecting a test set of 6 IDH Mut samples, and 36 WT samples. The model achieved 83% 






MUT 4 5 
WT 2 31 
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whereby there were many more WT samples than Mut. Nevertheless, those positive examples 
that did feature within the data were predicted reasonably well. The performance of the model 
was achieved by weighting the importance of the Mut samples 1000:1 at a cost of more false 
positives. Following this, 20 random forest models were then fit to random permutations of 
training/test data split to assess the stability of the predictions. Figure 3.24 shows the values 
for model accuracy and ROC AUC for each of the models as box plots. The results show a large 
variation in the AUC of the ROC which suggests that there are samples that are much harder 
to predict than others. 
 
3.4 Discussion 
Here we present results that have explored the use of texture features extracted from MR 
images of glioma, and the application of machine learning in order to classify images into IDH 
Mut or WT. Firstly a GA approach was taken for both feature selection and classification, 
however the resultant models were unsuccessful at classifying the images. We explored the 
use of random forests, again for both feature selection and classification. Although initial 
results indicated that this method was not successful at classification, we were able to identify 
several factors related to image acquisition that introduced unwanted bias into the data. 
Despite accounting for these extra factors, the final model showed variable performance upon 
cross validation, however this may be attributed to the low sample size, and an increase in 
patients within both testing groups may aid in building a representative model. 
The paradigm shift towards personalised medicine in oncological treatment has 
perpetuated the need for detailed diagnostic information at the earliest possible stages of 
tumour detection. Medical imaging is routinely used as a primary investigation when assessing 
patients presenting with potential tumours, and it has the capability to provide a wealth of 
data pertaining to the intra-tumour heterogeneity throughout the lesion volume. Here, we 
have investigated the use of two methods for feature selection and representative model 
construction, to determine if radiomic features are able to distinguish IDH Mut from WT 
patients using standard imaging data. 
 There have been a number of previous studies that have investigated the role of 
radiomics for the non-invasive detection of IDH mutation. A study by Lu et al looked at a 
combination of post-contrast T1, T2 (Fluid attenuated inversion recovery)FLAIR, T2 weighted 
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and diffusion weighted images (DWI)116. They reported that by using cubic support vector 
machine (SVM) and a quadratic SVM for glioblastomas and low grade gliomas (LGGs) 
respectively, they were able to achieve 95.7% sensitivity and 100% specificity for GMB IDH 
classification, and 85.7% sensitivity and 93.0% specificity for LGG IDH classification. These 
results, however, incorporated textures features calculated from all 4 contrast mechanisms, 
including DWI, which are not always routinely carried out on GBM patients for primary 
diagnostics in the UK. Furthermore, this study failed to report which of the texture features 
from the images were important for classification within the respective models. Further to this 
a study by Ren et al. also took a multiparametric approach, incorporating 3D arterial spin 
labelling (3D-ASL), T2 FLAIR and DWI to carry out classification of both IDH mutation and ATRX 
expression117. They reported 100% sensitivity and 85.7% specificity for IDH mutation 
classification. Although the incorporation of advanced imaging contrast mechanisms such as 
ASL and DWI may aid in the discrimination of IDH Mut from WT, the clinical utility of these 
contrast mechanisms must also be taken into consideration. One of the major limiting factors 
in the acquisition of ASL and DWI is the time taken for each patient in the magnet. One goal 
that our investigation set out to achieve was to focus on the ‘standard’ imaging sequences (T1 
and T2 weighted images) and determine if texture features calculated from these images are 
useful in the construction of a classifier for non-invasive IDH detection. During the data 
collection phase of this study it was observed that there was not a specific imaging protocol 
that was carried out on newly diagnosed patients. Each patient may receive a different number 
and combination of contrast mechanisms when scanned. Therefore, not every patient had 
undergone the same combination of post-contrast T1, T2 FLAIR, T2 weighted imaging. Here we 
have been investigating the utility of single contrast mechanisms for the radiological 
classification of IDH mutation as it seems this would have more clinical translatability. With this 
in mind, one of the big challenges in the use of standard MRI imaging sequences is that these 
are acquired in arbitrary units that are not comparable between acquisitions, although the 
discretization step described in the methods section is designed to help normalise the 
intensities to aid in inter-subject comparison. One of the benefits of utilising functional and 
quantitative imaging methods such as ASL and DWI are that the units used in the calculation 
of features are absolute, such as blood flow or mean diffusivity.  
 There were a number of other limitations associated with this study. As the data has all 
be previously collected between 2016-2019 by clinical radiologists, we had no control over the 
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acquisition parameters or the quality of image acquisition. As such, the images that were 
included encompassed a range of resolutions, dependent on which scanner they originated 
from. To allow comparison of features generated from images from different cohorts as well 
as making features rotationally invariant, interpolation was carried out on all images. This 
equalised all the image resolutions, however the cost of this was that some images had to be 
up-sampled and other had to be down-sampled, dependent on the original resolution of the 
image. This, in turn, may cause partial volume effect within the sampled region of the image. 
Therefore any change in MR signal that may occur as a result of the presence of 2-HG within 
the tissue of a given voxel, that in turn causes a change in the texture features generated from 
the image, may be masked if that 2-HG-containing voxel is blended with a neighbouring voxel 
that has no such signal change. By this method, partial volume effect may suppress the 
classification power of this technique. One way in which to mitigate this limitation would be to 
carry out prospective imaging data collection with more standardised sequences that were 
sampled at the same resolution.  
Another potential limitation was the use of such a high number of features for analysis. 
The approach of extracting 973 features from the images using a combination of filtered and 
unfiltered images was adopted as we had no clear sign as to what to look for that may indicate 
IDH mutation. It therefore stood to reason that extracting a large number of features in an 
attempt to fish for potential variables that could be discriminative would be a sensible 
approach. Retrospectively, working with such highly dimensional data, however, may have 
negatively impacted the discriminative power of the experiments, as potentially useful variable 
could have been masked by the large number of uninformative ones. One way in which to 
circumvent this limitation would be to generate less features from the images in the first 
instance. For example, reducing the number of filters applied, as the results here show that 
only features from the LoG filter with a sigma value of 1, and the wavelet bandpass filters 
produced features that were relevant to IDH classification. 
Finally, computing power required in order to attempt to extract different types of 
features from the images also acted to limit the scope of this investigation. Texture features 
are relatively simple to extract, using third party software, and they are tractable, as they are 
based on established mathematical definitions. However, the rigid way in which these imaging 
features are calculated may exclude inter-relationships between greyscales that could be 
present due to IDH mutation. One way to probe for patterns within the images that are 
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undefined is to use deep learning methods, such as convoluted neural networks (CNNs).There 
have been a number of studies that have shown the benefits to using hybrid deep learning 
approaches that carry out both tumour segmentation, along with feature extraction and image 
classification118–120. The value of these methods is rooted in several niches. Firstly, they are 
end-to-end, in that the resultant models are able to take normalised images, and carry out all 
radiomics steps, without user input, and produce a classified image. Further to this, the 
features upon which classification is based are not ridgid, and they are therefore able to search 
for patterns within the images that may have previously been overlooked. One of the major 
drawbacks to the study presented here, and why such methods were not pursued, was in part 
due to the low sample size, as deep learning requires very large datasets in order to train and 
optimise the model. Additionally, these models require very large amounts of computing 
power, often clusters, in order to run the algorithms, an infrastructure that our lab did not 
have in place. One way in which to overcome this and strengthen this investigation in the 
future would be to form a collaboration with another centre to pursue a deep learning 
approach. Already having the collaboration with the Walton Centre NHS Foundation trust is a 
great way to access a large amount of clinical data, a prospect that may serve as very attractive 
to a mathematics department looking to collaborate. 
A study by Zhang et al also looked at the ability of texture features calculated from 
multimodal MR imaging for IDH classification, the combination of T1, T2 FLAIR, T2 weighted and 
diffusion weighted images (DWI) contrast mechanisms, however they failed to report a 
number of crucial image standardisation steps, including grey level intensity discretisation and 
image interpolation121. In this study we have strictly adhered to the processing guidelines set 
out by the IBSI, we have also endeavoured to report fully all steps and parameters chosen to 
facilitate the reproducibility and replicability of the study81. Other studies have reported good 
classification ability of models but have failed in the full and proper reporting of how images 
were handled before and during the calculation of features, hampering the reproducibility and 
therefore translational capacity of such models. These include a study carried out by Yu et al122 
whereby all image pre-processing steps such as interpolation and discretisation were not 
discussed or reported. Similarly, the study by Lui et al123 reported the use of images with non- 
isotropic voxels, but failed to report the use of interpolation, which may confound the overall 
results as calculation of features from non-isotropic voxels renders them no longer rotationally 
invariant. One particular criticism of radiomics is the distinct lack of reproducibility. The 
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complex methods that underpin the practice of radiomics necessitates the comprehensive 
reporting of methodological parameters used, as well as external validation.  
 
3.4.1 GLAGO for feature selection and classification  
Here we have used a GA approach to select radiomic features derived from T1 post contrast 
whole brain and tumour segmented images, as well as T2 whole brain images. We wanted to 
explore the possibility of the computation of discriminative features being calculated from the 
whole brain as well as just the tumour, as it has been shown that diffuse microstructural 
damage occurs across the cerebrum in the presence of infiltrative glial cancer cells124,125. These 
microstructural changes, that have previously been demonstrated by diffusion imaging, may 
induce changes that alter the relaxation of the spins to facilitate alterations within the 
distribution of grey scale intensities within standard T1 and T2 imaging that remain 
undetectable by the human eye.  
Figure 3.3 illustrates the process of the GA approach for feature selection prior to 
classifier construction. First, we assessed the ability of radiomic features derived from contrast 
enhanced whole brain T1 analysis to discriminate IDH Mut from IDH WT patients. Following the 
GA feature selection process, it is possible to plot the evolution of the fitness function of the 
constructed chromosomes. Although the fitness function, which is a derivative of the 
classification error of the variables within the chromosome at distinguishing IDH Mut from WT, 
showed that we were able to surpass the pre-defined classification error value of 0.8. Although 
the initial fitness function plot indicates that the classification error of the chromosomes was 
greater than the minimum expected value following only 69 generations, this metric supplied 
limited information regarding the ability for the variables within the chromosomes to be able 
to classify the images accurately. To inspect this further, the mean sensitivity and specificity of 
the chromosomes must be calculated. When the sensitivity and specificity of both WT and Mut 
classification was examined, it was clear that the performance of the models in distinguishing 
a Mut glioma patient was poor (fig 3.7). We postulated that this imbalance in classification 
specificity may be attributed to the imbalance in class sample size, as there are far fewer Mut 
cases when compared to WT cases. To this end, we applied a subsampling scheme to artificially 
balance the contribution from both classes. This approach did not make much difference to 
Mut classification, as there was a negligible increase in the sensitivity. Moreover, there is 
evidence to suggest that the -nearest neighbour (KNN) algorithm is unaffected by an 
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imbalance in classes, as it takes into account the class distribution of a wide region of 
probabilities to predict instance labels126. Despite the poor sensitivity described by the 
confusion matrix plot, the forward selection procedure was followed to evaluate if a 
representative, or close to representative model, may be constructed from the features that 
have been shown to be most discriminative following the initial GA inspection. Figure 3.8 
illustrates the disparity between Mut and WT classification. From these results we can 
determine that we were unable to build a reliable and representative model for IDH 
classification based on these features derived from whole brain analysis.  
Further to this, we used the same approach to assess if we are able to classify the 
patients using data derived from whole brain T2 images. In these experiments the sensitivity of 
both WT and Mut classification for the chromosomes generated by the GA, calculated 
following the bootstrapping method was below the minimum expected value of 0.8. We 
wanted to understand the variability in the chromosome classification ability further, and 
continued with the forward selection procedure. From this we were able to deduce that not 
only did the best preforming model fail to surpass the minimum classification error boundary, 
but there was a huge amount of variation in the models that were proposed by the GA. 
Although calculating features over the whole brain was implemented in an attempt to 
capture some of the global changes that have been reported to occur in the presence of 
glioma, this inclusion of such a broad area from which to calculate features may have 
contributed to the poor classification. Whilst we understand that microstructural changes that 
occur during gliomagenesis and disease progression can be measured using diffusion MRI, such 
diffuse changes are minor when compared to the remaining amount of healthy brain 
tissue127,128. Therefore, since it is in fact the metabolic implications of the presence of IDH 
mutations within malignant cells that may facilitate the alterations in spin environments that 
in turn alter the distribution and relationship of signal intensities following Fourier transform 
of the MR signal, the inclusion of such a large amount of healthy tissue in which these 
metabolic changes are absent, may have introduced a large amount of noise/redundancy into 
the data. The presence of abundant healthy tissue may be masking the effect of IDH mutation 
on grey level distribution. There may be a number of other possible reasons as to why this 
approach failed to classify the samples with high enough accuracy for consideration of clinical 
translation. These data are highly dimensional, whereby the number of observations far 
exceeds the number of samples within the dataset. This curse of dimensionality leads to large 
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amounts of redundancy and overlap within the data itself. The great number of variables leads 
to a large search area for any algorithm, however the GA feature selection is optimised for 
such studies, as the multivariate method tests all variables in combination with each other by 
arranging such variables into smaller, more manageable groups of chromosomes. 
 To further investigate a potentially more robust method of detection, we 
generated the same texture features from within the tumour. More precisely, we segmented 
the tumours such that only the enhancing regions within the tumours were included for 
feature generation. We set out to include only the enhancing region of the tumour for a 
number of reasons. Firstly, this is the most active part of the tumour, whereby an abundance 
of proliferating and infiltrating glioma cells can be found. The other regions within the centre 
of the tumour that do not enhance may include a varying amount of active and proliferating 
cells, alongside necrotic regions, cystic components and  blood vessels. By including only the 
enhancing region, we are reducing the heterogeneity of the data, and therefore reducing the 
potential effect of masking features that may arise due to the presence of IDH mutation. 
Although radiomics is heralded for its ability to assess heterogeneity, as we have seen from the 
whole brain analysis, since this investigation is focused on finding features that correlate with 
a specific genetic mutation, inclusion of heterogenous regions of the tumour and/or  healthy 
brain that are known not to incorporate active cells with IDH mutations may, indeed, mask 
potentially discriminating features that could be important in classification. Further to this, one 
practical advantage to inclusion of only the enhancing region of the tumour is accuracy and 
reproducibility of tumour segmentation. Due to lack of radiology training it was postulated that 
the best method of segmentation would be to include only the enhancing region, so as to 
eliminate the potentiality of inclusion of non-tumour regions. The results of this line of 
investigation showed that following GA feature selection, the classification accuracy for Mut 
classification showed a sensitivity of only 0.181, compared to the WT classification sensitivity 
of 0.951 (fig 3.11). The disparity between Mut and WT classification using this approach was 
inflated when compared to that of the whole brain analysis. In addition, when the forward 
selection procedure was followed to identify the model that performed best at classification, 
the plot in figure 3.11b further demonstrates the disproportion between WT and Mut 
classification. The forward selection procedure also demonstrated the importance of 
understanding the calculation of mean classification errors when evaluating model 
performance, as at first glance the best performing model appeared to achieve a high 
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classification accuracy of 0.88, however this is calculated by dividing the number of 
misclassified samples by the total number of samples. As we have noted that there is a much 
larger number of samples in the WT class, and the sensitivity of classification was very good in 
this group, this will introduce a large amount of bias into the overall error calculation. The 
inflation of the difference between Mut and WT classification when compared to the whole 
brain analysis may be attributed, not to the imbalance in sample numbers within each class, 
but rather to the low number of samples within Mut class itself. Due to the low number of 
samples, the model simply doesn’t have the opportunity to learn any dependency of feature 
presence for class labelling. It has been previously suggested that whilst K-nearest neighbour 
(KNN) is less sensitive to imbalanced datasets, the results of classification can vary amongst 
datasets with lower sample sizes129. The lower number of samples of the segmented tumours 
was due to the required elimination of certain patient data due to difficulties during 
segmentation. Here we had to discount 26.5% of the T1 post-contrast images. The difficulties 
include the cases when the enhancing region of the tumour was too small and when there was 
no clear distinction between the tumour and other enhancing tissue such as meninges and 
blood vessels.  
 Taken together, utilising a GA for feature selection and model construction in 
this capacity did not yield results that represent a clinically translatable model. The failure of 
T1 and T2 whole brain imaging features to reach overall classification accuracy surpassing the 
minimum expected value, and the disparity between Mut and WT classification errors across 
all analyses, but in particular the T1 intra-tumoural features, has warranted that alternative 
routes of investigation are to be pursued.  
 
3.4.2 Random Forests for feature selection and classification  
The previous experiments explored the capacity of GA approach to feature selection to find 
the optimal feature subset for model construction. The GA approach belongs to the wrapper 
method family of feature selection algorithms, and whilst this group of techniques often 
execute well in providing the best performing feature set for a particular type of model, they 
are inherently computationally expensive, as for each subset of variables  a new model must 
be trained and evaluated. An alternative multivariate approach to feature selection and 
eventual classification would be to investigate the capabilities of an embedded method. In 
embedded techniques, the feature selection algorithm is integrated as part of the learning 
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process130. One of the most widely used embedded methods is the decision tree algorithm, 
and here we have used the popular random forest, implemented in the ‘mlr’ package in R131.  
 The random forest classifier is an ensemble method that works by constructing a vast 
number of uncorrelated decision trees based on averaging a random selection of predictor 
variables. One of the key concepts of random forests in performing as an embedded method 
for feature selection as well as a robust classifier, is that it is able to construct many 
uncorrelated models. The critical concept here is that the models are uncorrelated, the more 
independent observations we are able to make, the higher the chances of making correct 
predictions. Each individual decision tree error is protected by all the other trees in the forest, 
whilst some trees may make the wrong prediction, many other will be right, and so the 
predictive power of the population is able to advance in the correct direction. 
 Prior to the initial stage of this investigation, we plotted the raw texture feature data 
as  a heatmap, and carried out PCA to quickly analyse if there was any correlation between the 
vast amount of features and IDH mutation. Unsurprisingly, and most likely attributed to the 
high dimensionality and presence of redundancy within the unfiltered dataset, there was no 
pre-existing correlation between these features and mutational status.  
 An initial random forest model was trained on a 2/3 train 1/3 test split of the data, and 
the ROC for the model was plotted in figure 3.17. Upon inspection of the ROC, the AUC is 
calculated at 0.796 only just below out minimum accuracy threshold of 0.8. There is, however, 
a requirement to cross validate this result, to ensure that the model is detecting correct 
patterns within the data and it is not picking up too much of the noise or overfitting. The 
rationale behind the choice of K-Fold cross validation as a method of evaluating the model 
performance is due to the low sample size of our dataset. If we were to remove large parts of 
the data for validation purposes, then we risk losing potentially important patterns within the 
data, and therefore increasing error induced by bias. This method divides the data into k 
subsets, otherwise known as folds. From this, each one of the k subsets is used as the validation 
set, and the other k-1 subsets are amalgamated to form a training set. The plot in figure 3.18 
illustrates the high variability between all the models that were fitted using this method of 
validation. This variance in our model outcomes is likely due to overfitting. It is a reflection on 
the lack of generalizability of the model, as it illustrates how dramatically different the model 
would perform if we were to train it on different datasets. This overfitting is due to the model 
identifying patterns and complexity within random noise within the data, when what we are 
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actually looking for is a real trend. To further illustrate this, performance metrics from each of 
the cross validation iterations were plotted in figure 3.19, and it is obvious that the variation in 
model performance between each split of the data is large. 
 As it would appear that random forests seemed to be overfitting, potentially finding 
patterns within uninformative noise, or even patterns within the data that may be attributed 
to some other form of variance that may be present within the data due to factors other than 
IDH status, we decided to investigate if there was any correlation with the metadata. These 
metadata included pathological origin (oligo, astro, GBM or secondary GBM), scanner 
manufacture and size of the tumour. When visualised in heatmaps and following PCA 
calculation, it was evident that both tumour size and scanner manufacture were having an 
impact on the distribution of the data. The correlation between tumour size and a number of 
the features is logical, as although all the texture matrices may be both rotationally and 
translationally invariant, none of the matrices are scale invariant. It therefore stands to reason 
that there would be association of tumour size with texture matrix features81. 
 In addition to tumour size, scanner manufacturer was also found to have an impact on 
the distribution of the data, whereby the most pronounced difference was seen between GE 
and Siemens. Since the recent surge in popularity of radiomics studies employing MR images 
for correlation with clinical endpoints, molecular and genetic information, there have been a 
number of studies that have examined the impact of varying acquisition parameters on the 
calculation of radiomics features. Studies such as those by Yag et al132, Saha et al133 and Ford 
et al134 have shown that a varying number of features may be influenced by acquisition 
parameters. Between these studies there was no consensus on a definite list of parameters 
that are influenced by acquisition parameters and by what degree, however this variability that 
has been observed in the calculation, calls for caution to be taken when carrying out the 
machine learning stages of any radiomics workflow, particularly those ones that concern MR 
images. With this in mind, and following the observation that when we group the samples 
according to scanner manufacturer following PCA we are able to observe clustering, we 
decided to investigate each variable and evaluate in terms of the variance that each factor is 
accounted for. This allowed us to curate a list of 18 features that may contain discriminative 
information to classify IDH Mut from WT. Despite the more robust feature selection approach, 
and the dramatically reduced dimensionality of the data following assessment via multiple 
linear models, the AUC of the ROCs from 20 validation iterations had a large variability, ranging 
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from 0.47 to 0.82. This may be attributed to the low number of cases included in the fitting of 
the model. As opposed to the likely overfitting of random noise within the vast number of 
features that we experienced in the first random forest model, here there are simply not 
enough examples for the model to learn clear dependencies between the features and the 
outcome, and some cases that are rare within the data end up being learned as well. This 
model still seemed to do better than random, which suggests that there may be information 
within the features that could be useful for determining mutational status, however it will 
require more data to achieve useful performance.  
 
3.5 Concluding Remarks 
There were a number of limitations that were experienced throughout this study that were 
unavoidable, but must be considered when drawing conclusions. Foremost is that the imaging 
data that were used to generate features were retrospective. As we had no control over the 
acquisition of the images, 30.4% of T1 post-contrast and 25% of T2 images were immediately 
disregarded from the original cohort due to poor image quality. Furthermore, as we have 
already seen, all images were acquired across three different magnet vendors over a number 
of years. This is inherent of clinical data, as it is often the case that each hospital will house 
magnets from a number of manufacturers that are of different ages. We have noted that this 
may serve as a limitation to a radiomics approach, however, if we are to move the field forward 
towards building clinically translatable models that may be used in patient diagnostics, then 
we must take into account that each individual hospital will have a number of different scanner 
types. To this end, the relationship between scanner manufacture and acquisition parameters 
should be further explored. If we are able to understand more about the dependencies of 
particular imaging features within these factors, then perhaps these can be taken into account 
when attempting to construct models that can be used in multicentre investigations. 
Moreover, to fully assess the potential of this technology, first, our own investigation must be 
expanded, to validate if the trend that we have observed here, that there may be some 
information contained within the features that allows discrimination of the Mut and WT 
images, can be confirmed as a true classification. Next a multicentre, prospective study would 
be followed, whereby acquisition parameters are standardised as much as the practical limits 










4. NMR Metabolomics to 
Identify a Metabolic 




NMR spectroscopy in combination with a metabolomics analytical approach has the potential 
to provide a wealth of data pertaining to the metabolic state of a sample of tissue. This study 
has explored the use of both 1 dimensional (1D) and 2 dimensional (2D) spectroscopy to 
extract and collate a body of information that can allow us to further our understanding of how 
the mutation contributes towards the development and progression of the disease, as well 
uncovering consistent metabolic shifts that can serve as non-invasive markers for the detection 
of the mutation in-vivo.  
 For this study glioma tissue samples were collected during surgical resection and 
immediately snap-frozen in order to preserve the metabolic profile. Methods for the extraction 
of metabolites, as well as the analysis of spectra had to be optimised, as this was the first study 
to incorporate this type of tissue to be conducted in our centre. Combining metabolomics 
information produced by both 1D homonuclear and 2D heteronuclear NMR is something that 
has seldom been explored in the context of IDH mutation in glioma, however here we have 
demonstrated that merging results from these two investigatory avenues can strengthen the 
accuracy and precision of the observations. Each approach may help guide the other and vice 
versa, allowing one to build a strong body of evidence as to which metabolic shifts are present 
as a result, or in combination with the mutation.  
 The following results suggest a consistent metabolic phenotype with respect to a 
discrete group of molecules. They provide rationale for further investigation into how these 
shifts facilitate the overall clinical phenotype observed in IDH Mut glioma patients, which will 
allow is to deepen our knowledge of the underlying mechanisms of the pathology. This 
metabolic pattern may also provide metabolic alterations to look for on in-vivo spectra, 
potentially providing the grounds for investigation into non-invasive biomarkers for the 
detection of the mutation using MRS. 
4.1 Introduction  
4.1.1 NMR Metabolomics 
Metabolomics is a relatively new addition to the ‘-omics’ field of study, and focuses primarily 
on the downstream effects of the combined environmental, genetic and proteomic distinctions 
between cell/tissue types. By assessing which metabolites are present and their abundance, 
metabolomics studies can provide a myriad of information pertaining to the intracellular status 
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of a given tissue type, and facilitate the discovery of both biochemical signatures and 
biomarkers for specific disease states135. In addition to biomarker discovery, metabolomics 
provides a global view of cellular metabolism, and therefore can offer further insights into the 
pathophysiology of diseases such as glioma. Significant alterations in metabolite levels that can 
be observed in distinct tissue types may be indicative of modifications in a plethora of 
biochemical pathways, the detection of which may provide information on the pathogenesis 
of the disease136,137. Changes in gene expression, genetic mutations and protein dysregulation 
can have influences on metabolite flux, which in turn will alter the metabolic environment of 
the cell and dictate phenotypic expression138. Assessment at the metabolic level therefore 
seems a logical analytical pathway, as it reflects potential aberrations at all levels. The study of 
metabolomics provides both qualitative and quantitative information that is able to describe 
the biochemical profile of a given tissue139.    
 Nuclear magnetic resonance (NMR) spectroscopy may be applied for the identification 
and quantification of chemicals within complex mixtures. This technique has been a popular 
method of probing metabolism since the early pivotal study that saw its application in assessing 
ethanol metabolism using isotope-tracer analysis in the early 1970’s140. Since this point, NMR 
spectroscopy has been used in countless studies probing metabolism of all manner of living 
creatures, in vivo and in vitro, using 1H, 13C and 31P nuclei141. The technique is widely popular 
in metabolomic studies due to it being quantitative, reproducible and the spectra contain a 
wealth of biological information142–144.  
The technical details of both 1D and 2D spectral acquisition have been covered in 
chapter 2, however this section will discuss the differences, advantages and disadvantages of 
using 1D and 2D NMR spectroscopy to carry out metabolic profiling. As with all techniques that 
exploit the NMR phenomenon, acquisition of optimal signal to noise ratio in order to generate 
a spectrum following may be obtained in a matter of minutes, however in order to extract 
meaningful information from spectra  to answer complex biological questions, we must obtain 
a dataset with a high signal-to-noise ratio, which involves increasing the number of averages 
and therefore increasing acquisition time. A typical 1D in vitro NMR experiment takes 
approximately 30 minutes, and due to the advent of automated sample changers for liquid 
state NMR tubes, it is possible to collect data on hundreds of samples in a single experiment141. 
Metabolite concentrations are inherently dynamic throughout biological samples. Additionally, 
there are often a wide range of concentrations that may be considered physiologically normal 
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for a specific metabolite within a given tissue type145. These factors provide a source of bias 
when carrying out statistical analysis of 1D NMR data, as the resonant peaks produced by the 
more abundant metabolites often overlap and hide the NMR peaks from the less concentrated 
metabolites. A number of methods have been employed in an attempt to circumvent this 
spectral overcrowding, including ‘targeted’ metabolic profiling by fitting spectra to a library of 
known metabolites in a 1D NMR database146; on- or off-line sample fractionation and the use 
of isotopically enriched metabolites147,148. All of these techniques present with distinct 
limitations when considering quantitative interpretation. Targeted metabolite fitting requires 
a priori knowledge of the system in question, and isotope labelling is not widely used in human 
studies.  
Multidimensional approaches to NMR acquisition have been utilised in methods such 
as chromatography, electrophoresis and NMR spectroscopy in order to increase resolution149. 
Both homo- and heteronuclear NMR experiments , including total correlation spectroscopy 
(TOCSY), heteronuclear multiple bond correlation (HMBC) and heteronuclear single quantum 
coherence spectroscopy (HSQC), until recently were performed exclusively on selective 
proteomic samples for structural elucidation150. Popularity in the use of these techniques for 
high resolution NMR began to gain traction in the early 2000’s when groups such as Dumas et 
al. carried out 2D HMBC NMR on bovine urine samples that had been exposed to steroids151. 
When considering the challenge of increasing resolution, heteronuclear experiments 
exploiting the spin property of 13C may provide an attractive method of dealing with spectral 
overcrowding. The chemical shift range of 1H NMR is relatively narrow at 0-12 ppm, whereas 
the 13C chemical shift range observed in natural products is over 0-200 ppm, therefore 
acquiring signal in the second dimension using carbon can be of great benefit in inducing peak 
dispersion. One significant obstacle in the acquisition of 13C spectra is the very low natural 
abundance of 13C at around 1.1%. This makes HMBC an especially insensitive experiment with 
a long acquisition time. To overcome the issue of reduced signal and long acquisition when 
acquiring on the carbon, here we have used a HSQC pulse sequence, where magnetization is 
transferred from the proton to the carbon via an insensitive nuclei enhanced by polarization 
transfer (INEPT) step and then back onto the proton via a retro-INEPT step following time t1 (as 
discussed in further detail in chapter 2).  
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4.1.2 Metabolic Phenotype in IDH Mutant glioma 
As discussed in previous chapters, gliomas present a significant proportion of malignant 
intracranial tumours, and the presence or absence of a mutation in the IDH1/2 gene is 
deterministic of both diagnosis and prognosis7. The gain-of-function neomorphic enzymatic 
activity is well known to facilitate an aberrant accumulation of the oncometabolite 2-
hydroxygluarate (2-HG) within the cytoplasm. Although the presence of the oncometabolite 
has been suggested to contribute towards the malignant progression of the tumour, the 
mechanisms by which this process occurs are still widely debated152. Furthermore, the means 
by which the build-up of 2-HG confers enhanced prognosis and increased response to 
chemoradiotherapy whilst at the same time driving malignant progression, remain to be fully 
elucidated. Evaluation of the global metabolome of IDH mutated tumours has the power to 
provide us with information pertaining to the upstream affects that facilitate this juxtaposition 
of phenotypic manifestations. If we are able to understand the consequence of the mutation 
and subsequent intracellular build-up of 2-HG on processes such as gene expression, 
transcription and intracellular trafficking, then we may begin to understand the mechanisms 
behind disease progression, and the formulation of targeted therapies becomes a much more 
realistic prospect.  
 
4.1.3 Metabolism as a Biomarker 
Mutations in IDH1/2 catalyse the production of the oncometabolite 2-HG via reduction of αKG. 
The subsequent accumulation of the oncometabolite is facilitated by the heterozygous manner 
of the mutation, and the dominant effect that the gain-of-function mutation imparts over the 
remaining WT allele, which serves to provide the mutant enzyme with a continuous supply of 
αKG to be aberrantly reduced into 2-HG25 (Fig 1.1). It is well reported that these mutations are 
present in approximately 70% of astrocytomas and oligodendrogliomas of WHO grade II-III, 
and 12% of GBM of which are mostly secondary GBMs7,153. There is no other known cause for 
the production and accumulation of 2-HG in the brain, and it may be considered the only non-
invasively detectable biomarker that is a direct consequence of genetic alteration known in 
humans. 
 Here we have assessed the metabolic profile of glioma samples both with and without 
IDH1/2 mutations, in order to determine if there is an overall metabolic signature that may be  
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linked to the mutation and the accumulation of oncometabolite. The acquisition and 
interpretation of in vivo spectra for the detection of 2-HG is technically challenging, due to the 
large amount of spectral overlap of the 2-HG peaks by metabolites found in great abundance 
in the healthy and diseased brain. If we are able to identify other metabolic aberrations that 
are detectable via NMR, then it may be possible to form a metabolic fingerprint in order to 
non-invasively probe for the mutation, as well as to further study the pathophysiology of the 
disease.  
 
4.1.4 Scope of Study 
This study explores the use of a metabolomics approach to 1D and 2D NMR spectroscopy in 
order to identify a metabolic phenotype in IDH Mut glioma. The observation of consistent 
metabolic shifts in relation to IDH mutation can aid in furthering our understanding of how the 
mutation contributes towards pathological development and progression, as well as providing 
a potential metabolic fingerprint that may translate into a non-invasive biomarker to the 
mutation. 
 
4.2 Methods  
4.2.1 Sample Collection 
Patients for this study were identified at clinical multi-disciplinary tumour meetings at the 
Walton Centre NHS foundation trust. The study was approved by the Walton Centre Research 
Tissue Bank research ethics committee (REC) approval (Reference number 15/WA/0385).  
Patients were included if they were a suspected of a newly diagnosed glioma from radiological 
studies and were to undergo surgical resection. Inclusion criterion was that the patients must 
not have had any previous surgery or cancer treatment. Samples were collected during surgical 
resection and snap frozen in liquid nitrogen immediately following removal from the brain. 
Samples were kept at -80c until metabolite extraction. All patients had provided informed 
consent and the use of the tissue for the study was approved by the NHS foundation trust and 
sponsored by the University of Liverpool. A total of 22 patients, 18 IDH Mut and 9 IDH WT, 




4.2.2 Metabolite Extraction 
Metabolite extraction method was optimised by carrying out both a perchloric acid extraction 
and acetonitrile extraction on mouse brain samples in order to determine the method with the 
least intra-observer variability. Snap frozen mouse brain samples were divided into three 
approximately equal size sections of wet weights 400mg-900mg. For percholoric acid 
extraction, ice cold 4% percholoric (1:4, w/v) acid was added to each sample. Each sample was 
sonicated under ice cold conditions for 3x30 second bursts to prevent heating. The liberated 
samples where then vortexed for 1 minute, and centrifuged for 10 minutes at 4c. The 
supernatant was collected into a second Eppendorf and lyophilised overnight. To the 
lyophilised material 178l 100% D2O, 20l 1mM sodium phosphate pH7.4 in 100% D2O, 0.2l 
100mM TSP in 100% D2O and 0.2l 1.2mM NaN3 in 100% D2O was added. The mixture was 
then vortexed for 1 minute. NaOH was then added dropwise to each sample to neutralise the 
pH (7.0-7.5). The neutralised mixture was then vortexed again and centrifuged at room 
temperature x120000g for 2 minutes. 
 For acetonitrile extraction, ice cold 50% HPLC grade acetonitrile in double distilled 
water was prepared and added to each sample (1:4, w/v). each sample was sonicated under 
ice cold conditions for 3x30 second bursts to prevent heating. The liberated samples we then 
vortexed for 1 minute followed by centrifugation at 4c for 10 minutes. The supernatant was 
collected into a second Eppendorf and lyophilised overnight. To the lyophilised material, 178l 
100% D2O, 20l 1mM sodium phosphate pH7.4 in 100% D2O, 0.2l 100mMTSP in 100% D2O 
and 0.2l 1.2mM NaN3 in 100% D2O was added. The mixture was then vortexed for 1 minute. 
190l each from all samples from both extraction techniques were pipetted into separate 3mm 
NMR tubes for NMR analysis. 
 
4.2.3 NMR Spectroscopy  
All NMR experiments were conducted on Bruker 700MHz Avance IIIHD spectrometer equipped 
with 1H/13C/15N Cryoprobe with Z-gradient. NMR setup was performed by calibrating the 
temperature to 25C using the deuterated methanol thermometer method154. Tuning and 
matching was conducted followed by the automated optimisation of the acquisition 
parameters in order to adjust the residual water suppression. Automatic shimming routine was 
performed on each sample. All chemical shift values   were set relative to TSP at 0.00 ppm for  
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Neuropathological Diagnosis 
Astrocytoma II 4 
Astrocytoma III 5 
Oligodendroglioma II 4 
GBM IV 9 
IDH MGMT Methylation ATRX Loss/Retention 1p/19q Co-deletion 
Mut 13 Methylated 7 Lost 9 Co-deleted  3 











Table 4.1 A table to show the distribution of glioma samples included within this study. A total of 22 
samples were included in the investigation, from mixed pathological origin. The MGMT, ATRX and 
1p/19q status was not available for all samples however here we have reported all available 
information. 
 
both 1H and 13C. 1D acquisition was performed using a Carr-Purcell-Meiboom-Gill (CPMG) 
pulse sequence (cmpgpr1d) with 4 dummy scans, 256 scans, dwell time of 41.6s, 9.6ms echo 
time, 32,000 points and 3.1s acquisition time. The 2D acquisition used a 1H-13C heteronuclear 
single quantum coherence coupling (HSQC) sequence (hsqcetgpsisp.2) with 16 dummy scans, 
4 scans, 47.33s dwell time with 768 increments and a spectral width in the indirect dimension 
of 120ppm (offset at 50ppm). The spectra were Fourier transformed with vendor supplied 
standard processing routines (apk0.noe for 1D and 2dinv for 2D) comprising sine bell window 
function, zero filling and automated phase correction with 2D spectra subjected to additional 
manual phase adjustment. 
 
4.2.4 Metabolite Identification  
Metabolite identification was optimised via three methods. Initially, spectra were bucketed at 
regular intervals using the Bruker software AMIX. To create the bucket tables, spectra were 
imported into AMIX and regular rectangle buckets were selected. Integration mode was set to 
sum of the intensities and the scaling was set to the total intensity of the spectrum. The region 
of 4.6-4.8 ppm was excluded to negate the peak produced by residual water signal. Buckets 
were set at intervals of 0.04 ppm. The bucket table was exported for metabolomic analysis in 
Metaboanalyst. The integrals of the peaks within each bucket were used for metabolomics. 
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 The second method of metabolite identification was to create a pattern file containing 
the ppm range values for each metabolite in order to bucket all the spectra in a targeted 
manner. A list of metabolites contained in the pattern file can be found in appendix 2. For this, 
a publicly available pattern file derived from a neuroblastoma cell line containing 186 
metabolites was used as a base to be modified with the addition and deletion of relevant 
metabolites. The resultant pattern file contained 92 metabolites to be analysed. All spectra 
were uploaded onto the TAME NMR server, and the pattern file was overlaid. The ppm values 
were adjusted within the .csv pattern file, so as that each metabolite range would capture the 
majority of the relevant peaks. The spectra were then bucketed, using AMIX. To bucket the 
spectra into intervals of a pre-defined width based on the pattern file input, the ‘variable sized 
buckets’ option was selected and the path to the pattern file was given. The integration mode 
was set to sum of the intensities and the scaling was set to total intensity of the spectrum.  The 
region of 4.6-4.8 ppm was excluded to negate the water peak, and the resultant bucket table 
was exported for metabolomics analysis in metaboanalyst. 
 The final method of metabolite identification was to process the spectra using 
Chenomx NMR Suite 8.2 Software (Chenomx, Edmonton, Canada). Chemical shifts were 
referenced in relation to the TSP signal at 0.0 ppm. A semi-automated approach was used 
towards spectral profiling. The software provides a library of 350 metabolites that may be 
fitted in human samples. We edited this library so as to only contain metabolites that are 
known to be found in both healthy brain and brain tumour tissue. This edited library consisted 
of 78 metabolites in total. The reference library provides a Lorentzian peak shape model for 
each automatically fitted peak that is superimposed on top of the spectrum being analysed. 
Following automated fitting using this model, each peak was checked, and the optimal fit was 
achieved by manually adjusting the peak height and by making alterations to cluster locations. 
This was a necessary step in the metabolite identification and quantification in order to achieve 
the optimal result, as we observed a significant amount of spectral shift between samples.  This 
step was also necessary in order to eliminate any false positives that may have arisen from the 
fitting of peaks that are heavily overlapped. The linear combination of all modelled metabolites 
gave rise to total spectral fit, which can be evaluated within the software as a summation line 
superimposed onto both the analysed spectrum and the estimated fit. An estimated 
concentration was generated following peak integration and the concentration table was then 
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exported for each peak and concatenated for statistical metabolomic analysis in 
Metaboanalyst. 
 For metabolite identification and statistical metabolomic analysis of the 2D NMR 
spectroscopy data, the data were phase adjusted in TopSpin and analysed in CCPN NMR155. 
Once the spectra had been manually zero and first order phase corrected, the resultant spectra 
were converted to UCSF format to be imported into the software CCPN. Once spectra from all 
samples had been imported, contour levels were adjusted for each spectrum, so that a similar 
level of noise was present in all. To account for any spectral shift, all spectra were aligned to 
the lactate peak from one representative sample. To conduct metabolite identification, 
standard spectra of metabolites of interest that had been acquired in-house were imported 
and overlaid. Peaks corresponding to the standards were assigned. All unassigned peaks that 
then featured in all spectra across all samples were given numerical assignments prior to 
metabolomics analysis. Concentrations calculated from contour intensities were then 
exported for statistical metabolomics using metaboanalyst. Following statistical metabolomics, 
those peaks that were previously unidentified metabolites and assigned only a numerical 
identifier, and had shown to be significantly altered between the two groups, were queried 
using the biological magnetic resonance data bank156.  
 
4.2.5 Statistical Analysis  
Samples were divided into groups dependant on their IDH1/2 mutational status. Statistical 
analysis was carried out using in-house R scripts and Metaboanalyst. Both univariate and 
multivariate analyses were carried out on the data. Univariate testing is applied when 
individual variables are compared one at a time between the different testing groups. Here we 
applied Wilcoxon rank test. Wilcoxon rank sum test was chosen as the statistical test because 
it is commonly used to compare two groups of non-parametric data. As the data here is of 
unknown distribution, this stricter approach was appropriate. When carrying out multiple 
significance tests such as in the context of any ‘omics’ study, there is a requirement to correct 
for multiple tests to decrease the probability of detecting false positives157. This correction 
procedure can be considered as a fundamental part of univariate testing within an ‘omics’ 
framework, and as such must be taken into account when interpreting the results, as 
application of different methods of multiple comparison correction may facilitate the 
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production of different results. Metaboanalyst applies the Bonferroni correction for multiple 
comparisons, as well as providing the false discovery rate (FDR) adjusted P value. 
 Multivariate data arises from experiments whereby two or more variables are 
measured. When employing multivariate tests on high-dimensional data, it is important to 
understand that these methods make use of all variables simultaneously and deal with the 
simultaneous relationship amongst such variables. Whereas a univariate analysis considers 
only the mean of a single variable and its variance, multivariate analysis looks at covariances 
and correlations within the variables that may be able to describe the extent of the relationship 
between them. Here we applied two methods of multivariate analysis, principal component 
analysis (PCA) and partial least squares discriminant analysis (PLS-DA). PCA is a useful tool, 
particularly in metabolomic studies, as it allows the projection of data into a lower dimensional 
space whilst capturing a large amount of original information describing the variation. In this 
way, quick and convenient plots can be produced to visualise separation between testing 
groups. Principal components (PCs) involve the linear transformation of the data, and 
conversion of a set of correlated variables into sets of new, uncorrelated principal components. 
Principal components are derived in such a way that the first PC accounts for the maximum 
amount of variation in the original data. The second PC accounts for the maximum amount of 
variation that the first PC was unable to explain. This procedure produces a list of PCs that are 
ordered by the variance that they each account for.  
 PLS, much like PCA, aims at capturing a large amount of information from the original 
data that describes the variance, and plotting it in a lower dimensional space, often on smaller 
sets of individuals or samples, and in a more condensed way than PCA. This is realised by also 
considering the relationship between the independent and dependant variables within the 
analysis. As the dependant variables that we deal with in metabolomics are categorical, the 
PLS variant that is able to achieve this is PLS-DA. One of the primary caveats in PLS-DA model 
generation is the tendency to overfit the data. Therefore, cross-validation strategies are a 
requirement to circumvent this issue158. One other issue that can arise from the application of 
PLS-DA models in the search for biomarkers and biological signatures is interpretation, which 
out of the many variables tested and analysed contribute to the discrimination between the 
two testing groups.  
 
 100 
4.2.6 Normalisation Calibration  
Normalisation of the spectral data acquired from an NMR experiment, such as the data 
presented in this chapter, requires some form of normalisation strategy prior to quantitative 
statistical analysis so that the data from all the samples are comparable with each other. There 
are a number of reasons as to why unwanted variance within the data may be present. Dilution 
variability is a process that influences concentrations of all metabolites by the same factor 
within each sample, and thus all peak intensities will be affected by the same magnitude, which 
may also be referred to as unspecific alterations of metabolites. In contrast, we are assessing 
for differences that are present due to the presence/absence of IDH mutation, which will affect 
only a number of selected peaks by varying degrees of magnitude. There may also be variation 
within the data that is present due to technical reasons linked with the acquisition of the data. 
Normalisation allows the suppression of all of these factors that may mask the specific changes 
in metabolite concentration that we are seeking. Here we assessed the ability of three 
normalisation strategies to account for the intra-sample and intra-group variability, so that the 
biologically relevant information can be easily assessed. The normalisation procedures 
followed were normalisation to the mass of the tumour, to the TSP peak and to the total area 
underneath the spectrum all within metaboanalyst. The data that were used to assess the 
ability of these methods to account for the unwanted variability whilst preserving the biological 
importance were acquired from neuroblastoma tumours cultured in chick embryos for the 
study by Al-Mutawa et al154. 
 
4.2.7 Pathway Analysis 
Metabolites identified as significantly altered between IDH Mut and WT glioma were then used 
in pathway analysis in order to asses for relevant pathways that may have been altered in the 
presence of the mutation, providing information that can be used to form future research 
questions in order to probe the pathophysiology of IDH mutations. For this the pathway 
analysis tool in Metaboanalyst was used, which combines the results from pathway enrichment 
analysis and pathway topology analysis in order to help identify aberrant pathways. Data was 
inputted as metabolite names with one compound per row. The Homo sapiens library was 
selected, and the over representation analysis method selected was hypergeometric test. 
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4.3 Results  
4.3.1 Quality Control and Optimisation Experiments  
4.3.1.1 Extraction Calibration 
The PCA of the two different extraction methods, acetonitrile and perchloric acid, have been 
displayed in figures 4.1 and 4.2. During the extraction process, it is necessary to neutralise the 
pH of the sample with a basic solution, and in this case we used NaOH.  Due to the steep 
gradient of the pH curve when using a strong acid and base such as HClO4 and NaOH, the 
window of neutralisation is very small. As such, three samples were not neutralised to a pH in 
the range of 7.0-7.5, and were labelled as bad pH for analysis. This led to the formation of three 
testing groups.  
   The PCA score plot demonstrates the extent of variability seen between the different 
extraction methods. A three component model as seen in figure 4.1 facilitates 72.6% of the 
overall variance. In addition, the 4th and 5th components account for 7.9% and 7.6% of the 
variance respectively. In the PCA plot (figure 4.1) for all three components it is clear that the 
acetonitrile samples are clearly separated from both perchloric acid  pH groups.  
Consideration of the PCA score plot (figure 4.2) allows us to capture the maximum amount of 
varition within the data, in decreasing order. Here the variables correspond to spectral bins, 
whereby all aligned spectra were divided up into regular intervals and the value for testing is 
the integral of the peak within the limit of the bin. PCA evaluation shows a clear grouping of 
the acetonitrile extracted samples (red) with very little variance on either the first or second 
PCs. Conversly, both the percholric acid-extracted groups display a much larger amount of 
variance. These results formed the rationale for choosing acetonitrile extraction here. 
 
4.3.1.2 Normalisation Calibration  
Figure 4.3 shows the PCA score plots with the first two PCs for each of the normalisation 
methods explored. 4.3 (a) illustrates data that has been normalised using the mass of each of 
the tumour samples. As is evident, some of the data points skew the distribution, and there is 
a loss of biologically relevant information as a result of this. The remaining presence of 
unwanted variation following normalisation may be due to tumour heterogeneity. Tumours 
are composed of varying amounts of blood vessels,  necrotic tissue,  and active tumour. As the 








Fig 4.1 Three component pairwise plot representing the variance accounted for by each PC in the 
corresponding diagonal box. ACN = acetonitrile extraction (red). badpH = perchloric acid extraction with 
a pH outside the range of 7.0-7.5 (green). pH = perchloric acid extracted with a pH neutralised within 
the range of 7.0-7.5 (blue). There is a clear grouping of all samples that underwent acetonitrile 









Fig 4.2 Principal component analysis 2D score plot for all samples in the three groups pertaining to the 
two different extraction techniques. The samples extracted using the acetonitrile approach display the 
least amount of variance on both the first and second PCs. Both the groups with the perchloric acid 
extracted samples displayed a large amount of variation between each individual sample. Interestingly, 
a much larger variation was observed within the samples that had the pH appropriately neutralised to 








Figure 4.3 PCA score plots of NMR data acquired from neuroblastoma tumour samples. Three methods 
of normalisation were applied here in order to determine the optimal protocol for reducing variance 
whilst preserving biological importance. (a) samples were normalised to the mass of each tumour 
sample. Here the data has been vastly skewed and much of the biologically important information has 
been lost. (b) samples were normalised to the TSP peak. The data here is skewed slightly, and there is 
little separation between the two testing groups. (c) samples normalised to total area under the 






intensity that we are interested in, the variability introduced by the differing levels of other 
tissue components may be masking the biologically relevant data.  
 Figure 4.3 (b) shows the PCA score plot for data that was normalised to the TSP peak 
from each spectrum. Here the data is much less skewed when compared to the normalisation 
by mass protocol data, however, there seems to be a clear overlap of both the testing groups. 
Due to the lack of separation between the two groups, relevant biological information may be 
lost during the analysis. One reason for the suboptimal performance of TSP normalisation 
could be that it has been shown the protein can bind to TSP138. Although metabolites extraction 
was carried out, the complex nature of the tissues being analysed may have resulted in some 
residual protein present within the samples. This will in turn cause a variation in the final TSP 
concentration within each sample, introducing variability and skewing the data following 
normalisation using this method.  
 Figure 4.3 (c) shows the PCA score plot for the normalisation to the total integral of the 
spectrum for each sample. Here we can see a clear separation between the two testing groups, 
along with good clustering of the datapoints within each group. From this we are able to 
observe the apparent differences between the two groups that may be attributed to specific 
alterations in metabolite concentrations. Taken together, these results suggested that the 
most appropriate method for normalisation of the NMR data was to use the total area of the 
spectrum. 
 
4.3.1.3 Metabolite Annotation and Quantification – Spectral Binning  
Figure 4.4 shows a representative spectrum for IDH Mut and WT samples. The PCA plot and 
PCA score plot for the initial cohort of 17 glioma samples can be seen in figure 4.5. The two 
testing groups refer to the IDH mutational status. There was a large overlap between the two 
testing groups when considering PCs 1 and 2. In fact, when looking at the first 3 PCs, this only 
accounts for 68.3% of the overall variance seen throughout all samples. PCA involves the 
transformation of variables in one coordinate system into PCs within a new coordinate system, 
and it is therefore useful to estimate how much each of the old variables (in this case spectral 
bins) contribute to the formation of each of the new PCs. This can be displayed by way of a 
loading plot (figure 4.6). The annotated spectral bins (1.32500005, 1.33500004, 2.0250001, 
3.03500009, 3.2250014, 3.56500006, 3.78500009 and 3.93499994) are the main contributors 
to separation along the x-axis, which indicates biological significance, whereas the points  
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Fig 4.4 Two sample spectra acquired from IDH Mut (red) and WT (blue) patient samples. The insert 
shows a zoom of the crowded aliphatic region. The 2-HG peak at 2.25 is denoted by the yellow Asterix. 
 
scattered along the y-axis are more likely to contribute to the separation of technical 
replicates. The integrals of these spectral bins are at much lower values than others, and 
therefore are more likely to be affected by the presence of noise or any residual baseline 
distortion.  
Although there was not a clear separation in the initial PCA analysis, there is utility in 
assessing the spectral bin that the loading plot has shown to contribute to the slight degree of 
separation between groups that we are able to observe. To do this the spectra were overlaid 
on top of each other and the bins plotted over. Figure 4.7 illustrates sections of the spectra 
that correspond to the bins shown to contribute to the separation from the PCA loading plot. 
Upon inspection, it was evident that each bin did not contain the same integral area of each 
peak from each spectrum. This is due to a varying amount of spectral shift seen between 
samples. For this reason, a more tailored method for metabolite identification was followed, 
whereby a custom pattern file was produced in order to bin the spectra at variable intervals 




Fig 4.5 (a) PCA plot for NMR spectra that had undergone spectral binning at regular intervals of 
0.01ppm. the first three components only account for 68.3% of the variability and there is no obvious 
separation of the groups when plotted in any of the dimensions. (b) PCA score plot for the same dataset. 
There is a large amount of overlap between the WT and Mut groups, although there does seem to be 
a subgroup within the WT samples, demonstrating variability within the testing group that is not 











Fig 4.6 PCA loading plot. When the data is transformed from one coordinate system (spectral bins) to 
another (PCs) the contribution of each of the original variables to the new PCs can be assessed by way 
of a loading plot. The bins that contribute to the variation seen on the PCA score plots can be further 
assessed by evaluating the spectra. The labelled points grouped along the lower end of the x axis are 






Fig 4.7 (a) Raw spectra from all samples overlaid (both IDH WT and Mut). It is evident from this aspect 
that there is some spectral shift between spectra. (b) Zoomed view of the same spectra, plotted 
between 3.0 - 4.0-ppm. This was the region that a number of spectral highlighted in the PCA loading 
plot originate from. (c) The same section of spectra as in (b), but with the spectral bin ID’s plotted. Upon 
closer inspection, it is clear that this method of spectral binning at regular intervals is not appropriate 
as different aspects of peaks from individual spectra are contributing to each bin in varying amounts, 
which introduces bias in the statistical analysis. The bin labels are arbitrary numbers assigned 






4.3.1.4 Metabolite Annotation and Quantification – Custom Pattern File  
As highlighted by the method of binning at regular intervals, a significant level of spectral shift 
was observed between samples from different patients, which may be attributed to 
differences in pH and varying salt concentrations, the reasons for which will be discussed later 
in this chapter. Due to this inconsistency within the data, a different approach was taken 
toward metabolite identification. A pattern file was created that consisted of a spreadsheet 
containing the upper and lower ppm values for each bin, which would be determined peak-by-
peak, so that each bin was to contain the full integral from each peak. Figure 4.8 shows the 
PCA and score plot for metabolomics carried out using the custom edited pattern file to 
determine the bin limits for each peak. Initial inspection of this multivariate analysis shows that 
there is little-to-no separation of the IDH Mut when compared to the WT using this method of 
metabolite identification. When considering the PCA score plot, both the IDH groups are 
severely overlapped, with only 3 Mut samples lying outside the WT region. 
 It is sometimes the case that differences may be observed univariately but not via 
multivariate analysis, and vice versa, and the reasons for this imbalance are explored further 
in this chapter. Here we carried out Wilcoxon rank test as a univariate analysis to conduct 
pairwise comparisons between each identified peak. Using this approach, we were able to 
observe significant differences in 35 metabolites when comparing IDH Mut tumour samples to 
their WT counterparts. Figure 4.9 shows a scatter plot of all identified peaks (both assigned to 
metabolites and unassigned) plotted against the p-value generated from the univariate test, in 
addition to box and whisker plots of metabolites identified to be significantly altered. As 
expected, 2-HG was significantly altered, although unexpectedly the concentration in the WT 
appears to be >0.0mol. Upon closer inspection of the spectrum, the bins dedicated to 2-HG 
peaks contain varying levels of noise and baseline distortion, and the differences in spectral 
shift between samples caused the contributions from these artefacts to present at different 
amounts in each bin. This led to the false detection of 2-HG within the WT samples. 
Extrapolation of this observation throughout the rest of the bins covering the spectra gives a 
clear indication that this phenomenon has occurred in a number of spectral locations, leading 
to varying contributions of each integral to each bin, and therefore varying levels of bias in the 
statistical analysis. This varying contribution of misaligned peaks and noise formed the 
rationale for the individual metabolite fitting approach that was later adopted.  
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Fig 4.8 results from the 1D NMR custom pattern file approach. (a) A PCA plot displaying the first three 
PCs. Note that there is a great deal of overlap between the WT and Mut groups on all PC plots. (b) PCA 
score plot, there is a large amount of overlap between both the groups, with two outliers belonging to 






Fig 4.9 (a) A scatter plot of the adjusted -log(p values) when comparing IDH Mut and WT gliomas using 
a Wilcoxon Mann Whitney univariate test. There are 35 pink points that lie above the significance 
threshold where p<0.05. In the boxes are a selection of metabolite of interest 1. 2-HG. 2. Myo-inositol. 
3. Alanine. (b) Box plots showing the normalised concentrations estimated from the integrals of the 









































































4.3.2 Experimental Results  
4.3.2.1 Metabolite Annotation and Quantification – Spectral Fitting 
Using a custom pattern file order to bucket the spectra for quantification of individual peaks is 
a convenient approach when all the spectra are fully aligned and contain uniform, minimal 
noise and residual baseline distortion. This was not the case with the glioma samples used in 
this study, and elucidation as to why the effect occurred will be covered in the discussion. Due 
to this factor, an alternative approach was taken in order to quantify the metabolites measured 
by metabolomics.  
 Fitting of individual peaks on each spectrum using the Chenomx metabolites library 
allowed for accurate assignment of every peak of interest in all spectra, and therefore a reliable 
concentration to be calculated from the integral of each peak. Figure 4.10 shows scatter and 
box plots from the univariate analysis of both the 1D spectra. From the 1D analysis six 
metabolites were found to be significantly different when comparing the Mut relative to the 
WT tumours, namely an increase in myo-inositol (p<0.0005), an increase in 2-HG (p<0.0005), 
a lower choline (p<0.0005), an increase in 3-hydroxybutyrate (p<0.05), a decrease in alanine 
(p<0.05) and a decrease in methyl-succinate (p<0.05).  
 The metabolite concentrations exported from Chenomx following the fitting routine 
were then also analysed using multivariate approaches, both PCA and PLS-DA. The PCA and 
PCA score plots can be seen in figure 4.11. The PCA analysis shows that the first three PCs only 
account for 49.3% of the overall variance, and when the first two PCs are selected to plot 
against there is a large amount of overlap between the Mut and WT groups, with 2 outliers 
belonging to the WT group and 4 outliers belonging to the Mut group. From these multivariate 
analyses, there was no significant difference between the Mut and WT groups based on their 
metabolic profile.  
 Figure 4.12 and 4.13 shows the results from the supervised multivariate analysis of the 
1D. A PLS-DA model was built for the 1D spectra with 2 components (fig 4.12). The figure shows 
the score plot of the first 2 components and the variance in projection (VIP) scores (fig 4.13) 
for the 20 metabolites that were found to have a VIP score of greater than 1 and therefore 
most influential in discriminating between the groups. The area under the curve (AUC) for the 
receiver operator curve (ROC) for this model was 1 (figure 4.14). As expected, the six 
metabolites that were found to be significantly altered via univariate analysis also featured in 






Fig 4.10 (a) Scatter plot depicting the -log10(p) values from the univariate Wilcoxon Mann-Whiney test 
1) 2-HG. 2) 3-Hydroxybutyrate. 3) Alanine. 4) Choline. 5) Methyl-succinate. 6) Myo-inositol. (b) Box and 






























































Fig 4.11 Unsupervised multivariate analysis from the data generated from spectral fitting. (a) PCA plot 
for the first three PCs. Taking into account the first three PCs, these only account for 49.3% of the 
overall variance, and both Mut and WT groups have poor separation in each of the scatter plots for all 
PCs. (b) PCA score plot for the first two PCs. There is a large degree of overlap between both groups 




Fig 4.12 (a) PLS-DA plot of the first three components, these account for only 42.5% of the variability, 
less than reported by PCA. Like the PCA analysis, there is no obvious grouping on the scatter plots for 
all components. (b) PLS-DA score plot for PC 1 and 2. The pattern observed, including the degree of 
overlap and outlier position is very similar to that from the PCA analysis. Additionally, there is an outlier 









Fig 4.13 Variable importance in projection (VIP) plot, showing the contribution or importance of a 
variable to the model. Since VIP scores are calculated for each component, when more than one 
component is used to calculate the feature importance, such as here, the average of VIP scores is used. 
From this we can deduce that myo-inositol contributes to the most amount of variation, on average, 







Fig 4.14 ROC curve for the 2 compartment supervised multivariate PLS-DA model calculated from the 
1D NMR data. Here these data produced a model with a sensitivity and specificity of 100% resulting in 
an AUC of 1.  
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Fig 4.15 A 2D HSQC 1H – 13C spectrum of the aliphatic region of IDH WT(black) and IDH Mut (pink) 
overlaid. The yellow box indicates the location of the 2-HG peak. Here the 1H resonance can be seen on 
the x-axis and the 13C resonance on the y-axis.  
 
metabolites were shown to be influential in discriminating between IDH Mut and WT tumours. 
All metabolites with a VIP score >1 were used in the metabolite enrichment pathway analysis.  
 
4.3.2.2 2-Dimensional HSQC NMR for metabolite annotation and quantification 
Although there is a wealth of information that may be gathered from 1D NMR spectra, 
resolution and subsequent quantification of certain metabolites, especially those residing in 
the crowded 0.0-3.0 ppm range, can often be problematic. 2D NMR helps to circumvent 
overcrowding of peaks. An example 2D HSQC spectrum can be seen in figure 4.15. The 
presence of 2-HG in the IDH Mut tumours can unambiguously be confirmed via 2D NMR  
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Fig 4.16 (a) A scatter plot to display the -log10(p) values from the Wilcoxon rank test for the normalised 
concentrations calculated from 2D NMR following multiple comparisons correction. A total of 22 
metabolites were found to be significantly altered when comparing WT and Mut tumour groups. 1) 2-
HG p<0.05. 2) Adonitol p<0.0005. 3) Alanine p<0.0005. 4) Myoinositol p<0.0005.  (b)  Box and whisker 
pots to demonstrate the alterations in metabolite concentration between Mut and WT groups. 2-HG, 





















































































Fig 4.17 (a) PCA to show the first 3 PCs. Together these PCs only account for 50% of the variation seen 
throughout the data. There is a large amount of overlap observed when each of the first 3 PCs is plotted 
against each other. (b) PCA score plot for the first two PCs. There is a large amount of overlap observed 







Fig 4.18 (a) 2D score plot of the first two components. There is a degree of separation between the WT 
and Mut groups based on the metabolite concentrations calculated from 2D NMR. Although there is 
some residual overlap between the two groups with this model, certain metabolites appear to be 
significantly altered between the two disease states. (b) VIP scores for the first component of the PLS-
DA analysis. Here we can see a number of metabolites that were shown to be important ion the 






spectroscopy (fig 4.15). The results from the univariate analysis can be seen in figure 4.16. Of 
the 6 metabolites that were shown to be significantly altered when comparing IDH Mut and 
WT gliomas from the 1D NMR spectra, 4 metabolites were shown to be significantly altered 
between the two groups using the 2D quantification method, along with a further 18 
metabolites. From the 2D quantification and univariate analysis 22 metabolites were 
significantly altered. The scatter plot and selected box plots can be seen in figure 4.16. As 
expected, 2-HG was found to be significantly altered, however it was not the most significantly 
different metabolite.   
 The results from the multivariate PCA analysis can be seen in figure 4.17. The first three 
PCs only account for 50% of the variability within these samples, and when the first two PCs 
are plotted on the 2D score plot, there is a significant overlap between the two groups. The 
results from the PLS-DA analysis provided more separation between the two groups (figure 
4.18). Although the first three PCs only accounted for 46.5% of the overall variability, when 
considering the first two PCs plotted on the 2D score plot, there is a much clearer separation 
between the two groups. The VIP scores can be seen in figure 4.18, which shows that the 
choline peak contributed most to the separation seen in this model. When comparing this to 
the VIP scores calculated from the 1D analysis, myo-inositol again played a significant role to 
the separation, complementing the findings from 1D analysis. 
 
4.3.2.3 Pathway Analysis 
Following identification of  metabolites that were significantly altered between IDH WT and 
Mut gliomas using both a 1D and 2D NMR spectroscopic approach, one can use this 
information in order to estimate upstream cellular pathways that have been subject to 
alteration in the presence of the mutation. 
The pathway results from the metabolites identified as significantly different from the 
1D NMR analysis can be seen in table 4.2 and in graphical form in figure 4.19.  As the same 
pathways are being tested many times, the statistical p values needed to be adjusted for 
multiple comparisons. The total column in table 4.2 refers to the total number of metabolites 
within the pathway, and the hits is the number of metabolites from the input list that actually 
matched with metabolites known to be part of the pathway. From the 12 pathways that were 
found to have been affected by alterations in the metabolites highlighted by metabolomics 
statistics, only one metabolite from the input list was associated with each pathway.  
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Total Hits Raw p -log(p) Holm-adjust FDR Impact 
Synthesis and degradation of ketone bodies 6 1 0.012412 4.3891 0.99295 0.7671 0 
Taurine and hypotaurine metabolism 20 1 0.040894 3.1968 1 0.7671 0.03237 
Selenoamino acid metabolism 22 1 0.044909 3.1031 1 0.7671 0 
Alanine, aspartate and glutamate metabolism 24 1 0.04891 3.0178 1 0.7671 0.05698 
Glycerophospholipid metabolism 39 1 0.078494 2.5447 1 0.7671 0.0212 
Inositol phosphate metabolism 39 1 0.078494 2.5447 1 0.7671 0.13703 
Butanoate metabolism 40 1 0.080439 2.5202 1 0.7671 0.0048 
Galactose metabolism 41 1 0.082382 2.4964 1 0.7671 0 
Ascorbate and aldarate metabolism 45 1 0.090119 2.4066 1 0.7671 0 
Glycine, serine and threonine metabolism 48 1 0.095887 2.3446 1 0.7671 0 
Cysteine and methionine metabolism 56 1 0.11113 2.1971 1 0.8082 0 
Aminoacyl-tRNA biosynthesis 75 1 0.1465 1.9207 1 0.97666 0 
 
Table 4.2 Results from pathway analysis. Each of the pathways that have been identified as significantly 
altered between IDH WT and Mut only contain 1 hit from the input list of metabolites ascertained from 
1D NMR metabolomics. Following multiple comparison adjustment, no pathways were found to be 
significantly altered between the two disease states from this analysis. 
Fig 4.19 Graphical depiction of pathway result. X axis corresponds to pathway impact which is 
determined by the number and placing of nodes within the pathway. Y axis corresponds to -log10(p) 
determining the statistical significance of the alteration within the pathway. The size of the node 
corresponds to the total (number of nodes in pathway) and the colour reflects the significance level of 




Table 4.3 Results from the pathways analysis carried out using the list of 24 metabolites found to be 
significantly altered between IDH Mut and WT gliomas from 2D NMR metabolomics. As was seen in the 
pathway analysis using the 1D NMR identified metabolites, 2-HG has not been identified in any of the 
above pathways. Galactose metabolism was shown to be the alteration with the highest significance 
and incorporates 4 of the input metabolites from metabolomics analysis (Sucrose, D-glucose, D-
mannose, myoinositol). Galactose metabolism was the only pathway that was significantly altered 
following multiple comparison adjustment  
 Total Hits Raw p -log(p) Holm adjust FDR Impact 
Galactose metabolism 41 4 0.00018678 8.5856 0.014942 0.014942 0.01992 
Glycine, serine and threonine metabolism 48 3 0.0049228 5.3139 0.3889 0.19691 0.28435 
Aminoacyl-tRNA biosynthesis 75 3 0.016933 4.0785 1 0.45154 0 
Amino sugar and nucleotide sugar metabolism 88 3 0.02589 3.6539 1 0.51781 0.01122 
Glycerophospholipid metabolism 39 2 0.033241 3.404 1 0.53186 0.05375 
Starch and sucrose metabolism 50 2 0.05236 2.9496 1 0.69813 0.0765 
Cyanoamino acid metabolism 16 1 0.1135 2.1759 1 0.97347 0 
Taurine and hypotaurine metabolism 20 1 0.13991 1.9667 1 0.97347 0.03237 
Riboflavin metabolism 21 1 0.1464 1.9214 1 0.97347 0 
Selenoamino acid metabolism 22 1 0.15284 1.8784 1 0.97347 0 
Thiamine metabolism 24 1 0.16558 1.7983 1 0.97347 0 
Alanine, aspartate and glutamate metabolism 24 1 0.16558 1.7983 1 0.97347 0.05698 
Porphyrin and chlorophyll metabolism 104 2 0.18101 1.7092 1 0.97347 0 
Valine, leucine and isoleucine biosynthesis 27 1 0.18436 1.6909 1 0.97347 0 
Glycolysis or Gluconeogenesis 31 1 0.20877 1.5665 1 0.97347 0 
Pentose phosphate pathway 32 1 0.21476 1.5382 1 0.97347 0 
Glycerolipid metabolism 32 1 0.21476 1.5382 1 0.97347 0.00714 
Methane metabolism 34 1 0.22662 1.4845 1 0.97347 0 
Glutathione metabolism 38 1 0.24984 1.387 1 0.97347 0 
Nitrogen metabolism 39 1 0.25554 1.3644 1 0.97347 0 
Inositol phosphate metabolism 39 1 0.25554 1.3644 1 0.97347 0.13703 
Ascorbate and aldarate metabolism 45 1 0.28888 1.2417 1 0.97608 0 
Lysine degradation 47 1 0.29968 1.205 1 0.97608 0 
Primary bile acid biosynthesis 47 1 0.29968 1.205 1 0.97608 0.00822 
Fructose and mannose metabolism 48 1 0.30503 1.1874 1 0.97608 0.02948 
Pentose and glucuronate interconversions 53 1 0.33116 1.1052 1 1 0 
Cysteine and methionine metabolism 56 1 0.34639 1.0602 1 1 0 
Purine metabolism 92 1 0.50541 0.68239 1 1 0 
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Furthermore, 2-HG was not highlighted as a significant metabolite in any pathways highlighted, 
and following correction for multiple comparison, no pathways were found to be significantly 
altered from the 1D analysis.  
 The results of the pathway analysis carried out on metabolites shown to be 
significantly altered between IDH Mut and WT obtained from 2D NMR metabolomics can been 
seen in table 4.3. The only pathway that appeared to be significantly altered following multiple 
comparison correction was galactose metabolism, which incorporated 4 of the inputed 
metabolites within the network of 41 metabolites that comprise the pathway. Once again, 2-
HG was not implicated in any of the pathways found to be significantly altered from the input 
list of metabolites. 
 
4.4 Discussion  
4.4.1 NMR Metabolomics to Study IDH Mutation in Glioma 
Here we present results that have demonstrated a metabolic phenotype in IDH Mut glioma 
tissue samples using 1D and 2D NMR spectroscopy. In total 6 metabolites were found to be 
consistently altered across all experimental and analytical methods, and these results can 
suggest why IDH tumours behave in the way that they do, and may facilitate the formation of 
new hypotheses for future investigation into the pathophysiology of the disease.  
The importance of IDH mutation in glioma has been widely acknowledged and accepted 
for a number of years, which is reflected in its inclusion into the WHO diagnostic criteria for 
glioma in 2016. Although it is clear that the mutation is integral to diagnosis and 
prognostication, there is an unmet need to 1) find a reliable and reproducible way to non-
invasively probe for the mutation 2) understand the pathophysiology of the mutation on 
progression of the disease. Metabolomics provides an ideal avenue of investigation for both 
these purposes. The systematic profiling of metabolite concentrations provides an indication 
of global cellular function and has the ability to reflect aberrations in a myriad of cellular 
processes such as genetic stability, gene transcription, translation and protein homeostasis. If 
we are to understand more about the influence of IDH mutation within glioma, then a global 
view of metabolic modifications is an ideal place to start. Moreover, the utility of non-invasive 
detection in-vivo via MRS may be aided by assessing for metabolites other than 2-HG that are 
significantly altered in the presence of the mutation, in order to form a detectable metabolic 
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‘fingerprint’. The concept of combined metabolic biomarkers may benefit the acceleration of 
clinical translation of MRS diagnostic techniques, as currently the reliability and reproducibility 
of 2-HG detection methods is widely debated25.  
A number of previous studies that have looked into metabolic profiles of gliomas using 
a variety of 1 and/or 2D NMR spectroscopic methods at a range of magnetic field 
strengths37,159,160. Although it is well known that IDH mutation facilitates the production and 
subsequent accumulation of the oncometabolite 2-HG, quantitative information pertaining to 
overall metabolome alterations and phenotypic aberrations that expedite the progression of 
malignancy in the presence of the mutation is sparse. This is particularly true when considering 
information that has been ascertained from resected tumour samples. There are a number of 
studies concerned with the metabolic profiling of cultured glioma cell lines37,161,162, however 
1D cell culture does not reflect the true heterogenous tumour environment. It has been 
demonstrated that the heterogeneity of tumours, including gliomas, gives rise to discrete sub-
populations of tumour cells, and that this is a significant contributor towards malignant 
progression163–165. It is therefore reasonable to address the question as to what influence IDH 
mutation may have on the development and advancement of the disease, and which metabolic 
shifts are consistent with the mutation for in-vivo diagnostic detection. Thus, performing the 
metabolomic studies on extracted tumour tissue samples would enable better understanding 
of the factors contributing to the pathophysiology.  
Previous studies such as the investigation conducted by Hyung et al159 included a 
number of tumour samples from a range of cellular phenotypic origins, including ganglioma 
and neurocytoma, which are of mixed glial and neuronal cell progenitor origin. As mutations 
in the IDH gene have only been implicated in gliomas and acute myeloid leukaemia, inclusion 
of neurocytoma or ganglioma is not relevant to address the question about the impact of IDH 
mutation in NMR metabolomic profile. Here we have included only those tumours that are 
classed as glioma by the WHO guidelines, encompassing astrocytoma, oligodendroglioma and 
glioblastoma, and in which, IDH mutations are commonly observed. Although these samples 
may have different glial origins, and therefore different phenotypic manifestations, we are 
scrutinising the role of IDH and inspecting for potential biological signatures that may 
contribute towards non-invasive detection. The involvement of IDH mutation in the prognosis 
and diagnosis of all gliomas is analogous throughout the various subgroups. In addition, when 
considering the search for a spectroscopic signature combining additional metabolite 
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alterations with 2-HG for in-vivo detection, it is desirable to assess for metabolic changes that 
occur independent of tumour subtype.  
The initial phase of this investigation was carried out on a cohort of 17 tumour samples. 
The spectra that were acquired were analysed first using the spectral binning method as 
previously described. The results from the PCA showed there was some degree of separation 
between the Mut and WT groups, however there was still a significant amount of overlap 
between groups based on metabolite concentration. To investigate which peaks, if any, 
contributed to the degree of separation the PCA loading plot was examined. Loading plots 
allowed us to examine which of the original variables, which here are the metabolites, 
contribute most to the variation seen in the new PCs. The variation seen along the x axis is 
likely to have arisen due to biologically relevant factors, whereas the variation seen along the 
y axis is likely to be due to technical replicates. From inspection of this plot (fig 4.6) it was 
possible to determine which of the spectral bins had contributed to the separation seen in the 
PCA. Upon close inspection of the bins and the sections of each of the spectra that the bin 
boundaries bisected, a number of the spectral bins highlighted by the loading plot were not 
over a specific peak of interest, rather they contained varying amounts of residual baseline 
noise. Moreover, those bins that were flagged by the loading plot that were positioned over 
potential peaks of interest contained varying proportions of integrals of each of the peaks, as 
the spectra were not all aligned with each other. This indicates that the variation seen in the 
PCA that allowed for separation of the Mut and WT groups does not originate from biologically 
relevant distinction within the spectra. From this relatively rapid and simple analysis we were 
able to determine that the numerical data being used for metabolomics analysis was not 
appropriate, as it did not reflect metabolic changes within the samples, rather it was a 
reflection of spectral shift between each sample. 
In order to ascertain data that did reflect alterations in the metabolome of these 
samples, we constructed a custom pattern file to determine the ppm boundaries for each of 
the peaks of interest. For this process, a publicly available template of metabolites of interest 
found in neuroblastoma cells was used. Using literature searches, this list of metabolites was 
edited via the addition and subtraction of a number of molecules, so as to include only those 
metabolites that are relevant to glioma. All 22 subjects included in the study were plotted over 
each other and the upper and lower ppm bounds for each of the identified peaks of interest 
were used to determine the spectral bin limits. When metabolite concentration data calculated  
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 Fig 4.20 A geometric depiction of the relationship between univariate and multivariate hypothesis 
testing confidence intervals. The ellipse represents the 95% confidence interval of the multivariate 
distribution of the two metabolites A and B. The inner square represents the two independent 95% 
confidence intervals calculated from normal distribution of the two (uncorrelated) metabolites with the 
same variance166. 
 
from spectra using this method were used in an initial PCA analysis, the 2D plot showed almost 
complete overlap with no separation. When these data were analysed using a univariate 
approach, we were able to distinguish 35 metabolites that were significantly altered between 
Mut and WT groups. There are a number of reasons as to why significant differences between 
variables may be detectable univariately but not via multivariate testing and vice versa.  
As multivariate analysis methods must consider all variables at the same time, there is 
often a large amount of information to handle. Information may therefore easily be masked 
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attributed solely to a small subset of variables within large datasets consisting of hundreds of 
metabolites. If this subpopulation of biologically relevant variables is not previously known, 
then the requirement to measure as many variables as possible is irrefutable. Despite the 
measurement of a large number of variables increasing the probability of measuring something 
with biological significance, the burden of such an approach is that one must at the same time 
consider a large number of uninformative variables that may impede the power of the 
multivariate analysis166. In addition to the potential masking of biological data by uninformative  
variables, the difficulty in estimation of correlations and covariances may impact on the ability 
to detect significant differences when applying multivariate analysis when compared to 
univariate methods. This is a factor in the performance of multivariate methods, particularly 
when a large number of variables are being measured over a relatively small number of 
samples167. The use of multivariate methods requires that the true covariance matrix from the 
population from which the samples have been drawn are known. However, as this is not 
known, some estimate must be used. Estimating a covariance matrix across only a few samples 
is a known difficulty in statistics, and it has been shown that in cases where there are a large 
number of variables from a small sample size the usual estimation methods fail to generate 
reliable matrices166. An additional factor that may contribute towards the failure of 
multivariate testing to uncover significant differences where univariate testing performs well 
is that testing procedures from both methods may not overlap. To illustrate this let us consider 
two metabolites, A and B, belonging to two groups 1 and 2. In a univariate approach each of 
the metabolites A and B will be assessed by performing independent tests, such as a t-test. For 
this example, we will test the null hypothesis at the 95% confidence interval, whereby Ho is the 
difference between the means of metabolites A and B is 0. We accept H0 if the mean (o) lies 
within the 95% confidence interval.  In figure 4.20 the rectangular area represents the 
univariate 95% confidence interval. Using a multivariate method, the means of both 
metabolites A and B are assessed simultaneously. We are now assessing whether the means 
of both metabolites A and B (o, o) are within the simultaneous 95% confidence interval, which 
is represented by the ellipse in figure 4.20. At this point, it is clear from figure 4.20 that the 
95% confidence intervals for both the univariate and multivariate methods do not completely 
overlap, and therefore there may be a difference in acceptance or rejection of H0 dependant 
on location of the point (o, o). Figure 4.20 allows us to geometrically explain 4 instances that 
may arise when applying both univariate and multivariate methods: 
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1. The point zero lies within both the univariate and multivariate 95% confidence 
intervals (region P), and therefore application of either of these testing methods will 
both lead to acceptance of the H0 and there is no distinction between the two testing 
groups.  
2. The point zero lies outside both the univariate and multivariate 95% confidence 
intervals (region Q), indicating a significant difference at using either approach. 
3. The point zero is inside the ellipse, but resides outside the rectangle (region R). Here 
application of a multivariate methods will not detect a significant difference, and we 
will accept H0, however use of a univariate approach will lead to the detection of a 
significant difference in at least one of the metabolites, A or B, at the 95 % confidence 
interval.  
4. The point zero is outside the ellipse but can be seen inside the rectangle (region S, 
figure 4.22). In this instance the multivariate test will detect a significant difference at 
the 0.05 level, whereas the univariate test will fail to recognise any distinction 
between groups 1 and 2 based on metabolites A and B. 
The third point coupled with figure 4.20 describes why it may not be possible to detect 
significant differences using a multivariate approach, but it is possible to see discrimination 
between two testing groups using univariate methods. It is worth noting that in practice this is 
a more complex problem, as univariate testing requires correction for multiple testing, but put 
simply if we were to apply this to figure 4.20 it would result in broader univariate confidence 
intervals. Taking into account the aforementioned differences that can arise in the application 
of both statistical testing strategies, in addition to the fact that metabolomics is the practice of 
attempting to characterise and interpret biological phenomena based on the interrelation of 
metabolites, it may be argued that the most appropriate method for detecting biologically 
relevant information pertaining to differences between two testing groups is the employment 
of both univariate and multivariate analyses.  As can be seen in our results, both methods can 
produce complimentary information, as well as additional information regarding statistical 
differences. Although the results from univariate and multivariate analysis of the data 
produced by application of a custom pattern file to set bucket limits for spectral binning 
contradicted each other, the complimentary combination of statistical approaches is nicely 
illustrated when considering the results generated from individually fitted spectra. 
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 The results generated from the statistical analysis of the data ascertained from fitting 
each peak of interest in each spectrum show significant differences in 6 metabolites when 
using a univariate approach, and these results were complimented by the multivariate tests. 
Moreover, not only did the metabolites that were shown to be significantly altered in the 
univariate method yield significant results in the multivariate approach, a number of other 
potential metabolites were highlighted as contributing factors in the separation seen in the 
PLS-DA analysis. Considering the metabolites that have been shown to be significantly altered 
between the Mut and WT tumours in addition to 2-HG, both myo-inositol and alanine were 
consistent in both statistical analyses, as well as choline and 2-hydroxybutarate. In addition to 
the 1D analyses, we carried out quantitative metabolomics on 2D HSQC data and our findings 
complement the 1D results and provide additional information pertaining to metabolic 
alterations that have been observed in the presence of the mutation, whereby 22 metabolites 
were found to be significantly changed. Utilising heteronuclear 2D NMR allowed us to 
unequivocally identify the coupled metabolites, which is generally a problem in the over-
crowded 1D spectrum. Decoupling the peaks using 13C chemical shifts along the second 
dimension allowed us to observe alterations in metabolites that may have previously been 
overlapped by those metabolites found in greater abundance in both the healthy and diseased 
brain tissue. It is important here to note, however, that this method of 2D spectroscopy is not 
viable in vivo, especially not at clinical field strengths. 
 One drawback to the inclusion of 2D NMR in quantitative studies is that peak volumes 
are dependent on a number of peak-dependant parameters such as heteronuclear coupling 
constants, pulse delays and off-resonance effects. These confounding factors are much more 
intricate in 2D when compared to 1D quantitative NMR, where the peaks are solely dependent 
on the number of equivalent spins and the concentration of the analyte, given that full spin 
relaxation has been achieved168. The multi-pulse nature of 2D NMR has led to speculation 
within the spectroscopy community that such sequences may not be used to determine 
absolute concentrations and cannot be employed in a quantitative manner. In this 
metabolomics approach we were not concerned with absolute concentrations, rather we were 
interested in whether a given metabolite (or set of metabolites) is more abundant in one group 
of samples when compared to the other. For this, normalised values to the total intensity allow 
for inter-subject comparison in order to determine if there is fold-change in metabolite levels 
between WT and Mut samples.  
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 Another limitation of multidimensional quantitative NMR is the relatively long 
acquisition time due to the requirement to obtain an adequate number of t1 increments to 
sample the indirect F1 dimension in order to yield a sufficient resolution. In addition to the 
obvious impact on usage of the spectrometer, these long acquisition times can impact on the 
quality of the data collected, as spectrometer instabilities cumulate over time. These 
instabilities can include variation in receiver gain, phase, B0 inhomogeneity, lock instabilities 
and variations in pulse angle169,170. These perturbations, whist negligible in the direct F2 
dimension where points are acquired over a short space of time, can build up as additional 
noise within the indirect F1 dimension where acquisition requires long TR values. Consideration 
of these limitations is important when incorporating 2D quantitative approaches within 
metabolomics. Here we have combined both 1D and 2D to provide complementary 
information pertaining to metabolic aberrations, rather than relying on the quantitative 
capacity of just one of the methods of investigation. Further to this, with respect to clinical 
investigation, this type of spectroscopy is not possible in humans at clinical magnetic field 
strengths. The incredibly low natural abundance of 13C would require scan times of many hours 
in order to acquire enough signal to produce a spectrum that is interpretable. The spectra in 
this experiment were acquired on a 700 MHz magnet, which is equivalent to 16.5 tesla and 
required 8 hours of acquisition time, which already far surpasses clinical scan times. At 3 tesla 
to obtain spectra with reasonable SNR for clinical interpretation, this would be unfeasibly long. 
 The results of the 2D analysis showed that univariately 22 metabolites were indicated 
as significantly altered between IDH Mut and WT tumours, including 2-HG, alanine, myo-
inositol and choline, all of which had been highlighted in the 1D univariate analysis. 
Multivariate testing showed separation between the two testing groups, where the PLS-DA 
performed better than the PCA, which is to be expected when considering reduced sample size 
of a heterogeneous nature, such as here. Whilst the unsupervised PCA method is excellent at 
providing an unbiased way of reducing data dimensionality, it can only perform optimally when 
the intra-group variation is sufficiently less than the inter-group variation. The supervised 
approach of PLS-DA relies on class membership of each variable in order to reduce 
dimensionality and determine separation. The VIP scores generated from the PLS-DA provided 
additional complementary information implementing myo-inositol, alanine and choline as 
principal metabolites in the separation between the two testing groups. 
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 Our results showed that using a combination of both 1D and 2D NMR spectroscopy, in 
addition to both multivariate and univariate analysis, we have been able to identify six 
metabolites that are consistently altered in the presence of IDH mutation across all analyses. 
Furthermore, we have shown that by combining the various analyses of the different spectra, 
we were able to distinguish a number of other metabolites that may contribute towards our 
understanding of the clinical phenotype that could have been overlooked should only a single 
approach have been adopted. In addition to the expected 2-HG, we observed increases in level 
of myo-inositol and 3-hydroxybutyrate as well as decreases in choline, alanine and methyl-
succinate. 
 Myo-inositol and its phosphate derivative-namely inositol hexasixphosphate (InsP6)-
have been implicated in a wide variety of diseases and are gaining increasing momentum 
within the field of oncology171. Myo-inositol may be attributed to a multiplicity of functions 
throughout the human body and has been shown to have regulatory influence over processes 
such as chromatin remodelling, p53 activation, mRNA transcription and cytoskeletal 
configuration to name but a few. The significant increase in myo-inositol in IDH Mut tumours 
may contribute towards the increased radio-chemosensitivity and overall survival rate via a 
number of molecular mechanisms. First, via its influence over the p53 network within the 
apoptosis pathway. The selective activation of p53 is a crucial step in the commitment of 
cellular fate to apoptosis/proliferation inhibition171. It has been shown that an increase in 
Ins6/myo-inositol increases levels of p53 several fold, and that activation of p53 in turn, 
increases the endogenous production of further myo-inositol, re-enforcing apoptotic 
commitment via a positive feedback loop172. In addition, the observed increase in intracellular 
myo-inositol is known to support growth inhibition, and may contribute towards the 
prevention of the development of chemo-resistant cells172. Further to dysregulation of p53 by 
excess myo-inositol build-up in Mut tumours, increased survival may also be conferred via 
inhibition of the PI3K/Akt pathway. PI3K induces the phosphorylation-dependant activation of 
Akt, which in turn functions as a regulator of cell cycle progression, dictating the aggressive 
and invasive nature of cancer cells173,174. Myo-inositol and InsP6 have been shown to 
significantly reduce expression of both the protein and mRNA of PI3K expression, as well as 
inhibiting Akt phosphorylation173–175. With this in mind, the increase in myo-inositol that we 
observed within the Mut tumours may play a role in the protective phenotype that is observed 
clinically, however the absolute cause of myo-inositol increase within the Mut tumours is yet 
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to be elucidated, as our pathway analysis failed to identify a significantly altered pathway with 
its inclusion. Further investigation is required to uncover the mechanisms by which this 
particular metabolite functions as both a barrier to malignant progression and facilitator for 
increased radio-chemosensitivity.  
 In addition to the increase in myo-inositol within Mut tumours, we observed a 
significant decrease in alanine concentration. Cancer cells characteristically exhibit non-
oxidative D-glucose metabolism (glycolysis), whereby mitochondrial respiration is impaired, 
which according to Warburg’s hypothesis, is a driving force behind malignancy176. Although 
there is speculation as to whether the Warburg effect actually causes malignancy, it has been 
demonstrated that impairing D-glucose metabolism in malignant cells induces oxidative 
metabolism, which has been implicated in the slowing of malignant growth177,178. Further to 
this, it has been shown that the conversion of L-pyruvate into L-alanine via the enzyme L-
alanine aminotransferase (ALAT) is a crucial step in glycolysis, and therefore a factor in the 
development and progression of the malignancy179. Moreover, the administration of ALAT 
inhibitors can shift the metabolism of malignant cells towards a more oxidative phenotype179. 
Although here we were unable to determine the mechanism by which IDH mutation causes a 
decrease in alanine, the reduction in the metabolite concentration may reflect a shift away 
from glycolysis towards oxidative metabolism, whereby less pyruvate is undergoing conversion 
into L-alanine. This possible shift in metabolism may facilitate the decrease in the invasive 
nature of the cancer cell, slowing tumour growth in vivo. 
 The observed decrease in choline that we observed in the Mut tumours when 
compared to the WT may be coherent with the slower growth rate and increased overall 
survival of those patients harbouring the mutation, as it has previously been shown that 
increased choline correlates with increased cell density in glioma180. Furthermore, it has been 
demonstrated that choline is a crucial step in the synthesis of the phospholipid component of 
cell membranes, and that increased phosphocholine is intrinsically linked to increased 
cellularity and proliferation index in glioma181,182. 
 In addition to the above alterations, we also observed an increase in the ketone body 
3-hydroxybutyrate. It has been demonstrated that glioma cells that are under glucose 
restriction are unable to utilise ketone bodies for metabolism, suggesting a survival 
disadvantage183. This has led to the proposed benefits of a ketogenic diet in conjunction with 
chemo/radiotherapy for the treatment of glioma. Here, due to limited meta data collection, 
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we are unable to determine whether the increase in 3-hydroxybutyrate is a cause of a change 
in diet of the patient, or whether this increase is due to an intrinsic shift in intracellular 
metabolism in the presence of the mutation. Either due to external or internal factors, this 
metabolic observation is likely to contribute to the increased overall survival and obtaining 
detailed participant information would be of major benefit to future metabolomics studies of 
this nature. 
 The consistent observation of a reduction in methyl succinate may also fall in line with 
the favourable clinical phenotype of IDH Mut patients, as it has been shown that the 
accumulation of succinate, which is a product of hydrolysation of methyl-succinate, can 
become oncogenic184. Increased levels of the metabolite have been demonstrated to increase 
genome-wide histone methylation and accumulation of hypoxia-inducible factor-, both of 
which serve as oncogenic factors to push cells towards a malignant state184. Therefore, the 
reduction of this metabolite in the Mut tumours may aid in the acquisition of a favourable 
phenotype. 
 In addition to our statistical analysis of the spectra, we also carried out pathway 
enrichment analysis. This novel statistical approach uses online databases of metabolic 
pathway, available through metaboanalyst. It assesses which of these pathways are statistically 
enriched by any of the metabolites identified as significantly altered in the presence of IDH 
mutation, in the NMR experiments185. One of the major limitations to this approach with 
regards to this experiment, is that 2-HG, the major metabolic characteristic of IDH Mut 
tumours, does not feature in any of the pathways within the database. Furthermore, this tool 
has been constructed as a complimentary tool to guide further investigation. The method 
employs the use of statistics in order to suggest metabolic pathway shifts, rather than 
biological data itself. In conclusion, this approach did not contribute much benefit towards this 
study, as the metabolic pathways concerned are unknown. 
A number of limitations influenced the potential scope of this study. Firstly, the sample 
population was both small and unbalanced. We had originally set out to include a total of 40 
patient samples, with approximately 20 from each testing group. The tissue collection strategy, 
working alongside clinicians, took time to establish and identifying suitable patients for 
inclusion before they underwent surgical resection was difficult. As such, only 22 patients were 
included in the analysis. In addition to the small sample size, the heterogeneity of the tumour 
samples, in size and types of tumour tissue that were included (blood vessels, lipids such as 
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myelin, necrotic regions) may have introduced unwanted variability into the data. Finally, the 
previously described 2D NMR experimentation and analysis was carried out using the same 
metabolomics approach as the 1D. 2D NMR, however, inherently presents a larger number of 
variables for analysis, and consequently will additionally contain a larger number of 
uninformative variables for statistical analysis when looking at all the peaks identified. The 2D 
NMR sequence could have been optimised and tuned to the peaks that were previously 
identified in the 1D experiment, in order to further ratify the results. 
 
4.5 Concluding Remarks 
Mutations in the IDH1/2 gene in glioma have been shown to facilitate the aberrant production 
of the oncometabolite 2-HG, which has been suggested as a putative biomarker for the non-
invasive detection of the mutation in vivo. Furthermore, those tumours that possess the 
mutation have increased survival rates and have been shown to respond more favourably to 
radio- and chemotherapy. Here we have assessed the cellular metabolome in glioma samples 
in order to further understand the impact of the mutation on the development and 
progression of the disease, whilst additionally searching for other spectroscopic markers 
alongside 2-HG that may be used as a biomarker in the detection of the mutation. We have 
demonstrated that using high resolution 1D and 2D high-resolution NMR spectroscopy, a 
number of metabolites, including myo-inositol and alanine, were significantly altered between 
IDH Mut and WT tumours in addition to 2-HG. The viability of the use of these alterations as 
biomarkers needs to be further explored in order to determine reproducibility, moreover 
investigations into the recapitulation of these observations in vivo is required to assess 
translation potential. However, the shifts in metabolic phenotype that have been discerned 
may be used to form hypotheses in the investigation as to how IDH Mut tumours display 
increased survival and treatment response. A deeper understanding of the molecular 
mechanism driving the progression of the disease and the influence of individual molecular 
changes may guide the development of targeted strategies for the treatment of glioma, as we 
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The production and subsequent accumulation of the oncometabolite 2-HG, by IDH Mut glioma 
cells has been suggested to be a putative biomarker for the non-invasive detection of the 
mutation via MRS. This study set out to explore the clinical utility and translatability of a novel 
semi-LASER MRS pulse sequence with a TE of 110ms, which has been optimised for the in vivo 
detection of 2-HG, and therefore IDH mutation. 
 In order to carry out this investigation we originally planned to recruit a total of 40 
patients who would be scanned using a novel semi-LASER sequence prior to surgery. The 
mutational status of the patient would then be confirmed by a pathologist. The MRS sequence 
in question was developed by Uzay Emir at the fMRIB group at Oxford University186. As such it 
was shared with our group for the purpose of this study and had to be installed on a clinical 
system at the Walton Centre NHS Foundation Trust, where the work was carried out. Although 
delays in ethical approval and technical issues with the installation and running of the sequence 
stalled the commencement of the study, a number of spectra of varying quality, from a range 
of anatomical locations, where acquired from glioma patients. The spectra were analysed in 
the commercial software LCModel, using a custom basis set containing 2-HG that was also 
shared with us by the fMRIB group led by Uzay Emir186,187. This work focuses on the clinical 
translation of novel MRS advancements in order to strengthen radiological diagnostic 
practices.  
 
5.1 Introduction  
5.1.1 Detection of 2-HG via MRS 
There are few known biomarkers that are as reflective of the underlying molecular changes 
seen in tumour pathology as 2-HG. In fact, accumulation of this metabolite is the only known 
direct consequence of a genetic mutation that can be detected and quantified using non-
invasive imaging techniques. The markedly increased concentration of 2-HG in IDH mutant 
tumours has been demonstrated to correlate with tumour cellularity, and its accumulation 
may also be used to guide tissue sampling during surgery16. Although 2-HG represents as an 
attractive marker for diagnosis and monitoring of disease progression, unambiguous detection 
via MRS has proven difficult to establish. Complex spectral overlap by a number of metabolites, 
such as glutamate, glutamine and gamma-aminobutyric acid (GABA) (Figure 5.1), found in 
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abundance within healthy brain tissue, often confound the identification and detection of 2-
HG as well as compromise accurate quantification of metabolite concentration. 
2-HG  consists of five non-exchangeable scalar coupled protons comprising a complex 
5-spin system (Figure 5.1)188. In addition to the 5-spin system, the J-coupling pattern of 2-HG 
leads to several multiplets with peaks identifiable at three spectral locations at a field strength 
of 3T centred around 4.02 ppm (H2), 2.25 ppm (H4 and H4′) and 1.9 ppm (H3 and H3′)189. The 
largest identifiable peak is located at 2.25 ppm due to the H4 and H4′ protons that resonate 
proximally to each other190. However, there is a severe spectral overlap from a number of other 
physiologically occurring metabolites at this location, including glutamate (Glu), glutamine 
(Gln) and N-acetlyaspartylglutamate (NAAG), among others16,191. The influence of these 
overlapping resonances becomes more prevalent at clinically used field strengths (1.5-3T), as 
lower fields and shorter acquisition times lead to inadequate spectral resolution, resulting in 
complex spectra that are challenging to resolve189,192. 
 Several methods for detection of 2-HG in-vivo have been proposed to optimise MRS for 




Fig 5.1. Simulated MR spectrum of 2-HG and overlapping metabolites. The largest 2-HG peak at 2.3 ppm 
is overlapped by a number of other metabolites found in abundance in brain tissue. 2-HG = 2-
hydroxygluarate, Glu = Glutamate, Gln = Glutamine, GABA = gamma-aminobutyric acid, NAAG = N-





Fig 5.2. In vivo MR spectra from glioma patients acquired using single-voxel Echo Time (TE) 97 ms PRESS 
sequence at 3T, fitted using an LCModel. (a) grade IV Glioblastoma (GBM) IDH Wild Type (WT), notice 
the absence of the 2-HG peak at 2.25 ppm; (b) grade III Oligodendroglioma IDH1R132H, 2-HG peak at 
2.25ppm. Taken from Choi et al.16 
 
designed to eliminate the confounding spectral overlap, and reliably quantify the 2-HG 
concentration in patients with IHD mutant glioma. The spectral overlap observed at the 
multiplets generated by the H4 and H3 peaks may induce a high rate of false positives when 
attempting to identify 2-HG if spectra are acquired via conventional 1H-MRS methods, and 
fitted using standard post-processing techniques.  
The feasibility of detection of 2-HG in-vivo at clinical field strengths, using a standard 
single-voxel point-resolved spectroscopy (PRESS) sequence with a TE of 30 ms has been 
reported by Pope et al.19 The acquired spectra were fitted with the LCModel software (http://s-
provencher.com/lcmodel.shtml) using standard spectral fitting algorithms187. Using this 
method, the authors19 reported a 26% false positive detection rate in IDH-WT tumours, due to 
severe overlap of the 2-HG signal with Glu and Gln at 2.25 ppm. Although short echo PRESS 
sequences are widely available in most clinical scanners, the high false positive detection rate 
limits the practical potential of this method for detection of 2-HG. Ex vivo quantitation via liquid 




MRS 2-HG measurements and true alterations in 2-HG concentration19. Additionally,  although 
no changes in Glu or Gln could be observed in the IDH mutated subjects, there were additional  
 
Fig 5.3. 2D Correlation Spectroscopy (COSY) of human patients acquired at 3T, where the 3 × 3 × 3 cm3 
voxel was placed over the tumour region, shown by the red box. (a) primary GBM patient IDH WT, there 
is a clear absence of cross peak in the region of 2-HG (demarked by green rectangle); (b) grade III 
anaplastic astrocytoma patient IDH1R132H; the 2-HG signal is unambiguously identifiable at the centre of 
crosshair intersection. Adapted from Andronesi et al.191 
 
metabolic alterations such as increased Choline (Cho). Cho levels were found to be further 
elevated in WT when compared to Mut tumours, a measurement validated via LC-MS, and a 
finding in line with previous studies that have examined metabolome-wide alterations  in IDH 
mutated tumours19,197. Such observations via MRS may be applied to furthering our 
understanding of the underlying mechanisms of the pathology, as elevated Cho levels have 
previously been correlated with tumour cell density, due to its involvement in cell membrane 
formation and proliferation198,199. Although the clinical utility of the short TE PRESS acquisition 
method is limited by the high false positive detection rate of 2-HG, it may be applicable within 
a research setting, aimed at evaluating the role of IDH mutation in development and 
progression of glioma pathology. 
Improved spectral resolution and reduced overlap can be achieved when applying a 




evolution seen in coupled spin systems200. The differential variation between coupled-spin 
system signal has been shown to allow adequate suppression of overlapping signals from 
background metabolites such as Glu and Gln, whilst maintaining sufficient signal-to-noise for 
accurate quantification of 2-HG (Figure 5.2)201. To take advantage of this method of spectral 
editing, an optimized PRESS sequence with a TE of 97 ms has been proposed16. Although 
spectral editing of uncoupled spins requires implementation of the longest possible TE to 
eliminate baseline noise, the complex 5-spin system of 2-HG requires optimization of 
interpulse durations and a specific TE in order to minimise signal loss from target metabolites 
whilst eliminating background noise202. To determine the optimal TE for isolation of the 2-HG  
signal, Choi et al.16 conducted quantum mechanical simulations. It was concluded that a 
shorter first subecho time and longer second subecho yielded the greatest H4 resonances, 
cumulating to a TE of 97 ms (Figure 5.2)16. The study reported 100% specificity and sensitivity 
for the detection of 2-HG. Furthermore, various voxel sizes were tested to ascertain optimal 
parameters, whereby six out of the six voxels >8 mL in volume belonging to WT tumours did 
not show any 2-HG signal16.  
The potential role of difference editing in MRS to untangle the 2-HG signal was also 
investigated. Difference editing, much like the long TE approach, takes advantage of J-coupling 
to generate spectral contrast203. This technique involves the application of frequency-selective 
radio-frequency pulses tuned at the H3 spins (1.9 ppm), the weak coupling partner to the H2 
spins located at 4.0 ppm16. Alternate application of such pulses allows for selective 180° 
rotation of the H3 spins, producing a number of uneven H2 multiplets in the acquired 
subspectra that may then be subtracted from the overall signal, resulting in the cancellation of 
all other resonances unaffected by the 180° rotation. In the study carried out by Choi et al.16, 
difference editing was also applied to six subjects and yielded 100% sensitivity. However, 
employment of this method may not provide absolute metabolic concentrations as it incurs 
imperatively long total TE, and, as such, may be subject to quantification errors that occur 
owing to signal loss due to relaxation204. Such errors associated with relaxation reduce the 
potential of the editing technique to track 2-HG for disease progression and appropriately 
monitor drug response.  
In addition to the TE 97 ms PRESS sequence at 3T, the same group have recently 
proposed an optimized extended TE sequence at 7T205. The suggested method incurs a TE of 
78 ms, taking into account the altered relaxation times at higher field strengths. The authors 
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directly compared both the 3T and 7T methods, whereby five patients were scanned at both 
magnetic fields within the same week. It was apparent that application of the optimized PRESS 
sequence at higher field strengths conferred increased signal – noise ratio (SNR), a point that 
was demonstrated by the reduction in mean 2-HG Cramer–Rao Lower Bounds (CRLB), a 
measure of spectral fitting, from 8% at 3T to 5% at 7T205. Importantly, it was established that 
the mutual dependence of 2-HG and GABA signals were greatly reduced at 7T compared to 3T. 
The peak resonating at 2.25 ppm experiences a significant amount of spectral overlap from 
GABA resonances, and application of an extended TE PRESS sequence at 7T induced the 
opposite polarity and narrowing of signals from both 2-HG and GABA, allowing for enhanced 
signal separation when compared to the TE 97 ms PRESS at 3T16,205.  
 To further understand the clinical applicability of the TE 97 ms PRESS sequence, de la 
Fuente et al.200 demonstrated the limitations of the MRS sequence in detecting 2-HG, and the 
ability of MRS to non-invasively monitor response to cytoreductive treatments. They indicated 
that increased sensitivity for 2-HG-detection when applied to tumours with a volume >3.4 mL. 
In addition, they investigated the potential role of this sequence in monitoring response to 
glioma treatment, demonstrating that 2-HG levels correlated with tumour cellularity as 
measured by increased apparent diffusion coefficient and histopathology200.  
Unambiguous detection of 2-HG in glioma patients has been reported by using a 2D correlation 
spectroscopy (COSY) sequence at a field strength of 3T, to counteract the known cofounding 
spectral overlap observed in standard 1D MRS spectra (Figure 5.3)191. 2D COSY allows for 
separation of the chemical shifts of spins that are scalar coupled to each other, and exploits 
the unlikely possibility that two metabolites would share identical chemical shifts in two 
dimensions. 2D COSY is particularly well suited for identifying 2-HG, as the cross peak 
generated by the metabolite appears in a spectral location shared by no other resonance. It 
was shown that 2D COSY was capable of unambiguous detection of 2-HG, providing full 
spectral information for accurate and reliable quantification. The abundance of spectroscopic 
information supplied by 2D methods represents a compromise between accuracy of 
measurements and complexity of acquisition. Although the most sensitive and specific 
detection method for identifying 2-HG, the clinical applicability of such a technique is limited 
by the extended acquisition time. This is an important factor when considering magnetic 
resonance imaging (MRI) scan time for patients, as current 2D COSY sequences are unlikely to 
be accommodated alongside clinical MRI brain tumour protocols within standard practice.  
 145
2D L-COSY MRS at 7T has been used to not only identify the resonant peaks of 2-HG, but to 
further assess and resolve the spectra of other brain metabolites that may experience a change 
in concentration in the presence of IDH mutation (Figure 5.4)195,206. The 2D L-COSY method  
 
Fig 5.4. 2D L-COSY of human glioma patients at 7T. (a) spectrum acquired from an 11.0 mL voxel from 
a IDH mutant grade III anaplastic astrocytoma patient; (b) spectrum acquired from an 8.8 mL voxel form 
a patient with a WT grade I ganglioglioma patient. The increased field strength not only benefitted the 
spectral separation of the 2-HG cross peak, but also allowed for increased spectral resolution and 
reliable quantification of other cancer associated metabolites such as Lactate. Taken from Biomed 
Central195. 
 
provided unambiguous detection of the metabolite in question; moreover, the higher field 
strength of 7T allowed for a reduction in voxel size and proportionally higher spectral 
separation, facilitating increased specificity of detection and quantification of 2-HG195. Whilst 
the clinical translational potential of the suggested 7T method is limited due to the high field 




appreciate and investigate the shift in the metabolic profile of IDH mutated tumours. For 
example, the study demonstrated reliable quantification of increased levels of lactate, a useful 
tool in grading tumours, as it has been shown to reflect changes in glycolysis and tissue  
 
 
Fig 5.5. In vivo spectra acquired at 3T using an optimized semi-LASER sequence with a TE of 110 ms, 
the voxel was placed over area demarked by yellow box with LCModel fits and Cramer–Rao lower 
bounds (%) displayed for Glutamte, Glutamine, Gamma-anminobutyric acid and Lactate shown. (a) IDH 
WT glioma patient, there is an unambiguous absence of 2-HG peak; (b) IDH1R132H glioma patient 
where the 2-HG peak is easily identifiable. Adapted from tomography186 
 
perfusion206. Reliable quantification of lactate concentration has previously proven 
problematic when applied to standard MRS methods, due to intense overlapping resonances 
from lipids often found in brain neoplasms that may be circumvented by the use of 2D L-
COSY195,207. 
 Although 2D MRS presents as an attractive method for accurate, reliable and sensitive 
detection and quantification of 2-HG, along with other glioma-associated metabolites, the 
clinical potential of this modality is limited when considering the incorporation of non-invasive 




detection of 2-HG utilizes an optimized semi-localization by an adiabatic selective refocusing 
(semi-LASER) sequence at 7T capable of providing quantitative measurements adequate 
enough to differentiate between cytosolic IDH1 mutant and mitochondrial IDH2 mutant18. 
Spectral changes induced by the presence of IDH mutation were characterised, and feature 
abnormalities were input into Fisher Linear Discriminant Analysis, where the resulting plot 
categorised two distinct cluster patterns, pertaining to IDH1 and IDH2 mutation. This detailed 
analysis was possible as a result of vastly improved localisation of the spectral volumes 
facilitated by employing a semi-LASER pulse sequence in combination with outer volume 
suppression, to eliminate contaminating signals from the area outside the volume of interest. 
The resultant spectra were free from artefacts normally generated from areas of surrounding 
tissue, and exhibited a flat baseline between the spectral locations of 1.6 ppm and 4.2 ppm18. 
In addition to the method for detection and quantification proposed at 7T, the same group has 
recently established a method for improved localisation of 2-HG detection at 3T by applying 
an optimized long-TE semi-LASER pulse sequence186. The use of broadband adiabatic 
localisation on strongly coupled spins allows for the acquisition of 2-HG spectra with a peak 
identifiable at 1.9 ppm that retains many features of the peak expected using adiabatic hard 
pules186,207. The outlined 3T semi-LASER method has been directly compared to the TE 97 ms 
PRESS sequence developed by Choi et al.16. The loss of the H3/H3′ peak as seen in TE 97 ms 
PRESS was circumvented by the use of adiabatic refocusing pulses in the semi-LASER sequence. 
Application of such refocusing pulses result in significantly reduced compartmental artefacts 
that would normally arise from extended J-evolution times under enhanced chemical shift 
displacements seen when narrow bandwidth RF pulses are applied186,208. The overall effect is 
total refocusing of the resonance at 1.9 ppm (H3 spins), which, when combined with 
diminished Glu and Gln peaks, allows for reliable detection of 2-HG (Figure 5.5). The 
significance of this method is highlighted by its translational potential and clinical applicability. 
Semi-LASER is a sequence that is increasingly being made available on 3T MRI within the clinical 
setting, and could be used for non-invasive in vivo assessment of IDH mutational status. 
 The mutated IDH pathway represents a possible target for novel glioma therapies, and, 
as such, there has begun a significant shift towards development of imaging strategies for the 
reliable longitudinal assessment and quantification of 2-HG levels during treatment and 
throughout clinical trials. Andronesi et al. propose a 3D functional spectroscopic mapping 
technique for the monitoring of 2-HG during clinical trials of drugs that may target the mutated 
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pathway194. In order to quantify spatiotemporal changes of metabolite levels associated with 
IDH mutated glioma, a novel analysis metric was proposed, termed functional spectroscopic 
mapping (fSM)194. The resultant 3D analytical framework is able to provide comprehensive 
metabolic information over time. Standard single voxel or single slice MRS may often incur a 
sampling bias when probing for 2-HG in longitudinal analysis due to positional errors; however, 
3D metabolite mapping is able to reduce the variance of spectral measurements obtained 
throughout the trial period194. 
 In addition to the in vivo detection methods described above, efforts to characterize 
the metabolic profile of IDH1 mutated gliomas using ex vivo spectroscopic techniques have 
also been correlated with in vivo MRI parameters209. In a study conducted by Elkhaled et al.209, 
image-guided biopsies were acquired and subsequently evaluated using magic angle spinning 
NMR spectroscopy. Although they failed to determine a link between tumour grade and 
relative abundance of 2-HG, a number of metabolites associated with tumour progression 
were correlated with the oncometabolite levels. Choline-containing species are some of the 
best spectroscopic markers for tumour evaluation and have been significantly utilized to 
determine tumour cellularity. In the study conducted by Elkhaled et al.209, total choline was 
shown to significantly correlate with 2-HG levels, indicating the role of detection of the 
metabolite in determining phenotypic characterisation of glioma209. Moreover, the 
histopathology of the tissue samples was assessed, where both immunostaining and 
histological investigations were used to assess for a number of parameters, including mitotic 
activity, relative tumour content and cellular density. 2-HG levels were found to correlate with 
a number of histopathological markers for mitotic activity, elevated tumour score and cellular 
density209. The strong correlations between 2-HG and increased cellularity of IDH mutant 
tumours fall in line with the hypothesis that there is increased cellularity in tumours where 2-
HG is present. These findings may also play an important role in the further development of in 
vivo MRS for both diagnosis and treatment response monitoring. If 2-HG levels can confidently 
aid in non-invasively determining histopathological characteristics of glioma, the acceleration 
of novel treatments and the diagnostic accuracy of pre-surgical MRI could greatly benefit. 
 Here we have employed the semi-LASER acquisition protocol at 3T described by 
Berrington et al, in order to determine if MRS is able to reliably and unambiguously detect 2-
HG within a clinical setting. 
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5.1.2 Scope of Study 
The aim of this study is to determine whether the MRS sequence was able to unambiguously 
detect 2-HG, and therefore identify IDH mutation non-invasively. This is achieved by comparing 
MRS detection results with gold standard diagnostic histopathological results.   
 
5.2 Methods 
5.2.1 Patient Recruitment  
This study was approved by the Walton Centre Research Tissue Bank research ethics 
committee (REC) (Reference number 15/WA/0385). Patients for this study were identified via 
two channels. The first method of recruitment saw patients identified at clinical multi-
disciplinary tumour meetings at the Walton Centre NHS foundation trust. The inclusion criteria 
for patients in this study was that they presented with a suspected glioma and were yet to 
undergo any treatment or 3T MR imaging. The second method used the vetting stage of the 
imaging process, whereby radiographers were able to identify qualifying patients for the study. 
All patients had provided informed consent and the use of the acquired spectroscopic data for 
the study was approved by the Walton Centre NHS foundation trust and sponsored by the 
University of Liverpool. A total of 6 patients were included in this study. Table 5.1 shows the 
IDH status and pathology for each of the patients. 
 
5.2.2 In-vivo Magnetic Resonance Spectroscopy Acquisition  
We used a semi-LASER sequence as described by Berrington et al186. The sequence was kindly 
shared with us by our collaborator Uzay Emir from the fMRIB group at Oxford University. The 
sequence uses an optimised TE of 110ms. Patients were imaged on a 3T whole body MR 
Skyra/Trio Siemens system and was implemented as described by Berrington et al186. Spectra 
were acquired both with and without VAPOR water suppression and outer volume saturation 
bands at a TR of 2000ms. A voxel of 20x20x20 mm3 were positioned in the centre of the 
tumour. 64 averages were acquired using a 16 channel head coil. This cumulates in an 
acquisition time of 2mins 15seconds. For each patient the water flip angle was optimised by 
acquiring incremental scans whereby the flip angle was in increased by 2-10 for each 
acquisition with a bandwidth of 80Hz. and the angle that resulted in the optimal water 
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suppression was selected. An unsuppressed water scan was also acquired for absolute 
quantification purposes. Spectra were anonymised and files were exported in the .rda format.  
 
Table 5.1 The IDH status and pathological diagnosis of each of the patients included in this study. Roman 
numerals in bracket denote the WHO grade of each of the tumours at time of scanning. 
 
5.2.3 Analysis 
Basis sets were provided by our collaborator, and the construction of these is described by 
Berrington et al186. Metabolite assignment was carried out using LCModel187 and the basis sets 
comprised of the metabolites 2-HG, alanine (Ala), ascorbate (Asc), aspartate (Asp), Gamma 
aminobutyric acid (GABA), total creatine (Cr+PCr:tCr) glutamine (Gln), glutamate (Glu), glycine. 
(Gly), lactate (Lac), N-acetyl aspartate (NAA), phosphocholine (PCho), 
phosphatidylethanolamine (PE), scyllo-inositol (scyllo-Ins), taurine (Tau), glucose (Glc), and 
glutathione (GSH). The values in the %SD column of each of the LCModel outputs represent 
the estimated standard deviations or Cramér-Rao lower bounds (CRLB) which are expressed as 
a percentage of the estimated concentrations. Multiplication of these lower bounds by 2 gives 
the 95% confidence interval. A CRLB >50 suggests that the concentration of the metabolite 
may range from zero to double the estimated concentration, and it can therefore be 
determined that the metabolite is not reliably detectable within this spectrum. A CRLB value 
of 20% suggests that only changes of approximately 40% that can be detected with reliability 
and a CRLB <20% may be considered as a rough criterion for estimates with acceptable 
reliability. 
 
Patient Number Pathology IDH status 
1 Oligodendroglioma (III) WT 
2 GBM (IV) Mut 
3 GBM (IV) WT 
4 GBM (IV) Mut 
5 Astrocytoma (III) WT 
6 GBM (IV) Mut 
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5.3 Results 
We set out to assess the utility of the semi-LASER sequence with a TE of 110ms, developed and 
described by Berrington et al186 for non-invasive detection of 2-HG in a clinical setting. Figure 
5.6 shows the processed spectrum of patient 1 following analysis using LCModel187. Table 5.2 
shows the concentration table displaying the calculated concentrations of metabolites of 
interest from the basis set, along with the CRLB (%SD). The plot shows the real part of the 
frequency domain data plotted as a thin black curve, whilst the thick red curve that overlies 
this is the LCModel fit to this data. At the top of the plot you can see the residuals, which 
equates to the actual data, minus the LCModel fit to the data, and provide a useful and 
sensitive diagnostic to the analysis. A residual plot that is randomly scattered about zero 
suggests a good fit within experimental error and no apparent systematic errors. The plot seen 
in figure 5.6 shows a poorly fitted spectrum, with a residual comprising of systematic peaks 
with high amplitude. This diagnostic metric suggests the data contained systematic errors. 
Further to this, it is not possible to distinguish resolved peaks of highly abundant metabolites 
that we would normally expect to see, such as NAA at 2.0 or the creatine peak at 3.0 ppm. 
When we consider the concentration table on the left, only 3 out of the 37 metabolites within 
the basis set had a CRLB <20% (highlighted in blue), and only 5 out of the 37 metabolites had 
an CRLB20% (up to 22%). This suggests that it is not possible to reliably detect these 
metabolites from this spectrum. This spectrum was acquired with only 8 averages, as shown 
in the printed acquisition parameters above the plot. Further to this, the tumour was located 
in the temporal pole of the temporal lobe, adjacent to the bone of the middle cranial fossa in 
this patient. This location resulted in poor shimming, and the proximity to the bone is likely to 
have introduced susceptibility artefact into the data.  
 Figure 5.7 shows the spectrum acquired from patient 2. Similar to the spectrum 
acquired from patient 1, this spectrum is also poorly fitted with a large residual and no 
identifiable peaks upon initial inspection. This patient was identified as IDH Mut following 
surgical resection, and although the concentration table (table 5.2) suggests that 2-HG was 
identifiable from these data, the CRLB is listed at 294%, indicating poor reliability for detection. 
This tumour was located in the superior part of the motor cortex, and was located much further 
away from skull or meningeal tissue when compared to the tumour seen in patient 1, was 
much less likely subject to susceptibility artefact within the data. Despite this, the spectrum is  
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Fig 5.6 (a) LCModel processed spectrum of patient 1. A large residual, very poor baseline and high SD 
values contribute to the poor quality of these data. It was not possible to resolve any potential 2-HG 
peaks. (b) The processed spectrum from patient 2. There is a large amount of residual in the plot, 
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Table 5.2 Shows the CRLB (%SD) and calculated concentration values for metabolites of interest 
calculated by LCModel fitting. Acceptable CRLB (<20%) in boldface. 
 
of poor quality, and this may be attributed to the low number of averages as only 8 were 
acquired. However the shimming routine was not optimised, and these data may be 
considered as low quality based on a number of diagnostic metrics including large systematic 
residual, poor baseline, high CRLB values for the vast majority of metabolites and the inability 
to visually identify clearly resolved peaks that we would expect to see in a spectrum of a human 
glioma such as NAA, lactate, choline and creatine. During the acquisition of both datasets from  
patient 1 and 2, we struggled to correctly implement the procedure for the calibration of the 
optimum flip angle for water suppression. In turn these data are likely to contain residual water 
signal, and the values given in the concentration table may not be considered as absolute 
concentrations.  
 Figure 5.8 shows the spectrum acquired from patient 3. Upon first inspection there are 
a number of clearly distinguishable peaks at 3.2 (choline), 3.0 (creatine), 2.0 (NAA) and a poorly 
phased peak at 1.3 (lactate). This tumour was diagnosed as IDH WT by the pathologist following 
resection. When we consider the residual plot at the top of the figure, there are a number of 
systematic peaks of high amplitude throughout the plot suggesting a number of experimental 
errors, which may be attributed to the low number of averages. Similar to the previous two 















2-HG 999% 0 294% 4.02E+03 999% 0 22% 1.16E+05 67% 2.991 20% 2.431 
Ala 38% 3.02E+05 40% 3.67E+04 213% 6.53E+03 42% 3.04E+04 107% 1.531 999% 0 
GABA 999% 0 206% 721.789 142% 3.06E+03 155% 2.89 129% 0.352 57% 0.141 
Cr 21% 2.01E+05 16% 2.99E+04 12% 1.25E+05 8% 1.08E+05 12% 6.553 6% 2.603 
Gln 57% 7.79E+04 65% 1.7E+04 99% 3.27E+04 59% 3.26E+04 101% 1.767 18% 2.069 
Glu 999% 0 999% 0 106% 3.14E+04 14% 1.55E+05 36% 4.725 999% 0 
Myo-Ins 324% 4.68E+05 999% 0 28% 1.35E+05 52% 6.96E+04 71% 2.726 17% 3.823 
Lac 67% 1.45E+05 30% 3E+04 24% 2.19E+05 24% 4.4E+04 39% 2.872 17% 0.725 
NAA 999% 0 999% 0 37% 3.15E+04 7% 1.08E+05 9% 7.035 999% 0 
PCho 999% 0 121% 9.52E+03 999% 0 122% 3.29E+04 999% 0 80% 0.631 
tCr 11% 3.2E+05 16% 2.99E+04 12% 1.25E+05 7% 1.34E+05 9% 8.673 6% 2.77 
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patients these data were acquired with only 8 averages, which has led to the presence of a 
large amount of noise within the data, and a poor fit. When we consider the concentration  
Fig 5.7 (a) The processed spectrum from patient 3, where no 2-HG was observed and its WT status was 
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etc.) the residual is large suggesting poor fit. (b) Processed spectrum from patient 4, improved baseline, 
it was possible to detect 2-HG (table 5.2)   
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table (table 5.2), there are only 2 metabolites from within the basis set shown to have a CRLB 
<20%. This large amount of variation within the data may again be attributed to the low 
averages and high level of noise. There was, however, no 2-HG detected, and although this 
spectrum is far from reliable in order to form a firm diagnostic decision, this result does 
correlate with the histopathological findings. During the acquisition of these data we were able 
to identify the correct brain shimming routine, however we did not have a clear value for the 
water suppression flip angle following the calibration protocol, which may have given rise to  
latent water signal within the data and poor calculation of absolute concentrations of each 
metabolite in LCModel.  
 The processed spectrum from patient 4 can be seen in figure 5.7. Initial examination of 
the plot shows a number of clearly identifiable peaks within the spectrum such as choline (3.2), 
creatine (3.0), glutamate/glutamine/GABA (2.2-2.4) and NAA (2.0). There is also an inverted 
lactate peak, however this has a much smaller amplitude when compared to patient 3, which 
is likely due to the pathological diagnosis as patient 3 was a grade IV GBM, whereas patient 4 
was diagnosed as a grade III astrocytoma. We would normally expect to see increased lactate 
in the high grade tumours due to increased extracellular acidification. When we consider the 
concentration table (table 5.2) 2-HG has been identified as present within the spectrum, and 
the CRLB was calculated at 22%, which suggests that the metabolite peak was present in the 
spectrum. The identification of 2-HG and therefore the suggestion that this patient is IDH Mut 
is conducive with the pathological diagnosis as this patient was shown to be carrying the 
mutation following histopathological investigations. The residual plot at the top of the 
spectrum shows a large amount of noise which is reflective of a low signal to noise ratio (SNR) 
and poor fit of the data, which can be attributed to only 8 averages being used to acquire this 
dataset. During the acquisition of these data both the water flip angle calibration and the 
shimming routine was conducted smoothly, and this is reflected in the linewidths. It is possible 
to distinguish 2 peaks at 2.2-2.4, which are contributed to by glutamate, glutamine and GABA, 
which reflects the increase in quality of the shimming routine when compared to previous 
spectra. If additional averages had been acquired, it may have been possible to resolve these 
metabolites. All these factors assist in determining the quality and reliability of the data. 
Although the detection of 2-HG from this spectrum appears to  be within the boundaries of 
reliability according to the %SD of CRLB, all the other attributes of the dataset suggest that the 
spectrum is of poor quality and was difficult to fit. 
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Fig 5.8 (a) Processed spectrum from patient 5. The increased number of averages for this acquisition 
has contributed to a much better fit of the data. Although 2-HG was shown to be present in these data 
this was found to be a false positive, and the broad linewidths may be attributed to bad shimming. (b) 
Processed spectrum from patient 6. Improved linewidths and residual indicate a much better fit of the 
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Figure 5.8 shows the processed spectrum acquired from patient 5. These data were acquired 
with 64 averages, and when we consider the residual plot at the top of the figure it is evident 
that the fit of these data was much improved when compared to the fit of the previous patients 
where only 8 averages were used. The residual plot contains randomly scattered peaks with 
low amplitude about zero. When we consider the fitted data plot, there are clearly identifiable 
peaks in the spectrum (choline, creatine and NAA) however the linewidth of these peaks is 
broad and has contributed to difficulties in resolving smaller multiplets such as 
glutamate/glutamine and 2-HG. The difficulties in resolution of the 2-HG peak have been 
reflected in %SD as shown in the table 2 for this metabolite, whereby the CRLB is 67%. This 
patient was determined to be IDH WT, based on histopathology, and therefore according to 
these data has shown to be somewhat of a false positive, however as the CRLB is >50% the 
metabolite may well range from zero to twice the stated value, and therefore the metabolite 
may be considered as undetectable within these data and the fit may have contributed to a 
false positive.  
 The LCModel output for patient 6 can be seen in figure 5.8. These data have very clearly 
identifiable peaks at 3.2 and 3.0 from choline and creatine respectively. Furthermore, the 
linewidth of each of these peaks is narrower than the previous patient indicating improved 
shimming. The residual plot at the top of the figure shows random peaks of much lower 
amplitude than previous patients, suggesting an improved fit of the data. When considering 
the values in table 5.2, the CRLB of 20% suggests that the concentration estimate may be 
considered as  reliable187. The identification of 2-HG within this spectrum was confirmed by 
histopathology and the diagnosis for this patient was IDH Mut. The improved linewidths and 
data fit may be attributed to the improved quality of the acquisition of this spectrum, as with 
64 averages and good shimming and water flip angle calibration we were able to resolve a 
number of peaks, including the 2-HG peak, more robustly than previous efforts in this study. 
 
5.4 Discussion 
The results that have been presented here demonstrate that the MRS sequence was able to 
accurately, and with confidence, identify IDH mutation by way of 2-HG detection on one 
occasion, however a larger sample size is required in order to ratify these findings. It has also 
highlighted the technical difficulties of implementing such sensitive MRS sequences in clinical 
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practice, and how clinical translation of novel MR advancements requires both academic and 
industrial institutions to work more closely in the future, in order to deliver new technologies 
into modern day medicine. 
5.4.1 semi-LASER 110ms TE for 2-HG Detection 
As the delivery of cancer care continuously evolves to incorporate a more individualised 
approach, there is a requirement to procure as much information about a tumours’ profile at 
the earliest possible stages in order to deliver the most efficient and effective treatment for 
the patient. The non-invasive detection of IDH mutation by way of 2-HG measurement using 
MRS has shown promise, and since it was first proposed in 2012 by Pope et al.19 a variety of 
studies have emerged that explore a number of strategies for the improved detection and 
localisation of  the 2-HG signal. As was previously discussed, there are a range of technical 
limitations that exist around the detection of the oncometabolite including spectral overlap 
from a number of peaks produced by metabolites found in abundance within both healthy and 
diseased brain tissue. Here we investigated the utility of an optimised semi-LASER sequence 
with a TE of 110ms at 3T, proposed by Berrington et al.186 for the detection of 2-HG in vivo. We 
chose to investigate the clinical potential of this sequence for several reasons. Firstly, the use 
of a broadband adiabatic refocusing pulse allows for retention of the H3/H3’ peak at 1.9 ppm, 
a characteristic of the 2-HG spectrum that is lost when using optimised PRESS sequences at 3T. 
Further to the peak retention, the use of the refocusing pulse allows for a significant reduction 
in compartmental artefacts and facilitates a flatter baseline within the often crowded and 
difficult to resolve ppm range of in-vivo MRS data. 
 This study comprises of only 6 patients, 3 IDH WT and 3 IDH Mut tumours from different 
pathological origins. The initial intention of this investigation was to acquire a minimum of 40 
good quality spectra with a test group split of approximately 20 IDH WT and 20 IDH Mut 
tumours. As this was the first time our lab was to form a collaboration with the Walton Centre 
NHS foundation trust, there were a number of hurdles to overcome before work would be 
approved to commence. The process of obtaining the relevant ethical permissions for both 
conducting the study as well as installation of a research pulse sequence on the magnet took 
2 years. We were finally able to begin to install the binaries on the clinical system in October 
2018. From this point we suffered further delays as the system needed to be updated to later 
version in order to facilitate the binaries shared with us by the developers at the FMRIB group 
in Oxford. Once the system had been updated to support the installation, the protocol for 
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patient recruitment also needed to be established and it wasn’t until April 2019 when we were 
able to acquire the first dataset. Due to these issues we were unable to achieve the 40 patient 
cohort that we initially anticipated.   
When considering the diagnostics that form part of the LCModel output of each of the 
spectra, the spectra acquired from patients 1,2,3 and 4 were of insufficient quality in order to 
obtain any true determination as to whether the 2-HG oncometabolite was present. This can 
be primarily determined by the residual plot seen at the top of figures 5.6-5.8. These residual 
plots suggest that the data were fitted poorly to produce the main plot as well as determination 
of the values within the concentration table. The poor fit of each of these spectra can likely be 
attributed to the presence of a large amount of noise within the data which is a consequence 
of the low number of averages. As this was the first time both installing and operating a custom 
MRS sequence on a Siemens system, we were unfamiliar with the setup process. As a result of 
unfamiliarity with the sequence and system, alongside complexity of acquisition set up with 
manual water suppression FA calibration and shimming, it was not recognised that the scans 
we were acquiring did not have a sufficient number of averages in order to acquire suitable 
data with a reasonable signal to noise ratio. Following the initial scans the developers were 
consulted, and they advised that the number of averages was too low and in fact needed to be 
at least 64, which was how we acquired the datasets for patient 5 and 6. Although the dataset 
for patient 5 was acquired using the appropriate number of averages, the shimming for this 
particular tumour was poor, due to the anatomical position at the base of the skull in the 
temporal lobe. Shimming has a high impact on signal to noise ratio, and this is evident if we 
compare both the magnitude of the residual plot as well as the linewidths of the spectrum of 
patient 5 with that of patient 652. The shimming routine should homogenise the magnetic field 
of the MRS voxel so that the entire region that is being scanned is subject to the same field 
strength and therefore the same Larmor frequency. The Larmor equation dictates that if there 
is a variation of B0 across the scanned region, there will in return be a distribution of 
frequencies for each of the resonance lines, causing a broadening of the NMR lines52.  
The impact of poor shimming is a reality faced in the acquisition of in vivo data, 
especially when imaging brain tumours that are located in close proximity to the skull and 
sinuses due to air-bone, and bone-tissue interface susceptibility. These factors are likely to 
have contributed to the production of the false positive peak from 2-HG seen in patient 5. This 
investigation set out to determine the clinical applicability of using the proposed semi-LASER 
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TE 110ms in order to detect the presence of 2-HG. Although the sequence has been optimised 
in order to circumvent spectral overlap of the 2-HG peak, the complexity in acquisition and the 
sensitivity of the routine to sources of variability, including poor shims due to anatomical 
location, raise the question as to whether this practice could be routinely and successfully 
carried out in a clinical setting with confidence that the result would be indicative of the true 
IDH status of the patient.  
The spectrum acquired from patient 6 allowed for true positive identification of 2-HG 
with a calculated CRLB = 20% representing the most reliable detection of 2-HG187. Whilst this 
was shown to be a true positive, it was the only dataset that was of suitable quality in order to 
extract reliable information from. These results are therefore inadequate in determining 
whether or not this semi-LASER pulse sequence is able to consistently measure 2-HG in IDH 
Mut glioma patients within a clinical setting. The complexity surrounding the implementation 
of this particular pulse sequence including the water suppression flip angle calibration and 
shimming routine presented a number of opportunities for the introduction of experimental 
error during the scanning. Moreover, there are further limitations to the translatability of this 
technique into the clinic when we consider the practicality of radiographers carrying out the 
calibration and acquisition on each patient. There is a very tight restriction on time required 
for each scan when using clinical systems, and the relatively long iterations between shimming, 
FA calibration and acquisition of both water supressed and unsuppressed spectra cumulates 
into an MRS routine that is difficult to ubiquitously employ throughout healthcare systems. 
Although the sensitivity of this pulse sequence for 2-HG detection was outlined by Berrington 
et al.186 there is yet to be any multicentre validation. Perhaps this has highlighted that in order 
to accelerate translation and overcome the disparity between academic innovation and clinical 
implementation, there needs to be a closer collaboration between industrial manufacturers 
and research institutions, in order to make such techniques more accessible. Increased 
accessibility and coherence with user interfaces of clinical systems could propel validation 
studies and facilitate the translation of cutting edge technology into the delivery of 
personalised healthcare. 
One of the major limitations of this study, as previously discussed, was the ethical 
approval and technical installation of the sequence. In addition to these limiting factors, one 
other substantial confounder is that the 2-HG peak appears within the spectrum proximally to 
the NAA peak. 2-HG is most often seen in lower grade (II-III) tumours, or those higher grade 
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(IV) tumours that have progressed from a lower grade lesion. NAA is known to occur in high 
abundance within LGG210. The large NAA peak in LGG may mask the 2-HG peak in a number of 
tumours, especially those lower grade, more juvenile lesions that have not built up 2-HG 
concentration to high levels. This can impact the clinical translatability of these methods. This 
confounding factor could be overcome by implementing 2D in vivo spectroscopy. This would 
allow decoupling of the 2-HG signal, and clear differentiation of the peak, as has been 
demonstrated by Verma et al195. Although 2D in vivo spectroscopy may present as a clear 
alternative for overcoming the limitations of 1D MRS, the long acquisition times, such as the 
17 minutes required for the 2D L-COSY MRS described by Verma et al, are unfeasible within a 
clinical setting. The reason for this is due to the requirement to reduce the amount of time a 
patient spends in the scanner. Although MRS can provide information regarding the metabolic 
phenotype of the tumour, the diagnostic information is limited, as it does not contain any 
spatial data. Typically, the longest time a clinic will allow any patient to be in a scanner is 
somewhere between 45-60mins. Using 30-40% of the imaging time on spectroscopy alone will 
sacrifice the acquisition of other diagnostic information. Clinics often aim to cap MRS 
acquisition at somewhere around 5minutes, or in certain cases 10 minutes maximum, in order 
to allow for other sequences to be implemented. One potential method for reducing these 
long acquisition times would be to decrease the number of averages. If one decreases the 
number of averages, then the signal will also decrease, and in the case of LGG where 2-HG 
concentration may not be so high, the important peak may be lost within the spectrum.  
 The acquisition time for the scans performed in this study was 3 min, and therefore 
one way in which the data collection may be improved is to increase the number of averages 
per scan. Here, the scans carried out on patients 5 and 6 were acquired with 64 averages, this 
may be doubled to 128 averages, increasing the acquisition time to 6 minutes and increasing 
the signal, thereby facilitating better separation of the 2-HG peak from NAA. This amount of 
acquisition time would also be clinically feasible, and may facilitate better translation of the 




5.5 Concluding Remarks 
Here we aimed to investigate the ability of the proposed semi-LASER sequence in the detection 
of 2-HG in IDH Mut glioma patients in a clinical setting. A combination of technical and 
administrative hurdles contributed to the late commencement of the study, and time 
constraints resulted in the acquisition of only a single reliable spectrum. Although we have 
been unable to determine the utility of this sequence in non-invasive detection of IDH 
mutation, this work may be considered as a foundation upon which further validation 
investigations may be conducted. If the proposed sequence is shown to be reliable at 
consistently identifying IDH Mut patients by way of MRS, this would be an invaluable tool in 














Tumours of the central nervous system represent approximately 2% of all identified primary 
tumours in the UK, whereby each year roughly 12,000 people are newly diagnosed and around 
5,500 of those are malignant.211 Although these tumours only account for a small percentage 
of newly diagnosed malignancies, the inherent infiltrative and aggressive nature by which they 
propagate along and between vital tissue within the brain makes treatment of the disease 
difficult, and mortality rates high. Only around 30% of adults diagnosed with a primary glioma 
survive past 1 year post-diagnosis, and only 13% survive more than 5 years211. The median 
survival for patients with anaplastic astrocytoma is approximately 2-3 years, whereas the 
median survival for GBM patients is around 1 year post-diagnosis211. The importance of 
understanding the molecular and genetic composition of a tumour was highlighted by the 
incorporation of a number of molecular markers into the WHO diagnostic criteria in 2016. 
Amongst others,  mutations in the IDH1/2 gene were highlighted as integral for the correct 
diagnosis and prognostication of gliomas.  
 It is thought that in those tumours carrying an IDH mutation, this genetic aberration is 
one of the first events to occur in the development of a primary glioma. The subsequent 
production and accumulation of 2-HG has been suggested to drive the cellular phenotype 
towards malignancy, potentially aiding in the facilitation of a number of molecular events. 
Despite this, interestingly those patients who harbour the mutation have increased survival 
and better prognosis. The current standard practice for determining IDH mutational status, 
where immediate resection is not necessary, is to obtain a biopsy via an invasive procedure, 
and conduct a combination of immunohistochemical and sequencing investigations. Clearly 
there is an unmet need in the non-invasive procurement of molecular diagnostic information, 
as well as understanding further the downstream effects of IDH mutation on the development 
and progression of the disease. In this thesis we have presented a number of investigations 
that have been aimed at using various magnetic resonance methods to non-invasively probe 
for IDH mutation, as well as understanding the cellular metabolic consequences.  
 Radiomics is an emerging and rapidly evolving technology, and the utility of it is being 
investigated in a wide range of applications and modalities, including computed tomography 
(CT), positron emitting tomography (PET) and MRI101,212–214. Although the utility of the 
technology has been demonstrated in a number of proof-of-concept studies, the translation 
of this technique into clinical settings has been hampered by issues surrounding the reliability 
and replicability. In an attempt to address this the IBSI published guidelines for the correct 
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conduct of radiomics studies81. In this thesis we explored the application of both genetic 
algorithms and random forests in combination with multiple linear models for variable 
selection and classifier construction. Although we were unable to build a robust model for 
classification of IDH tumour based on T1-post contrast image texture features, our 
investigations highlighted the importance of image quality and consistency across data 
acquisition when carrying out radiomics studies. Further to this, it has also raised the question 
of clinical applicability when considering radiomics models. All the data used here were 
collected within the same centre by radiographers during routine clinical examinations. 
Despite this we found that the large number of variables that were introduced during the 
acquisition presented bias within the data and impeded on the ability to single out 
discriminatory features that would facilitate the classification of IDH Mut tumours. This is a 
factor to consider when contemplating the scaling up of any particular model that may have 
been shown to allow classification of images during a study. Every imaging department in every 
hospital operates differently, with a range of different hardware and software. If these factors 
are likely to affect the ability of a model to classify images then this must be taken into account 
in order to enable clinical translation. In addition to the variability within the data used in the 
construction of radiomics models, the processing of images, generation of texture features and 
final classification is a long and convoluted process that requires a large amount of user input. 
Within the busy schedules of radiologists, implementation of these techniques via the 
currently available platforms is arduous and unachievable. If a model is found to be robust 
across multiple centres with varying acquisitions, then the process of radiomics classification 
must be streamlined in order to be considered by healthcare professionals as a viable 
diagnostic tool. This being said, radiomics is showing a large amount of promise, and the use 
of artificial intelligence in order to extract as much information from images is an interesting 
and potentially invaluable tool. The technology is still in its infancy, and it may be the case that 
with continued development, aided by international collaboration, will see the beginning of 
clinical translation in years to come. 
 Here we have presented NMR metabolomics in order to assess the metabolic 
phenotype of IDH mutant tumours. Although the importance of the mutation has been 
acknowledged for a number of years, it is not yet clear how its presence and subsequent 
accumulation of 2-HG affects the process of gliomagenesis and disease progression. By 
employing a combination of 1D and 2D NMR, in conjunction with both univariate and 
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multivariate analyses, we have been able to distinguish a potential metabolic phenotype of IDH 
Mut tumours. We identified a number of metabolites that appear to be consistently changed 
within the Mut tumours, which may aid in further investigations to understand the cellular 
impact of the mutation. Cellular metabolism is an inherently complex matrix of interlocking 
pathways, each one having both up- and downstream effects on an array of other intracellular 
processes. Changes in metabolism can act as driving forces in the evolution and advancement 
of disease, and by observing and quantifying these changes we may begin to understand the 
impact that IDH mutation has. These findings may be of particular importance when 
considering future drug development, especially those aimed at IDH inhibition215. Here the 
combined utility of both 1D and 2D NMR, as well as the use of quantitative 2D NMR for 
metabolomics has been demonstrated and it is hoped that this will continue to grow, as it has 
been shown here that incorporation of this technique into metabolomics studies can add a 
great deal of value. 
 The most obvious method for non-invasively probing for the mutation is to use in-vivo 
MRS in order to detect the 2-HG resonance. As has been previously outlined, there are a large 
number of technical difficulties that hamper the robust measurement of the metabolite. Here 
we were able to collect one dataset that was able to correctly identify the presence of the 
metabolite and therefore the mutation, it may be considered that the current convoluted 
acquisition, and subsequent specialist analysis remains as a barrier for clinical implementation. 
With continued development, and potential industrial collaboration, this method of detection 
will begin to make its way into hospitals worldwide, however there needs to be a considerable 
collaborative effort between scanner manufacturers and academic research institutes in order 
to facilitate this. 
 Taken together the work presented here demonstrates the versatility of magnetic 
resonance for both the potential non-invasive diagnosis, as well as unwinding the mysteries of 
tumour biology of IDH Mut tumours. With continued development and collaboration, 
incorporating multi-centre studies and cross validation, magnetic resonance can play an 
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Imaging acquisition parameters for radiomics study 
 
Patients for this study were identified by histology report. All glioma patients who had 
undergone IDH mutation investigation and had been imaged were included. 
All T1 images were acquired as gradient echo images with gadolinium contrast enhancement, 
across 3 scanners manufactured by Philips, Siemens and GE. The acquisition parameters for 
the images collected on each scanner were as follows: 
GE –  
TR:8.132ms, TE: 3.164ms, Number of averages: 1, Echo train length:1, Bandwidth: 244.14, 
Acquisition time: 4mins 22seconds , Resolution 256x256x280, Voxel spacing: 1.016x1.016x0.7, 
Number of slices: 180 
A total of 107 patients were scanned with this sequence and included in the analysis. 
Philips –  
TR: 9.0ms, TE: 1.369ms, Number of Averages: 1, Echo train length: 1, Bandwidth: 343, 
Acquisition time: 4min 38seconds, Resolution 288x288x180, Voxel spacing: 0.868x0.868x1, 
Number of slices: 180 
A total of 68 patients were scanned with this sequence and included in the analysis. 
Siemens –  
TR: 8.42ms, TE: 1.362ms, Number of Averages: 1, Echo train length: 1, Bandwidth: 287, 
Acquisition time: 4min 32seconds, Resolution 256x256x280, Voxel spacing: 0.946x0.946x1, 
Number of slices: 180 
A total of 36 patients were scanned with this sequence and included in the analysis. 
 
All T2 images as Spin echo sequences as PROPELLER(GE)/BLADE(Siemens)/MultiVane(Philips) 
across three scanner. The acquisition parameters for the images collected were as follows: 
GE –  
TR: 6736.544ms, TE: 102.18ms, Number of averages: 2, Echo train length: 26, Bandwidth: 195, 
Acquisition time: 2min 04seconds, Resolution:512x512x29, Voxel spacing: 0.4688x0.4688x5, 
Number of slices, 29   
A total of 77 patients were scanned with this sequence and included in the analysis. 
 180 
 
Philips –  
TR: 2999.99ms, TE: 80ms, Number of averages: 1, Echo train length: 15, Bandwidth: 204, 
Acquisition time: 3min 35seconds, Resolution: 512x512x27, Voxel spacing: 0.4492x0.4492x5, 
Number of slices: 27 
A total of 43 patients were scanned with this sequence and included in the analysis. 
Siemens –  
TR: 3800ms, TE: 100ms, Number of averages: 2, Echo train length: 17, Bandwidth: 220, 
Acquisition time: 3min 47seconds, Resolution: 512x512x32, Voxel spacing: 0.4492x0.4492x5.2, 
Number of slices: 32 
A total of 38 patients were scanned with this sequence and included in the analysis. 
 
Tumour Type 
GBMs from a number of different origins were included in this study. These were progressions 
from either astrocytic or oligodendrocytic tumours, as well as GMB. The breakdown of these 
tumour types are as follows: 
Astrocytoma: 13 
GBM: 129  
Oligodendroglioma: 11 
The segmented enhancing region of the tumour that was used in the study ranged in size from 




NMR Pattern file metabolites  
2-HG 
Adenosine 
ADP 
Alanine 
Aspartate 
ATP 
Cystathionine 
Cytidine 
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Formate 
Fumarate 
GDP 
Glucose 
Glutothione 
Glycine 
GTP 
Guanosine 
Histidine 
Hypoxanthine 
Imidazole 
Inosine 
Lactate 
Lactulose 
Malonate 
Myo-insoitol 
N-Acetylglutamate 
NAD+ 
NADP 
Niacinamide 
Nicotinurate 
Phenyalanine 
s-adenosylhomocysteine 
sn-Glycero-3-phosphocholine 
Sucrose 
Syringate 
Trimethylamine-N-oxide 
Tyrosine 
Tyrosine 
UDP-Galactose 
UDP-Glucose 
UDP-N-acetylglucosamine 
UDP-N-acetylglucosamine-UDP-Glc 
UMP 
Uridine 
Valine 
Xanthine 
 
 
